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PVD Peripheral vascular disease
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REDUCE-IT Reduction of Cardiovascular Events with
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REWIND Researching Cardiovascular Events With a
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SAVOR-TIMI 53 Saxagliptin Assessment of Vascular
Outcomes Recorded in Patients with
Diabetes Mellitus-Thrombolysis In
Myocardial Infarction 53
SBP Systolic blood pressure
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SGLT2 Sodium-glucose co-transporter 2
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SUSTAIN-6 Trial to Evaluate Cardiovascular and Other
Long-term Outcomes with Semaglutide in
Subjects with Type 2 Diabetes
SYNTAX Synergy between Percutaneous Coronary
Intervention with TAXUS and Cardiac
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T1DM Type 1 diabetes mellitus
T2DM Type 2 diabetes mellitus
TBI Toebrachial index
TECOS Trial Evaluating Cardiovascular Outcomes
with Sitagliptin
TOSCA.IT Thiazolidinediones Or Sulfonylureas and
Cardiovascular Accidents Intervention
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TZD Thiazolidinedione
UKPDS United Kingdom Prospective Diabetes
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VADT Veterans Affairs Diabetes Trial
VKA Vitamin K antagonist
VT Ventricular tachycardia
WHO World Health Organization
WIfI Wound, Ischaemia, and foot Infection
1 Preamble
Guidelines summarize and evaluate available evidence with the aim of
assisting health professionals in proposing the best management
strategies for an individual patient with a given condition. Guidelines
and their recommendations should facilitate decision making of
health professionals in their daily practice. However, the final deci-
sions concerning an individual patient must be made by the responsi-
ble health professional(s) in consultation with the patient and
caregiver as appropriate.
A great number of guidelines have been issued in recent years by
the European Society of Cardiology (ESC) and its partners such as
the European Society for the Study of Diabetes (EASD), as well as by
other societies and organisations. Because of their impact on clinical
practice, quality criteria for the development of guidelines have been
established in order to make all decisions transparent to the user.
The recommendations for formulating and issuing ESC Guidelines
can be found on the ESC website (http://www.escardio.org/
Guidelines-&-Education/Clinical-Practice-Guidelines/Guidelines-deve
lopment/Writing-ESC-Guidelines). The ESC Guidelines represent
the official position of the ESC on a given topic and are regularly
updated.
The ESC carries out a number of registries which are essential to
assess, diagnostic/therapeutic processes, use of resources and adher-
ence to Guidelines. These registries aim at providing a better under-
standing of medical practice in Europe and around the world, based
on data collected during routine clinical practice.
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material addressing the cultural and professional needs for cardiolo-
gists and allied professionals. Collecting high-quality observational
data, at appropriate time interval following the release of ESC
Guidelines, will help evaluate the level of implementation of the
Guidelines, checking in priority the key end points defined with the
ESC Guidelines and Education Committees and Task Force members
in charge.
The Members of this Task Force were selected by the ESC and
EASD, including representation from relevant ESC sub-specialty
groups, in order to represent professionals involved with the medical
care of patients with this pathology. Selected experts in the field from
both societies undertook a comprehensive review of the published
evidence for management of a given condition according to ESC
Committee for Practice Guidelines (CPG) policy. A critical evaluation
of diagnostic and therapeutic procedures was performed, including
assessment of the riskbenefit ratio. The level of evidence and the
strength of the recommendation of particular management options
were weighed and graded according to predefined scales, as outlined
in the tables below.
Table 2 Levels of evidence
Level of 
evidence A
Data derived from multiple randomized clinical trials 
or meta-analyses. 
Level of 
evidence B
Data derived from a single randomized clinical trial
or large non-randomized studies. 
Level of 
evidence C
Consensus of opinion of the experts and/or small studies, 
retrospective studies, registries.
©
ES
C
 2
01
9
Table 1 Classes of recommendations
C
la
ss
es
 o
f r
ec
om
m
en
da
tio
ns Class I Evidence and/or general agreement 
that a given treatment or procedure is 
Is recommended or is indicated
Wording to use
Class III Evidence or general agreement that the 
given treatment or procedure is not 
useful/effective, and in some cases 
may be harmful.
Is not recommended
     Class IIb
established by evidence/opinion.
May be considered
    Class IIa Weight of evidence/opinion is in Should be considered
Class II 
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The experts of the writing and reviewing panels provided declara-
tion of interest forms for all relationships that might be perceived as
real or potential sources of conflicts of interest. These forms were
compiled into one file and can be found on the ESC website (http://
www.escardio.org/guidelines). Any changes in declarations of interest
that arise during the writing period were notified to the ESC and
EASD Chairpersons and updated. The Task Force received its entire
financial support from the ESC and EASD without any involvement
from the healthcare industry.
The ESC CPG supervises and coordinates the preparation of new
Guidelines. The Committee is also responsible for the endorsement
process of these Guidelines. The ESC Guidelines undergo extensive
review by the CPG and external experts. After appropriate revisions
the Guidelines are approved by all the experts involved in the Task
Force. The finalized document is approved by the CPG for publica-
tion in the European Heart Journal. The Guidelines were developed
after careful consideration of the scientific and medical knowledge
and the evidence available at the time of their dating.
The task of developing ESC Guidelines also includes the creation
of educational tools and implementation programmes for the re-
commendations including condensed pocket guideline versions,
summary slides, booklets with essential messages, summary cards
for non-specialists and an electronic version for digital applications
(smartphones, etc.). These versions are abridged and thus, for
more detailed information, the user should always access to the full
text version of the Guidelines, which is freely available via the ESC
website and hosted on the EHJ s’ website. The National Cardiac
Societies of the ESC are encouraged to endorse, translate and
implement all ESC Guidelines. Implementation programmes are
needed because it has been shown that the outcome of disease
may be favourably influenced by the thorough application of clinical
recommendations.
Health professionals are encouraged to take the Guidelines fully
into account when exercising their clinical judgment, as well as in the
determination and the implementation of preventive, diagnostic or
therapeutic medical strategies. However, the Guidelines do not over-
ride in any way whatsoever the individual responsibility of health pro-
fessionals to make appropriate and accurate decisions in
consideration of each patient’s health condition and in consultation
with that patient or the patient’s caregiver where appropriate and/or
necessary. It is also the health professional’s responsibility to verify
the rules and regulations applicable in each country to drugs and devi-
ces at the time of prescription.
2 Introduction
This is the third set of Guidelines produced by the ESC in collabora-
tion with the EASD, designed to provide guidance on the manage-
ment and prevention of cardiovascular (CV) disease (CVD) in
subjects with, and at risk of developing, diabetes mellitus (DM). The
last Guidelines on this subject were published in the European Heart
Journal in 2013. The interval between preparing the previous
Guidelines and the current document has been relatively short, but it
has been a period in which we have seen an unprecedented increase
in the evidence base available for practicing healthcare professionals
to refer to in their daily consultations. This has been characterized by
the presentation and publication of a number of CV safety trials for
type 2 DM (T2DM) treatments, the results of which, to the casual
observer, must seem both exciting and bewildering. Exciting, because
while all the recent studies have reported CV safety, several have
also reported, for the first time, clear evidence of CV benefit.
Bewildering, because these trials continue to be dogged by various
side effects that dull the clarity of decision-making. It is one of our
aims to guide the reader through this important data set.
In other ways, and on a global scale, little has changed. The preva-
lence of DM worldwide continues to increase, rising to 10% of the
population in countries such as China and India, which are now
embracing western lifestyles. In 2017, 60 million adult Europeans
were thought to have T2DM—half undiagnosed—and the effects of
this condition on the CV health of the individual and their offspring
create further public health challenges that agencies are attempting
to address globally.
These massive numbers led to the prediction that >600 million
individuals would develop T2DM worldwide by 2045, with around
the same number developing pre-DM.1 These figures pose serious
questions to developing economies, where the very individuals who
support economic growth are those most likely to develop T2DM
and to die of premature CVD. Awareness of specific issues associated
with age at onset, sex, and race—particularly the effects of T2DM in
women (including epigenetics and in utero influences on non-
communicable diseases)—remains of major importance, although
there is still much work to be done. Finally, the effects of advancing
age and comorbidities indicate the need to manage risk in an individu-
alized manner, empowering the patient to take a major role in the
management of his or her condition.
The emphasis in these Guidelines is to provide information on the
current state of the art in how to prevent and manage the effects of
DM on the heart and vasculature. Our aim has been to focus mostly
on the new information made available over the past 56 years, and
to develop a shorter, concise document to this end. The need for
more detailed analysis of specific issues discussed in the present
Guidelines may be met by referring to the plethora of specialist
Guidelines from organizations such as the ESC and the American
Diabetes Association (ADA).
It has been a privilege for us to have been trusted with the oppor-
tunity to guide the development of these Guidelines and to work
alongside acknowledged experts in this field. We want to extend our
thanks to all members of the Task Force who gave freely of their time
and expertise, to the referees who contributed a great deal to the
final manuscript, and to the ESC and EASD committees that oversaw
this project. Finally, we express our thanks to the Guidelines team at
the European Heart House, in particular Veronica Dean, Nathalie
Cameron, Catherine Despres, and Laetitia Flouret for their support
in making this process run smoothly.
Francesco Cosentino and Peter J. Grant
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3 What is new in the 2019 Guidelines?
Table 3 What is new in the 2019 Guidelines?
Change in recommendations
2013 2019
BP targets
BP target <140/85 mmHg is recommended
for all
Individualized BP targets are recommended
SBP to 130 mmHg and, if well tolerated, <130 mmHg, but not <120 mmHg
In older people (>65 years) target SBP to a range of 130 - 139 mmHg
DBP to <80 mmHg but not <70 mmHg
On-treatment SBP to <130 mmHg should be considered for patients at high risk of cerebrovascular
events or diabetic kidney disease
Lipid targets
In DM at high CV risk, an LDL-C
target of <2.5 mmol/L (<100 mg/dL)
In DM at very high CV risk, an LDL-C
target of <1.8 mmol/L (<70 mg/dL)
is recommended
In patients with T2DM at moderate CV risk, an LDL-C target of <2.6 mmol/L (<100 mg/dL) is recommended
In patients with T2DM at high CV risk, an LDL-C target of <1.8 mmol/L (<70 mg/dL) and LDL-C reduction
of at least 50% is recommended
In patients with T2DM at very high CV risk, an LDL-C target of <1.4 mmol/L (<55 mg/dL) and LDL-C reduction
of at least 50% is recommended
Antiplatelet therapy
Aspirin for primary prevention is not
recommended in DM at low CVD risk
Aspirin (75 - 100 mg/day) for primary prevention may be considered in patients with
DM at very high/high risk in the absence of clear contraindications
Aspirin for primary prevention is not recommended in patients with DM at moderate CV risk
Glucose-lowering treatment
Metformin should be considered
as first-line therapy in patients with DM
Metformin should be considered in overweight patients with T2DM without CVD and at moderate CV risk
Revascularization
DES rather than BMS
is recommended in DM
Same techniques are recommended in patients with and without DM (see 2018 ESC/EACTS
myocardial revascularization Guidelines)
PCI may be considered as an alternative
to CABG in patients with DM and
less complex CAD (SYNTAX score <_22)
One- or two-vessel CAD, no proximal LAD
CABG PCI
One- or two-vessel CAD, proximal LAD
CABG PCI
Three-vessel CAD, low complexity
CABG PCI
Left main CAD, low complexity
CABG PCI
CABG recommended in complex
CAD (SYNTAX score >22)
Three-vessel CAD, intermediate or high complexity
CABG PCI
Left main CAD, intermediate complexity
CABG PCI
High complexity
CABG PCI
Management of arrhythmias
Oral anticoagulation in AF (paroxysmal or persistent)
VKAs or NOACs (e.g. dabigatran,
rivaroxaban, or apixaban) are recommended
It is recommended to give preference to NOACs (e.g. dabigatran, rivaroxaban, apixaban, or edoxaban)
IIa IIb III Ia 
AF = atrial fibrillation; BMS = bare-metal stent; BP = blood pressure; CABG = coronary artery bypass graft; CAD = coronary artery disease; CV = cardiovascular; CVD = cardi-
ovascular disease; DBP = diastolic blood pressure; DES = drug-eluting stent; DM = diabetes mellitus; EACTS = European Association for Cardio-Thoracic Surgery; ESC =
European Society of Cardiology; LAD = left anterior descending coronary artery; LDL-C = low-density lipoprotein cholesterol; NOAC = non-vitamin K antagonist oral anticoa-
gulant; PCI = percutaneous coronary intervention; SBP = systolic blood pressure; SYNTAX = Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac
Surgery; T2DM = type 2 diabetes mellitus; VKA = vitamin K antagonist.
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Table 4 New recommendations in the 2019 Guidelines
CV risk assessment
Resting ECG is recommended in patients with DM with hypertension or suspected CVD
Carotid or femoral ultrasound should be considered for plaque detection as CV risk modifier
Screening for CAD with coronary CT angiography and functional imaging may be considered
CAC scoring may be considered as risk modifier
ABI may be considered as risk modifier
Carotid ultrasound intimamedia thickness for CV risk is not recommended
Prevention of CVD
Lifestyle intervention is recommended to delay/prevent conversion from pre-DM to T2DM
Glycaemic control
Use of self-monitoring of blood glucose should be considered to facilitate optimal glycaemic control in T2DM
It is recommended to avoid hypoglycaemia
BP management
Lifestyle changes are recommended in hypertension
RAAS blockers rather than beta-blockers/diuretics are recommended for BP control in pre-DM
It is recommended to initiate pharmacological treatment with the combination of a RAAS blocker with a calcium channel blocker or thiazide/thiazide-like diuretic
Home BP self-monitoring should be considered in patients with DM
24 h ABPM should be considered for BP assessment, and adjustment of antihypertensive treatment
Dyslipidaemia
In patients at very high risk, with persistent high LDL-C despite treatment with maximum tolerated statin dose in combination with ezetimibe, or in
patients with intolerance to statins, a PCSK9 inhibitor is recommended
Statins may be considered in asymptomatic patients with T1DM aged >30 years
Statins are not recommended in women of childbearing potential.
Antiplatelet and antithrombotic drugs
Concomitant use of a proton pump inhibitor is recommended in patients receiving aspirin monotherapy, DAPT, or oral anticoagulant monotherapy who
are at high risk of gastrointestinal bleeding
Prolongation of DAPT beyond 12 months should be considered for <_3 years in patients with DM at very high risk who have tolerated DAPT without
major bleeding complications
Glucose-lowering treatment
Empagliflozin, canagliflozin, or dapagliflozin are recommended in patients with T2DM and CVD, or at very high/high CV risk, to reduce CV events
Empagliflozin is recommended in patients with T2DM and CVD to reduce the risk of death
Liraglutide, semaglutide, or dulaglutide are recommended in patients with T2DM and CVD, or very high/high CV risk, to reduce CV events
Liraglutide is recommended in patients with T2DM and CVD, or at very high/high CV risk, to reduce the risk of death
Saxagliptin is not recommended in patients with T2DM and a high risk of HF
Revascularization
Same revascularization techniques are recommended in patients with and without DM
Treatment of HF in DM
Device therapy with an ICD, CRT, or CRT-D is recommended
Sacubitril/valsartan instead of ACEIs is recommended in HFrEF and DM remaining symptomatic despite treatment with ACEIs, beta-blockers, and MRAs
CABG is recommended in HFrEF and DM, and two- or three-vessel CAD
Ivabradine should be considered in patients with HF and DM in sinus rhythm, and with a resting heart rate >_70 b.p.m. if symptomatic despite full HF treatment
Aliskiren (direct renin inhibitor) in HFrEF and DM is not recommended
DM treatment to reduce HF risk
SGLT2 inhibitors (empagliflozin, canagliflozin, or dapagliflozin) are recommended to lower risk of HF hospitalization
Metformin should be considered in patients with DM and HF if eGFR >30 mL/min/1.73 m2
GLP1-RAs and DPP4 inhibitors sitagliptin and linagliptin have a neutral effect on risk of HF and may be considered
Insulin treatment in HF may be considered
DPP4 inhibitor saxagliptin in HF is not recommended
Thiazolidinediones (pioglitazone and rosiglitazone) in HF are not recommended
Continued
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4 Diagnosis of diabetes and
pre-diabetes
Key messages
• DM should be investigated using fasting plasma glucose (FPG)
or haemoglobin A1c (HbA1c).
• An oral glucose tolerance test (OGTT) is necessary to diag-
nose impaired glucose tolerance (IGT).
• Individuals with established CVD should be screened using
HbA1c and/or fasting glucose; an OGTT can be carried out if
FPG and HbA1c are inconclusive.
The classification of DM and pre-DM [impaired fasting glycaemia
(IFG) and IGT] is based on recommendations from the World
Health Organization (WHO) and the ADA.25 IFG and IGT, referred
to as pre-DM, reflect the natural history of progression from normo-
glycaemia to T2DM. It is common for such individuals to oscillate
between different glycaemic states, and this needs to be considered
when investigations are being carried out. Different methods may be
used as a diagnostic test for DM and pre-DM (Table 6).25
Although the WHO and ADA diagnostic criteria are clear, there
are practical considerations when choosing a method to diagnose
DM. In accordance with other ESC Guidelines accepting non-fasting
lipids in risk scoring, most patients can have DM assessment by HbA1c
at any time of day. However, there are limitations with HbA1c to be
considered, such as interference as a result of haemoglobin variants,
anaemia, and availability in different parts of the world.
It is recommended that diagnosis of DM is based on HbA1c or
FPG, and on OGTT if still in doubt. Repeat testing is advisable to con-
firm the diagnosis. In patients with CVD, the methods employed for
the diagnosis of DM and pre-DM are essentially the same: glucose
testing with HbA1c and/or FPG first, and if inconclusive, an
OGTT,68 which is the only means of diagnosing IGT. The high prev-
alence of glucose abnormalities in this setting is well established. In
the Glucose Abnormalities in Patients with Myocardial Infarction
Management of arrhythmias
Attempts to diagnose structural heart disease should be considered in patients with DM with frequent premature ventricular contractions
Hypoglycaemia should be avoided as it can trigger arrhythmias
Diagnosis and management of PAD
Low-dose rivaroxaban 2.5 mg b.i.d. plus aspirin 100 mg o.d. may be considered in patients with DM and symptomatic LEAD
Management of CKD
SGLT2 inhibitors are recommended to reduce progression of diabetic kidney disease
IIa IIb III Ia 
ABI = anklebrachial index; ABPM = ambulatory blood pressure monitoring; ACEI = angiotensin-converting enzyme inhibitor; b.i.d. = twice daily (bis in die); b.p.m. = beats
per minute; CABG = coronary artery bypass graft; CAC = coronary artery calcium; CAD = coronary artery disease; CKD = chronic kidney disease; CRT = cardiac resynchroni-
zation therapy; CRT-D = cardiac resynchronization therapy with an implantable defibrillator; CT = computed tomography; CV = cardiovascular; CVD = cardiovascular
disease; DAPT = dual antiplatelet therapy; DM = diabetes mellitus; DPP4 = dipeptidyl peptidase-4; ECG = electrocardiogram; eGFR = estimated glomerular filtration rate;
GLP1-RA = glucagon-like peptide-1 receptor agonist; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; ICD = implantable cardioverter defibrillator;
LEAD = lower extremity artery disease; MRA = mineralocorticoid receptor agonist; o.d. = once daily (omni die); PAD = peripheral arterial disease; PCSK9 = proprotein con-
vertase subtilisin/kexin type 9; RAAS = reninangiotensinaldosterone system; SGLT2 = sodium-glucose co-transporter-2; T1DM = type 1 diabetes mellitus T2DM = type 2
diabetes mellitus.
Table 5 Revised concepts in the 2019 Guidelines
Risk assessment in DM and pre-DM
Classification of CV risk (moderate-to-very high risk) adapted from the
2016 ESC Guidelines on CVD prevention in clinical practice to the DM
setting (see section 5.2)
Lifestyle
Moderate alcohol intake should not be promoted as a means to protect
against CVD
BP control
Detailed recommendations for individualized BP targets are now
provided
Glucose-lowering treatment (a paradigm shift after recent
CVOTs)
For the first time, we have evidence from several CVOTs that indicate
CV benefits from the use of SGLT2 inhibitors and GLP1-RAs in patients
with CVD, or at very high/high CV risk
Revascularization
The recommendations have been extended following the addition of sev-
eral RCTs, and the choice between CABG and PCI depends on the com-
plexity of the CAD
HF
Treatment recommendations have been updated following positive
results from CVOTs
PAD
New evidence on diagnostic methods and management
CKD
A CKD classification by eGFR and albuminuria is presented to stratify
severity of disease and guide treatment
BP = blood pressure; CABG = coronary artery bypass graft; CAD = coronary
artery disease; CKD = chronic kidney disease; CV = cardiovascular; CVD = cardio-
vascular disease; CVOT = cardiovascular outcome trial; eGFR = estimated glomeru-
lar filtration rate; ESC = European Society of Cardiology; GLP1-RA = glucagon-like
peptide-1 receptor agonist; HF = heart failure; PAD = peripheral arterial disease;
PCI = percutaneous coronary intervention; RCT = randomized controlled trial.
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(GAMI) study, OGTTs revealed that two-thirds of patients without
DM had newly detected DM or pre-DM.9 The Euro Heart Survey on
Diabetes and the Heart10 and EUROASPIRE IV11 demonstrated that
an OGTT may diagnose a greater proportion of patients with CVD
as having glucose abnormalities than FPG or HbA1c. Similar findings
have been reported in patients admitted for coronary angiography.12
In acute coronary syndromes (ACS), the OGTT should not be per-
formed earlier than 45 days, to minimize false-positive results.13,14
Gaps in the evidence
• Measurement of glycaemia at 1 h instead of 2 h during an
OGTT for the diagnosis of pre-DM and DM needs validation.
• Further work needs to be carried out to establish the effects
of sex, ethnicity, and age on diagnostic criteria.
• Direct comparison of the predictive abilities of HbA1c- vs.
OGTT-derived measures for hard outcomes in people with
CVD.
5 Cardiovascular risk assessment
in patients with diabetes and pre-
diabetes
Key messages
• Routine assessment of microalbuminuria should be carried
out to identify patients at risk of developing renal dysfunction
and/or CVD.
• A resting electrocardiogram (ECG) is indicated in patients
with DM and hypertension, or if CVD is suspected.
• Other tests, such as transthoracic echocardiography, coro-
nary artery calcium (CAC) score, and anklebrachial index
(ABI), may be considered to test for structural heart disease
or as risk modifiers in those at moderate or high risk of
CVD.
• Routine assessment of novel biomarkers is not recom-
mended for CV risk stratification.
5.1 Diabetes, pre-diabetes, and cardiovas-
cular risk
The Emerging Risk Factor Collaboration, a meta-analysis of 102 pro-
spective studies, showed that DM in general (data on DM type were
unavailable) confers a two-fold excess risk of vascular outcomes
(coronary heart disease, ischaemic stroke, and vascular deaths), inde-
pendent of other risk factors (Figure 1).23 The excess relative risk of
vascular events with DM was greater in women and at younger ages.
Both relative and absolute risk levels will be higher in those with
Table 6 Diagnostic criteria for diabetes mellitus and
pre-diabetes according to the 2006/2011 World Health
Organization and 2019 American Diabetes Association
recommendations
Diagnosis/
measurement
WHO 20063/20114 ADA 20195
DM
Can be used Recommended
HbA1c If measured, >_6.5%
(48 mmol/mol)
>_6.5% (48 mmol/mol)
Recommended
FPG >_7.0 mmol/L
(126 mg/dL)
>_7.0 mmol/L
(126 mg/dL)
or or
2hPG >_11.1 mmol/L
(>_200 mg/dL)
>_11.1 mmol/L
(>_200 mg/dL)
RPG Symptoms plus
>_11.1 mmol/L
(>_200 mg/dL)
Symptoms plus
>_11.1 mmol/L
(>_200 mg/dL)
IGT
FPG <7.0 mmol/L
(<126 mg/dL)
<7.0 mmol/L
(<126 mg/dL)
2hPG >_7.8 to <11.1 mmol/L
(>_140200 mg/dL)
>_7.8 to <11.0 mmol/L
(>_140199 mg/dL)
IFG
FPG 6.16.9 mmol/L
(110125 mg/dL)
5.66.9 mmol/L
(100125 mg/dL)
2hPG <7.8 mmol/L
(<140 mg/dL)
<7.8 mmol/L
(<140 mg/dL)
2hPG = 2 h plasma glucose; ADA = American Diabetes Association; DM = diabe-
tes mellitus; FPG = fasting plasma glucose; IFG = impaired fasting glycaemia;
IGT = impaired glucose tolerance; HbA1c = haemoglobin A1c; RPG = random
plasma glucose; WHO = World Health Organization.
Recommendations for the diagnosis of disorders of glucose metabolism
Recommendations Classa Levelb
It is recommended that screening for potential T2DM in patients with CVD is initiated with HbA1c and FPG, and that an
OGTT is added if HbA1c and FPG are inconclusive.1318
I A
It is recommended that an OGTT is used for the diagnosis of IGT.24,1622 I A
It is recommended that the diagnosis of DM is based on HbA1c and/or FPG, or on an OGTT if still in doubt.14,9,10,1622 I B
CVD = cardiovascular disease; DM = diabetes mellitus; FPG = fasting plasma glucose; HbA1c = haemoglobin A1c; IGT = impaired glucose tolerance; OGTT = oral glucose tol-
erance test; T2DM = type 2 diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
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..long-standing DM and microvascular complications, including
renal disease or proteinuria. The Swedish National Diabetes Register
has provided important insights into the prevalence of CVD and
CV death in both type 1 DM (T1DM)24 and T2DM.25 For T1DM,
27 195 subjects were stratified by age and sex. Early onset at 1 - 10
years of age was associated with a hazard ratio (HR) of 7.38 for CV
mortality, 30.95 for acute myocardial infarction (MI), and 12.9 for
heart failure (HF). The corresponding figures for T1DM onset
between the ages of 26 and 30 years were 3.64, 5.77, and 5.07,
respectively. Development of T1DM between 110 years of
age resulted in loss of 17.7 years of life in women and 14.2 years in
men.24 For T2DM, a huge cohort of 435 369 patients was
matched with controls and followed for 4.6 years. CVD mortality
was 17.15/1000 patient-years for T2DM and 12.86/1000 patient-
years for controls. In this cohort, age at DM diagnosis, glycaemic con-
trol, and renal complications were the major determinants of out-
come.25,26 Although T2DM is far more common than T1DM, these
results confirm the loss of years of life in both populations, which is
particularly severe in the young in general and perhaps in young-
onset female individuals with T1DM, emphasizing the need for inten-
sive risk-factor management in these groups. In this document, we
will be referring mostly to DM; this can be taken as relating to both
types of DM unless otherwise specified.
The elevated risk of coronary artery disease (CAD) starts at glu-
cose levels below the cut-off point for DM (<7 mmol/L), and
increases with increasing glucose levels (Figure 2).
5.2 Stratification of cardiovascular risk in
individuals with diabetes
As outlined in the 2016 European Guidelines on cardiovascular dis-
ease prevention in clinical practice,27 individuals with DM and CVD,
or DM with target organ damage, such as proteinuria or kidney failure
[estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2],
are at very high risk (10 year risk of CVD death >10%). Patients with
DM with three or more major risk factors, or with a DM duration of
>20 years, are also at very high risk. Furthermore, as indicated in sec-
tion 5.1, T1DM at the age of 40 years with early onset (i.e. 1 - 10 years
of age) and particularly in female individuals is associated with very
high CV risk.24 Most others with DM are high risk (10 year risk of
CVD death 5 - 10%), with the exception of young patients (aged <35
years) with T1DM of short duration (<10 years), and patients with
T2DM aged <50 years with a DM duration of <10 years and without
major risk factors, who are at moderate risk. The classification of risk
level applied in these Guidelines is presented in Table 7. When DM is
present, female sex is not protective against premature CVD, as seen
in the general population.28,29
5.3 Stratification of cardiovascular risk in
individuals with pre-diabetes
Individuals without CVD who have pre-DM are not necessarily at
elevated CV risk,23,30 but warrant risk scoring for CVD in the same
way as the general population.
5.4 Clinical assessment of cardiovascular
damage
5.4.1 Biomarkers
The addition of circulating biomarkers for CV risk assessment has
limited clinical value.27 In patients with DM without known CVD,
measurement of C-reactive protein or fibrinogen (inflammatory
markers) provides minor incremental value to current risk assess-
ment.31 High-sensitivity cardiac troponin T (hsTnT)-estimated 10
year CV mortality for individuals with undetectable (<3 ng/L), low
Number
of cases
Coronary heart disease* 26 505 2.00 (1.83–2.19) 64 (54–71)
Other vascular deaths 3 826
1 2 4
1.73 (1.51–1.98) 0 (0–26)
Coronary death 11 556 2.31 (2.05–2.60) 41 (24–54)
Non-fatal myocardial infarction 14 741 1.82 (1.64–2.03) 37 (19–51)
Stroke subtypes*
Ischaemic stroke 3 799 2.27 (1.95–2.65) 1 (0–20)
Haemorrhagic stroke 1 183 1.56 (1.19–2.05) 0 (0–26)
Unclassified stroke 4 973 1.84 (1.59–2.13) 33 (12–48)
HR (95% CI) I2 (95% CI)
©
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Figure 1 Hazard ratios for vascular outcomes in people with vs. without diabetes mellitus at baseline, based on analyses of 530 083 patients.
Reproduced with permission.23 Hazard ratios were adjusted for age, smoking status, body mass index, and systolic blood pressure, and—where appropri-
ate—stratified by sex and trial arm. The 208 coronary heart disease outcomes that contributed to the grand total could not contribute to the subtotals of
coronary death or non-fatal myocardial infarction because there were <11 cases of these coronary disease subtypes in some studies. CI = confidence
interval; HR = hazard ratio. aIncludes fatal and non-fatal events.
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detectable (314 ng/L), and increased (>_14 ng/L) levels was 4, 18,
and 39%, respectively.32 However, the addition of hsTnT to conven-
tional risk factors has not shown incremental discriminative power in
this group.22 In individuals with T1DM, elevated hsTnT was an inde-
pendent predictor of renal decline and CV events.33 The prognostic
value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in
an unselected cohort of people with DM (including known CVD)
showed that patients with low levels of NT-proBNP (<125 pg/mL)
have an excellent short-term prognosis.34 The value of NT-proBNP
in identifying patients with DM who will benefit from intensified con-
trol of CV risk factors (CVRFs) was demonstrated in a small random-
ized controlled trial (RCT).21 The presence of albuminuria (30299
mg/day) is associated with increased risk of CVD and chronic kidney
disease (CKD) in T1DM and T2DM.20,3537 Measurement of albumi-
nuria may predict kidney dysfunction and warrant renoprotective
interventions.27
5.4.2 Electrocardiography
A resting ECG may detect silent MI in 4% of individuals with DM,38
which has been associated with increased risk of CVD and all-cause
mortality in men but not women.39 Additionally, prolonged cor-
rected QT interval is associated with increased CV mortality in
T1DM, whereas increasing resting heart rate is associated with risk of
CVD in T1DM and T2DM.40,41 Low heart rate variability (a marker of
diabetic CV autonomic neuropathy) has been associated with an
increased risk of fatal and non-fatal CAD.42,43 In prospective cohorts,
2040% of patients with DM presented silent ST-segment depres-
sion during exercise ECG.4448 The sensitivity and specificity of exer-
cise ECG in diagnosing significant CAD in asymptomatic DM patients
were 47 and 81%, respectively.49 The combination of exercise ECG
and an imaging technique provides incremental diagnostic and prog-
nostic value patients with in DM.5052
5.4.3 Imaging techniques
Echocardiography is the first choice to evaluate structural and func-
tional abnormalities associated with DM. Increased left ventricular
(LV) mass, diastolic dysfunction, and impaired LV deformation have
been reported in asymptomatic DM and are associated with worse
prognosis.5356 A cluster analysis from two large cohorts of asymp-
tomatic patients with DM showed that those with the lowest LV
masses, smallest left atria, and lowest LV filling pressures (determined
by E/e’) had fewer CV hospitalization or death events, compared
with those with advanced LV systolic and diastolic dysfunctions, or
greater LV masses.53,57 CV magnetic resonance and tissue
Number
of cases
Number of
participants (%)
Fasting blood glucose
concentration
Known diabetes at baseline
8.0 1 2 4
≥7 mmol/L 13 122 (4.7%) 2.36 (2.02–2.76)
<7 mmol/L 5 807 (2.1%) 1.61 (1.42–1.82)
No known diabetes at baseline
≥7 mmol/L 7 240 (2.6%) 1.78 (1.56–2.03)
6.1 to <7 mmol/L 19 607 (7.0%) 1.17 (1.08–1.26)
5.6 to <6.1 mmol/L 32 008 (11.5%)
1 186
380
452
1 011
1 631 1.11 (1.04–1.18)
HR (95% CI)
3.9 to <5.6 mmol/La 185 590 (66.5%) 1.00 (0.95–1.06)
<3.9 mmol/L 15 916 (5.7%)
9 508
646 1.07 (0.97–1.18)
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Figure 2 Hazard ratios for coronary heart disease by clinically defined categories of baseline fasting blood glucose concentration. Reproduced with per-
mission.23 Analyses were based on 279 290 participants (14 814 cases). Hazard ratios were adjusted as described in Figure 1. The hazard ratio in those with
fasting plasma glucose 5.606.99 mmol/L was 1.12 (95% confidence interval 1.061.18). CI = confidence interval; HR = hazard ratio. aReference group.
Table 7 Cardiovascular risk categories in patients with
diabetesa
Very high risk Patients with DM and established CVD
or other target organ damageb
or three or more major risk factorsc
or early onset T1DM of long duration (>20 years)
High risk Patients with DM duration >_10 years without tar-
get organ damage plus any other additional risk
factor
Moderate risk Young patients (T1DM aged <35 years or T2DM
aged <50 years) with DM duration <10 years,
without other risk factors
CV = cardiovascular; CVD = cardiovascular disease; DM = diabetes mellitus;
T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus.
aModified from the 2016 European Guidelines on cardiovascular disease preven-
tion in clinical practice.27
bProteinuria, renal impairment defined as eGFR <30 mL/min/1.73 m2, left ventric-
ular hypertrophy, or retinopathy.
cAge, hypertension, dyslipidemia, smoking, obesity.
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characterization techniques have shown that patients with DM with-
out CAD have diffuse myocardial fibrosis as the mechanism of LV sys-
tolic and diastolic dysfunction.55,58,59 However, the value of these
advanced imaging techniques in routine practice has not yet been
demonstrated.
Screening for asymptomatic CAD in patients with DM remains
controversial. With computed tomography (CT), non-invasive esti-
mation of the atherosclerotic burden (based on the CAC score) and
identification of atherosclerotic plaques causing significant coronary
stenosis [CT coronary angiography (CTCA)] can be performed. The
presence of plaques on carotid ultrasound has been associated with
increased CV events in subjects with DM.6062 In addition, patients
with DM have a higher prevalence of coronary artery calcification
compared with age- and sex-matched subjects without DM.63 While
a CAC score of 0 is associated with favourable prognosis in asympto-
matic subjects with DM, each increment in CAC score (from 1 - 99
to 100 - 399 and >_400) is associated with a 25 - 33% higher relative
risk of mortality.63 Importantly, CAC is not always associated with
ischaemia. Stress testing with myocardial perfusion imaging or stress
echocardiography permits the detection of silent myocardial ischae-
mia. Observational studies and RCTs report the prevalence of silent
myocardial ischaemia in asymptomatic DM as 22%.47,48,64 RCTs
evaluating the impact of routine screening for CAD in asymptomatic
DM and no history of CAD have shown no differences in cardiac
death and unstable angina at follow-up in those who underwent
stress testing, or CTCA, compared with current recommen-
dations.47,6468 A meta-analysis of five RCTs (Table 8) with 3299
asymptomatic subjects with DM showed that non-invasive imaging
Table 8 Overview of randomized controlled trials
Study/author Faglia et al.69 DIAD68 DYNAMIT64 FACTOR-6467 DADDY-D70
Year of publication 2005 2009 2011 2014 2015
Patients (n) 141 (þ1)a 1123 615 899 520
Inclusion criteria T2DM T2DM T2DM T1DM or T2DM T2DM
4576 years 5075 years 5075 years # aged >_50 years/
$ aged >_55 years,
DM for >_3 years
5075 years
>_2 other CVRFs >_2 other CVRFs # aged >_40 years/
$ aged >_45 years,
DM for >_5 years
CV risk >_10%
Sinus rhythm
Able to do EET
Mean age (years) 60.1 60.8 63.9 61.5 61.9
Male sex (%) 55.6 53.5 54.5 52.2 80.0
Screening test EET and SE MPI EET or MPI CTCA and CAC
score
EET
Positive screening test (%) 21.1 5.9 moderate or
large defects
21.5 positive or
uncertain
11.9 moderate; 10.7
severe
7.6
Treatment strategy ICA and cardiac fol-
low-up if any test
was positive
At the referring
physician’s
discretion
According to the
cardiologist’s
decision
Recommendation
based on stenosis
severity and CAC
score
ICA if EET positive
ICA performed after
positive test (%)
93.3 15.2 55.9 47.3 85.0
Mean follow-up (years) 4.5 4.8 3.5 4.0 3.6
Annual rate of major CEs (%) 1.9 0.6 1.0 0.8 1.4
Main results of screening Significant # of major
and all CEs
Non-significant # of
major CEs
Non-significant # of
MI; no effect on
combined CEs
Non-significant # of
combined CEs
Non-significant # of
major CEs, but sig-
nificant # in those
aged >60 years
Reproduced/adapted with permission.
# = men; $ = women; CAC = coronary artery calcium; CE = cardiac event (major CE = cardiac death or MI); CTCA = computed tomography coronary angiography; CV = car-
diovascular; CVRF = cardiovascular risk factor; DADDY-D = Does coronary Atherosclerosis Deserve to be Diagnosed earlY in Diabetic patients?; DIAD = Detection of
Ischaemia in Asymptomatic Diabetics; DYNAMIT = Do You Need to Assess Myocardial Ischemia in Type 2 Diabetes; DM = diabetes mellitus; EET = exercise electrocardiogram
test; FACTOR-64 = Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64; ICA =
invasive coronary angiography; MI = myocardial infarction; MPI = radionuclide myocardial perfusion imaging; RCT = randomized controlled trial; SE = stress echocardiography;
T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus.
aOne patient excluded for early non-cardiac death was reincluded.
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for CAD did not significantly reduce event rates of non-fatal MI (rela-
tive risk 0.65; P=0.062) and hospitalization for HF (relative risk 0.61;
P=0.1).65
The Detection of Ischaemia in Asymptomatic Diabetics (DIAD)
study showed no difference in the prevalence of silent ischaemia
between men and women (24 vs. 17%, respectively), and a signifi-
cantly lower event rate for non-fatal MI and cardiac death in women
compared with men (1.7 vs. 3.8%; P=0.047).71 The low event rates in
RCTs and the disparities in the management of screening results
(invasive coronary angiography and revascularization were not per-
formed systematically) may explain the lack of benefit of the screen-
ing strategy. Accordingly, routine screening of CAD in asymptomatic
DM is not recommended.71 However, stress testing or CTCA may
be indicated in very high-risk asymptomatic individuals [with periph-
eral arterial disease (PAD), a high CAC score, proteinuria, or renal
failure].72
Carotid intimamedia thickness has been associated with CAD.73
In patients with DM, carotid intimamedia thickness has not shown
incremental value over the CAC score to predict CAD or CV
events.73 In contrast, detection of carotid plaque has shown incre-
mental value over carotid intimamedia thickness to detect CAD in
asymptomatic DM.74 Additionally, echolucent plaque and plaque
thickness are independent predictors of CVD events (CAD, ischae-
mic stroke, and PAD).75 ABI is associated with an increased risk of all-
cause and CV mortality in DM and non-DM patients76 (see further
details in section 10).
Gaps in the evidence
• The prognostic value of advanced imaging techniques, such as
strain imaging or CV magnetic resonance with tissue charac-
terization, needs validation in prospective cohorts.
• Asymptomatic subjects with significant atherosclerosis burden
(i.e. CAC score >400) may be referred for functional imaging
or CTCA; however, identification of the presence of signifi-
cant coronary artery stenoses has not been shown to be bet-
ter than aggressive medical treatment for CVRFs.
• Sex-specific differences in the diagnosis of CAD require fur-
ther investigation.
• The uptake of CV risk assessment in different ethnic groups
requires evaluation.
Recommendations for the use of laboratory, electrocardiogram, and imaging testing for cardiovascular risk assessment
in asymptomatic patients with diabetes
Recommendations Classa Levelb
Routine assessment of microalbuminuria is indicated to identify patients at risk of developing renal dysfunction or at
high risk of future CVD.27,38
I B
A resting ECG is indicated in patients with DM diagnosed with hypertension or with suspected CVD.38,39 I C
Assessment of carotid and/or femoral plaque burden with arterial ultrasonography should be considered as a risk
modifier in asymptomatic patients with DM.6062
IIa B
CAC score with CT may be considered as a risk modifier in the CV risk assessment of asymptomatic patients with
DM at moderate risk.c 63
IIb B
CTCA or functional imaging (radionuclide myocardial perfusion imaging, stress cardiac magnetic resonance imaging, or
exercise or pharmacological stress echocardiography) may be considered in asymptomatic patients with DM for
screening of CAD.47,48,64,65,6770
IIb B
ABI may be considered as a risk modifier in CV risk assessment.76 IIb B
Detection of atherosclerotic plaque of carotid or femoral arteries by CT, or magnetic resonance imaging, may be con-
sidered as a risk modifier in patients with DM at moderate or high risk CV.c 75,77
IIb B
Carotid ultrasound intimamedia thickness screening for CV risk assessment is not recommended.62,73,78 III A
Routine assessment of circulating biomarkers is not recommended for CV risk stratification.27,31,3537 III B
Risk scores developed for the general population are not recommended for CV risk assessment in patients with DM. III C
ABI = anklebrachial index; CAC = coronary artery calcium; CAD = coronary artery disease; CT = computed tomography; CTCA = computed tomography coronary angiog-
raphy; CV = cardiovascular; CVD = cardiovascular disease; DM = diabetes mellitus; ECG = electrocardiogram.
aClass of recommendation.
bLevel of evidence.
cSee Table 7.
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6 Prevention of cardiovascular
disease in patients with diabetes
and pre-diabetes
6.1 Lifestyle
Key messages
• Lifestyle changes are key to prevent DM and its CV
complications.
• Reduced calorie intake is recommended to lower excessive
body weight in patients with DM.
• A Mediterranean diet supplemented with olive oil and/or
nuts reduces the incidence of major CV events.
• Moderate-to-vigorous physical activity of >_150 min/week is
recommended for the prevention and control of DM.
American and European Guidelines advocate lifestyle changes as a
first measure for the prevention and management of DM.27,7981
Even modest weight loss delays progression from pre-DM to
T2DM.82,83 A recent meta-analysis of 63 studies (n=17 272, mean age
49.7 years), showed that each additional kilogram loss was associated
with 43% lower odds of T2DM.84 The relatively small Finnish
Diabetes Prevention Study and the Da Qing Diabetes Prevention
Study have both shown that lifestyle intervention in IGT significantly
reduces the development of T2DM, with a reduction in vascular
complications in the Chinese cohort.85,86 The 30 year results from
the Da Qing study are further strengthening this conclusion.87
Results from the long-term follow-up of the Diabetes Prevention
Program support the view that lifestyle intervention or metformin
significantly reduce DM development over 15 years.88
In established DM, lower calorie intake causes a fall in HbA1c and
improves quality of life.83 Maintenance of weight loss for 5 years is
associated with sustained improvements in HbA1c and lipid levels.89
For many obese patients with DM, weight loss of >5% is needed to
improve glycaemic control, lipid levels, and blood pressure (BP).90
One-year results from the Action for Health in Diabetes (Look
AHEAD) trial, investigating the effects of weight loss on glycaemia and
the prevention of CVD events in patients with DM, showed that an
average 8.6% weight loss was associated with a significant reduction in
HbA1c and CVRFs. Although these benefits were sustained for 4 years,
there was no difference in CV events between groups.91 The Diabetes
Remission Clinical Trial (DiRECT)—an open-label, cluster-randomized
trial—assigned practices to provide either a weight-management pro-
gramme (intervention) or best-practice care by guidelines (control).
The results showed that at 12 months, almost one-half of the partici-
pants achieved remission to a non-diabetic state and were off glucose-
lowering drugs.92 Sustained remissions at 24 months for over one-
third of people with T2DM have been confirmed recently.93
Bariatric surgery causes long-term weight loss, and reduces DM
and risk factor elevations, with effects that are superior to lifestyle
and intensive medical management alone.94,95
6.1.1 Diet
Nutrient distribution should be based on an individualized assess-
ment of current eating patterns, preferences, and metabolic
goals.81,83 In the Prevencion con Dieta Mediterranea (PREDIMED)
study, among people at high CV risk (49% had DM), a Mediterranean
diet supplemented with olive oil or nuts reduced the incidence of
major CV events.96
6.1.1.1 Carbohydrate
The role of low-carbohydrate diets in patients DM remains unclear. A
recent meta-analysis based on 10 RCTs comprising 1376 individuals has
shown that the glucose-lowering effects of low- and high-carbohydrate
diets are similar at 1 year or later, and have no significant effect on
weight or low-density lipoprotein cholesterol (LDL-C) levels.97
6.1.1.2 Fats
The ideal amount of dietary fat for individuals with DM is controver-
sial. Several RCTs including patients with DM have reported that a
Mediterranean-style eating pattern,96,98,99 rich in polyunsaturated
and monounsaturated fats, can improve both glycaemic control and
blood lipids. Supplements with n-3 fatty acids have not been shown
to improve glycaemic control in individuals with DM,100 and RCTs do
not support recommending n-3 supplements for the primary or sec-
ondary prevention of CVD.101,102 The Reduction of Cardiovascular
Events with Icosapent EthylIntervention Trial (REDUCE-IT)—using
a higher dose of n3-fatty acids (4 g/day) in patients with persistent ele-
vated triglycerides, and either established CVD or DM, and at least
one other CVD risk factor—showed a significant reduction of the
primary endpoint of major adverse CV events (MACE).103 Patients
with DM should follow guidelines for the general population for the
recommended intakes of saturated fat, dietary cholesterol, and trans
fat. In general, trans fats should be avoided.
6.1.1.3 Proteins
Adjusting daily protein intake is not indicated in patients with DM
unless kidney disease is present, at which point less protein is
recommended.
6.1.1.4 Vegetables, legumes, fruits, and wholegrain cereals
Vegetables, legumes, fruits, and wholegrain cereals should be part of
a healthy diet.104
6.1.1.5 Alcohol consumption
A recent meta-analysis indicated that whilst low levels of alcohol
(<_100 g/week) were associated with a lower risk of MI, there were
no clear thresholds below which lower alcohol consumption
stopped being associated with a lower disease risk for other CV out-
comes such as hypertension, stroke, and HF. Moderate alcohol intake
should not be promoted as a means to protect against CVD.27,105
6.1.1.6 Coffee and tea
Consumption of more than four cups of coffee per day was associ-
ated with a lower risk of CVD in Finnish patients with DM.106 An
exception should be made for coffee brewed by boiling ground cof-
fee, which increases cholesterol levels.107 In a meta-analysis of 18
observational studies, increasing coffee or tea consumption appeared
to reduce the risk of DM.108
6.1.1.7 Vitamins and macronutrients
Vitamin or micronutrient supplementation to reduce the risk of DM
or CVD in patients with DM is not recommended.96,97
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6.1.2 Physical activity
Physical activity delays conversion of IGT to T2DM, and improves gly-
caemic control and CVD complications.109 Aerobic and resistance
training improve insulin action, glycaemic control, lipid levels, and
BP.110 RCTs support the need for exercise reinforcement by health-
care workers,111 and structured aerobic exercise or resistance exer-
cise has been shown to reduce HbA1c by 0.6% in patients with
DM.111 Clinical trials in adults with DM have provided evidence of the
HbA1c-lowering value of resistance training, and of an additive benefit
of combined aerobic and resistance exercise.112 Patients with pre-DM
and DM should do two sessions per week of resistance exercise; preg-
nant women with DM should engage in regular moderate physical
activity.113 Encouragement to increase activity by any level yields bene-
fits; even an extra 1000 steps of walking per day would be advanta-
geous and may be a good starting point for many patients.
6.1.3 Smoking
Smoking increases the risk of DM,114 CVD, and premature death115
and should be avoided, including passive smoking.116 If advice,
encouragement, and motivation are insufficient, then drug therapies
should be considered early, including nicotine replacement therapy
followed by bupropion or varenicline.117 Electronic cigarettes (e-cig-
arettes) are an emerging smoking cessation aid worldwide; however,
consensus regarding their efficacy and safety has yet to be reached.
Smoking cessation programmes have low efficacy at 12 months.118
Gaps in the evidence
• Adherence to lifestyle changes.
• Ethnicity and diet.
• Effects of lifestyle measures on clinical outcomes.
• Lifestyle advice in different stages of life, e.g. in frail and elderly
patients.
• Tailored exercise interventions in different ethnic groups and
patient categories.
6.2 Glucose
Key messages
• Glucose control to target a near-normal HbA1c (<7.0% or
<53 mmol/mol) will decrease microvascular complications in
patients with DM.
• Tighter glucose control initiated early in the course of DM in
younger individuals leads to a reduction in CV outcomes
over a 20 year timescale.
• Less-rigorous targets should be considered in elderly patients
on a personalized basis and in those with severe comorbid-
ities or advanced CVD.
6.2.1 Glycaemic targets
A meta-analysis of three major studies—Action to Control
Cardiovascular Risk in Diabetes (ACCORD), Action in Diabetes and
Vascular Disease: Preterax and Diamicron Modified Release
Controlled Evaluation (ADVANCE), and the Veterans Affairs
Diabetes Trial (VADT)—suggested that in T2DM, an HbA1c reduc-
tion of 1% is associated with a 15% relative risk reduction in
non-fatal MI, without beneficial effects on stroke, CV, or all-cause
mortality121 or hospitalization for HF.122 Intensive glucose control
was beneficial for CV events in patients with a short duration of DM,
lower HbA1c at baseline, and no CVD.122 In addition, the Diabetes
Control and Complications Trial/Epidemiology of Diabetes
Interventions and Complications study (DCCT/EDIC) (T1DM), the
UK Prospective Diabetes Study (UKPDS), and VADT (T2DM)
showed that long follow-up (<_20 years) is necessary to demonstrate
a beneficial effect on macrovascular complications, and that early glu-
cose control is associated with long-term CV benefits (legacy
effect).123 An HbA1c target of <7% (<53 mmol/mol) reduces micro-
vascular complications, while evidence for an HbA1c target to reduce
macrovascular risk is less compelling. However, HbA1c targets
should be individualized, with more-stringent goals [6.06.5%
(4248 mmol/mol)] in younger patients with a short duration of DM
and no evidence of CVD, if achieved without significant hypoglycae-
mia. Less-stringent HbA1c goals [e.g. <8% (64 mmol/mol) or <_9%
(75 mmol/mol)] may be adequate for elderly patients with long-
standing DM and limited life expectancy, and frailty with multiple
comorbidities, including hypoglycaemic episodes.
6.2.1.1 Additional glucose targets
Post-prandial glucose testing should be recommended for patients
who have pre-meal glucose values at target but HbA1c above target.
Recommendations for lifestyle modifications in patients
with diabetes and pre-diabetes
Recommendations Classa Levelb
Smoking cessation guided by structured advice is
recommended in all individuals with DM and pre-
DM.27,117
I A
Lifestyle intervention is recommended to delay or
prevent the conversion of pre-DM states, such as
IGT, to T2DM.85,86
I A
Reduced calorie intake is recommended for low-
ering excessive body weight in individuals with
pre-DM and DM.c 82,83,89,90
I A
Moderate-to-vigorous physical activity, notably a
combination of aerobic and resistance exercise, for
>_150 min/week is recommended for the prevention
and control of DM, unless contraindicated, such as
when there are severe comorbidities or a limited life
expectancy.d 110,111113,119
I A
A Mediterranean diet, rich in polyunsaturated and
monounsaturated fats, should be considered to
reduce CV events.96,97
IIa B
Vitamin or micronutrient supplementation to
reduce the risk of DM, or CVD in patients with
DM, is not recommended.79,120
III B
CV = cardiovascular; CVD = cardiovascular disease; DM = diabetes mellitus; IGT
= impaired glucose tolerance; T2DM = type 2 diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
cA commonly stated goal for obese patients with DM is to lose 5% of baseline
weight.
dIt is recommended that all individuals reduce the amount of sedentary time by
breaking up periods of sedentary activity with moderate-to-vigorous physical
activity in bouts of >_10 min (broadly equivalent to 1000 steps).
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Several epidemiological studies have shown that high post-challenge
(2 h OGTT) or post-prandial glucose values are associated with
greater CV risk, independent of FPG.124126 Intervention trials have
failed to support the role of post-prandial glucose as a CVRF inde-
pendent of HbA1c. The Hyperglycemia and Its Effect After Acute
Myocardial Infarction on Cardiovascular Outcomes in Patients With
Type 2 Diabetes Mellitus (HEART2D) trial, an RCT that assigned
patients with DM within 21 days after an acute MI to insulin regimens
targeting either post-prandial or pre-prandial glucose, reported dif-
ferences in FPG, less-than-expected differences in post-prandial PG,
similar levels of HbA1c, and no difference in risk of future CV
events.127 However, in a post hoc analysis, this risk was significantly
lower in older patients treated with an insulin regimen targeting post-
prandial glycaemia.128 The ACE (Acarbose Cardiovascular
Evaluation) trial, in Chinese patients with CAD and IGT, showed that
acarbose did not reduce the risk of MACE, but did reduce the inci-
dence of DM by 18%.129
FPG variability has been reported to be a strong predictor of all-
cause and CVD-related mortality in patients with DM, suggesting that
management of glucose variability may become an additional goal.130
In the intensive arm of the ADVANCE study, an increase in HbA1c
and fasting glucose variability was associated with the risk of macro-
vascular events.131 In insulin-treated DM, an association between
fasting glucose variability and total mortality was also reported in the
pooled population of the Trial Comparing Cardiovascular Safety of
Insulin Degludec versus Insulin Glargine in Patients with Type 2
Diabetes at High Risk of cardiovascular Events (DEVOTE).132
Glucose variability increases in the presence of pre-DM.133
However, the role of glucose variability in CVD is difficult to dissect.
In patients with DM, mean blood glucose and HbA1c are more
strongly associated with CVD risk factors than FPG, post-prandial
glucose levels, or measures of glucose variability using continuous glu-
cose monitoring.134 Drugs that reduce post-prandial glucose excur-
sions, including glucagon-like peptide-1 receptor agonists (GLP1-
RAs), dipeptidyl peptidase-4 (DPP4) inhibitors, and sodium-glucose
co-transporter 2 (SGLT2) inhibitors, seem an attractive way to
reduce glucose variability.135
6.2.2 Glucose-lowering agents
Therapeutic agents that manage hyperglycaemia can be broadly
characterized as belonging to one of five groups: (i) insulin sensi-
tizers (metformin and pioglitazone); (ii) insulin providers (insulin,
sulfonylureas, and meglitinides); (iii) incretin-based therapies
(GLP1-RAs and DPP4 inhibitors); (iv) gastrointestinal glucose
absorption inhibitor (acarbose); and (v) renal glucose
reuptake inhibitors (SGLT2 inhibitors). For further details see sec-
tions 7.1.1 and 7.1.2.
6.2.3 Special considerations
6.2.3.1 Hypoglycaemia
Although studies suggest an association between hypoglycaemia and
CV events, there is no clear evidence for causality. Prevention of
hypoglycaemia remains critical, particularly with advanced disease or
CVD (including HF), to reduce the risk of arrhythmias and myocardial
ischaemia.136 Several studies, including Diabetes Mellitus Insulin-
Glucose Infusion in Acute Myocardial Infarction 2 (DIGAMI 2),137
ADVANCE,138 and Outcome Reduction With Initial Glargine
Intervention (ORIGIN), have indicated that severe hypoglycaemia is
associated with increased risk of death and an impaired CV progno-
sis,139 whilst DEVOTE reported decreased hypoglycaemia but failed
to show a difference in MACE.140
6.2.3.2 Glucose monitoring
Structured self-monitoring of blood glucose and continuous glucose
monitoring are valuable tools to improve glycaemic control.141
Electronic ambulatory glucose142 has been shown to reduce the time
spent in hypoglycaemia and to increase the time when glucose is
within the recommended range.142144
Gaps in the evidence
• More research is needed to define a ‘personalized’ target for
patients with DM.
• The role of new glucose-monitoring technologies (continuous
glucose monitoring and electronic ambulatory glucose) in the
control of post-prandial glycaemia and glucose variability
needs to be defined.
• The roles of these new technologies in the prevention of
DM complications needs to be tested.
Recommendations for glycaemic control in patients
with diabetes
Recommendations Classa Levelb
It is recommended to apply tight glucose con-
trol, targeting a near-normal HbA1c (<7.0%
or <53 mmol/mol), to decrease microvascular
complications in individuals with DM.145149
I A
It is recommended that HbA1c targets are
individualized according to the duration of
DM, comorbidities, and age.122,150
I C
Avoidance of hypoglycaemia is
recommended.136,139,140,151
I C
The use of structured self-monitoring of blood
glucose and/or continuous glucose monitoring
should be considered to facilitate optimal gly-
caemic control.141144
IIa A
An HbA1c target of <7.0% (or <53 mmol/
mol) should be considered for the prevention
of macrovascular complications in individuals
with DM.
IIa C
DM = diabetes mellitus; HbA1c = haemoglobin A1c.
aClass of recommendation.
bLevel of evidence.
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6.3 Blood pressure
Key messages
• The BP goal is to target systolic BP (SBP) to 130 mmHg in
patients with DM and <130 mmHg if tolerated, but not <120
mmHg. In older people (aged >65 years), the SBP goal is to a
range of 130 - 139 mmHg.
• The diastolic BP (DBP) target is <80 mmHg, but not
<70 mmHg.
• Optimal BP control reduces the risk of micro- and macrovas-
cular complications.
• Guidance on lifestyle changes must be provided for patients
with DM and hypertension.
• Evidence strongly supports the inclusion of an angiotensin-
converting enzyme inhibitor (ACEI), or an angiotensin recep-
tor blocker (ARB) in patients who are intolerant to ACEI.
• BP control often requires multiple drug therapy with a
reninangiotensinaldosterone system (RAAS) blocker, and
a calcium channel blocker or diuretic. Dual therapy is recom-
mended as first-line treatment.
• The combination of an ACEI and an ARB is not
recommended.
• In pre-DM, the risk of new-onset DM is lower with RAAS
blockers than with beta-blockers or diuretics.
• Patients with DM on combined antihypertensive treatments
should be encouraged to self-monitor BP.
The prevalence of hypertension is high in patients with DM, reach-
ing <_67% after 30 years of T1DM152 and >60% in T2DM. Mediators
of increased BP in patients with DM involve factors linked to obesity,
including hyperinsulinaemia.153
6.3.1 Treatment targets
RCTs have shown the benefit (reduction of stroke, coronary events,
and kidney disease) of lowering SBP to <140 mmHg and DBP to <90
mmHg in DM patients. In a meta-analysis of 13 RCTs involving
patients with DM or pre-DM, a SBP reduction to 131135 mmHg
reduced the risk of all-cause mortality by 13%, whereas more-
intensive BP control (<_130 mmHg) was associated with a greater
reduction in stroke but did not reduce other events.154 In a meta-
analysis, antihypertensive treatment significantly reduced mortality,
CAD, HF, and stroke, with an achieved mean SBP of 138 mmHg,
whereas only stroke was reduced significantly, with a mean SBP of
122 mmHg.155 Reducing SBP to <130 mmHg may benefit patients
with a particularly high risk of a cerebrovascular event, such as those
with a history of stroke.154157 The UKPDS post-trial 10 year follow-
up study reported no persistence of the benefits of the earlier period
of tight BP control with respect to macrovascular events, death, and
microvascular complications, while initial between-group BP differen-
ces were no longer maintained.149 In the ADVANCE trial, the combi-
nation of perindopril and indapamide reduced mortality, and the
benefit was still present, but attenuated, at the end of the 6 year post-
trial follow-up, without evidence of a sex difference.159 Thus, optimal
BP control is important in reducing the risk of micro- and macrovas-
cular complications, and must be maintained if these benefits are to
be sustained.
In patients with DM receiving BP-lowering drugs, it is recom-
mended that office BP should be targeted to an SBP of 130 mmHg,
and lower if tolerated. In older patients (aged >_65 years) the SBP tar-
get range should be 130140 mmHg if tolerated. In all patients with
DM, SBP should not be lowered to <120 mmHg and DBP should be
lowered to <80 mmHg.160
6.3.2 Management of blood pressure lowering
6.3.2.1 Effects of lifestyle intervention and weight loss
Reduction of sodium intake (to <100 mmol/day); diets rich in vegeta-
bles, fruits, and low-fat dairy products; and Mediterranean diets have
all been demonstrated to improve BP control.161163 As a result of
long-term exercise training intervention, modest but significant
reductions in systolic (by -7 mmHg) and diastolic (by -5 mmHg) BP
are observed. Ideally, an exercise prescription aimed at lowering BP
in individuals with normal BP or hypertension would include a mix of
predominantly aerobic exercise training supplemented with dynamic
resistance exercise training.164
A marked improvement in CVRFs (hypertension, dyslipidaemia,
inflammation, and DM), associated with marked weight loss, was
observed after bariatric surgery.165 In the Look AHEAD trial, those
who lost 5 to <10% of body weight had increased odds of achieving a
5 mmHg decrease in SBP and DBP.166
6.3.2.2 Pharmacological treatments
If office SBP is >_140 mmHg and/or DBP is >_90 mmHg, drug therapy
is necessary in combination with non-pharmacological therapy. All
available BP-lowering drugs (except beta-blockers) can be used, but
evidence strongly supports the use of a RAAS blocker, particularly in
patients with evidence of end-organ damage (albuminuria and LV
hypertrophy).167170 BP control often requires multiple drug therapy
with a RAAS blocker, and a calcium channel blocker or a diuretic,
while the combination of an ACEI with an ARB is not recom-
mended.171 A combination of two or more drugs at fixed doses in a
single pill should be considered, to improve adherence. The beta-
blocker/diuretic combination favours the development of DM, and
should be avoided in pre-DM, unless required for other reasons.
Among beta-blockers, nebivolol has been shown not to affect insulin
sensitivity in patients with metabolic syndrome.172
A meta-analysis in which ACEIs or ARBs were compared with pla-
cebo reported a reduced incidence of new-onset DM [odds ratio 0.8,
95% confidence interval (CI) 0.80.9; P < 0.01] and CV mortality
(odds ratio 0.9, 95% CI 0.81.0; P < 0.01) on active therapy.173 In
patients with pre-DM, ramipril did not significantly reduce the inci-
dence of DM, but significantly increased regression to normoglycae-
mia.174 In patients with IGT, valsartan significantly reduced the
incidence of new-onset DM.175
6.3.2.3 Blood pressure changes with glucose-lowering treatments
Trials testing GLP1-RAs have shown evidence of a slight, but significant,
BP decrease, partly due to weight loss. In the Liraglutide Effect and
Action in Diabetes: Evaluation of Cardiovascular Outcome Results
(LEADER) trial, a sustained decrease was observed (SBP/DBP 1.2/
0.6 mmHg) with a slight increase in heart rate (3 b.p.m.).176 SGLT2
inhibitors induced a larger BP decrease (SBP/DBP 2.46/1.46
mmHg) without heart rate changes.177 The BP-lowering effects of
these drugs have to be taken into consideration when managing BP.
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Gaps in the evidence
• Optimal BP targets are unknown, particularly in young
patients with T1DM, recent-onset T2DM, and DM with
CAD.
• The role of stabilization or reversal of end-organ damage
(including albuminuria, LV hypertrophy, and arterial stiffness),
beyond BP control, is poorly known.
• Is treatment with GLP-RAs and SGLT2 inhibitors affecting
the current treatment algorithms for BP lowering?
• The interaction of GLP1-RAs and SGLT2 inhibitors with BP-
lowering treatments, in terms of CV prognosis, is unknown.
6.4 Lipids
Key messages
• Statins effectively prevent CV events and reduce CV mortal-
ity, and their use is associated with a limited number of
adverse events. Because of the high-risk profile of patients
with DM, intensive statin treatment should be used on an
individualized basis.
• Currently, statins remain state-of-the-art therapy in lipid-
lowering treatment in patients with DM.
• Ezetimibe or a proprotein convertase subtilisin/kexin type 9
(PCSK9) inhibitor on top of a statin—or alone, in case of
documented intolerance to statins—further contribute to
LDL-C reduction in patients with DM, thus improving CV
outcomes and reducing CV mortality.
A cluster of lipid and apolipoprotein abnormalities accompanies
DM. The two core components are moderate elevation of fasting
and non-fasting triglycerides, and low high-density lipoprotein choles-
terol (HDL-C). Other features comprise elevation of triglyceride-
rich lipoproteins, including chylomicron and very low-density lipo-
protein remnants, and normal-to-mildly elevated levels of LDL-C,
with small dense low-density lipoprotein particles. In well-controlled
T1DM, HDL-C levels tend to be normal (or even slightly elevated),
as do serum triglyceride levels.186
6.4.1 Lipid-lowering agents
6.4.1.1 Statins
Consistent data have demonstrated the efficacy of statins in prevent-
ing CV events and reducing CV mortality in patients with DM, with
Recommendations for the management of blood pressure in patients with diabetes and pre-diabetes
Recommendations Classa Levelb
Treatment targets
Antihypertensive drug treatment is recommended for people with DM when office BP is >140/90 mmHg.155,178180 I A
It is recommended that patients with hypertension and DM are treated in an individualized manner. The BP goal is to tar-
get SBP to 130 mmHg and <130 mmHg if tolerated, but not <120 mmHg. In older people (aged >65 years), the SBP goal
is to a range of 130 - 139 mmHg.155,159,160,181183
I A
It is recommended that target DBP is targeted to <80 mmHg, but not <70 mmHg.160 I C
An on-treatment SBP of <130 mmHg may be considered in patients at particularly high risk of a cerebrovascular event,
such as those with a history of stroke.154157,173
IIb C
Treatment and evaluation
Lifestyle changes [weight loss if overweight, physical activity, alcohol restriction, sodium restriction, and increased con-
sumption of fruits (e.g. 23 servings), vegetables (e.g. 23 servings), and low-fat dairy products] are recommended in
patients with DM and pre-DM with hypertension.161163,166
I A
A RAAS blocker (ACEI or ARB) is recommended in the treatment of hypertension in patient with DM, particularly in the
presence of microalbuminuria, albuminuria, proteinuria, or LV hypertrophy.167170
I A
It is recommended that treatment is initiated with a combination of a RAAS blocker with a calcium channel blocker or
thiazide/thiazide-like diuretic.167171
I A
In patients with IFG or IGT, RAAS blockers should be preferred to beta-blockers or diuretics to reduce the risk of new-
onset DM.173175
IIa A
The effects of GLP1-RAs and SGLT2 inhibitors on BP should be considered. IIa C
Home BP self-monitoring should be considered in patients with DM on antihypertensive treatments to check that their
BP is appropriately controlled.184
IIa C
24 h ABPM should be considered to assess abnormal 24 h BP patterns and adjust antihypertensive treatment.185 IIa C
ABPM = ambulatory blood pressure monitoring; ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; BP = blood pressure; DBP = diastolic
blood pressure; DM = diabetes mellitus; GLP1-RA = glucagon-like peptide-1 receptor agonist; IFG = impaired fasting glycaemia; IGT = impaired glucose tolerance; LV = left ven-
tricular; RAAS = reninangiotensinaldosterone system; SBP = systolic blood pressure; SGLT2 = sodium-glucose co-transporter 2.
aClass of recommendation.
bLevel of evidence.
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no evidence for sex differences. A meta-analysis including 18 686
patients with DM demonstrated that a statin-induced reduction of
LDL-C by 1.0 mmol/L (40 mg/dL) was associated with a 9% reduction
in all-cause mortality and a 21% reduction in the incidence of major
CV events.187 Similar benefits were seen in both T1DM and T2DM.
In patients with an ACS, intensive statin treatment led to a reduction
in all-cause and CV death, and contributed to a reduction in athe-
roma progression.188 In both T1DM and young-onset T2DM, there is
a paucity of evidence to indicate the age at which statin therapy
should be initiated. To guide an approach, statins are not indicated in
pregnancy,189,190 and should be avoided in women with T1DM or
T2DM who are planning pregnancy. In the absence of vascular dam-
age, and in particular microalbuminuria, it seems reasonable to delay
statin therapy in asymptomatic patients with DM until the age of 30
years. Below this age, statin therapy should be managed on a case-by-
case basis taking into account the presence of microalbuminuria, end-
organ damage, and ambient LDL-C levels.
Statins are safe and generally well tolerated. Adverse events, except
for muscle symptoms, are rare. In the majority of cases of myopathy or
rhabdomyolysis, there are drug interactions with a higher-than-
standard dose of statin or combination with gemfibrozil.191,192
Evidence indicates that most patients (7090%) who report statin
intolerance are able to take a statin when rechallenged.193196 Patients
may be rechallenged with the same statin unless they have creatine kin-
ase elevation. Evidence supports a lower rate of side effects with low-
dose rosuvastatin or pravastatin.193196
Statin therapy has been associated with new-onset DM: for every
40 mmol/L (mg/dL) reduction of LDL-C by statins, conversion to DM
is increased by 10%.197,198 The risk of new-onset DM increases with
age and is confined to those already at risk of developing DM.199
Nevertheless, the benefits in terms of CV event reduction greatly
exceed the risks of statin therapy, and this has been confirmed in
patients at low CV risk.187
6.4.1.2 Ezetimibe
Further intensification of LDL-C lowering occurs by adding ezetimibe
to a statin. In the Improved Reduction of Outcomes: Vytorin Efficacy
International Trial (IMPROVE-IT), a significant reduction of the pri-
mary endpoint event rate (HR 0.85, 95% CI 0.780.94) for post-
ACS patients with DM receiving simvastatin plus ezetimibe was
reported, with a stronger beneficial effect on outcome than in non-
DM. The results in this subgroup were mainly driven by a lower inci-
dence of MI and ischaemic stroke.200,201 The combination of ezeti-
mibe with a statin should be recommended to patients with DM with
a recent ACS, particularly when the statin alone is not sufficient to
reduce LDL-C levels to <1.4 mmol/L (55 mg/dL).
6.4.1.3 Proprotein convertase subtilisin/kexin type 9
The new entry among lipid-lowering therapies is the PCSK9 inhibi-
tors, which reduce LDL-C to an unprecedented extent. In the
Efficacy and Safety of Alirocumab in Insulin-treated Individuals with
Type 1 or Type 2 Diabetes and High Cardiovascular Risk
(ODYSSEY DM-INSULIN) trial, alirocumab, compared with pla-
cebo, reduced LDL-C by 50% in patients with DM after 24 weeks
of treatment.202 In the Further Cardiovascular Outcomes
Research with PCSK9 Inhibition in Subjects with Elevated Risk
(FOURIER) trial, patients with atherosclerotic CVD on statin ther-
apy were randomly assigned to a fixed dose of evolocumab or pla-
cebo. The results demonstrated that the primary composite
endpoint (CV death, MI, stroke, hospital admission for unstable
angina, or coronary revascularization) was significantly
reduced.203,204 Similar results were obtained from the ODYSSEY
OUTCOMES (Evaluation of Cardiovascular Outcomes After an
Acute Coronary Syndrome During Treatment With Alirocumab)
trial, which randomly assigned patients with CVD and LDL-C >1.8
mmol/L (70 mg/dL), despite high-intensity statins, to alirocumab or
placebo, with dose titration of the active drug targeting an LDL-C
level of 0.6 - 1.3 mmol/L (25 - 50 mg/dL). Alirocumab significantly
reduced the risk of the primary composite endpoint (CV death,
MI, stroke, or hospital admission for unstable angina) compared
with placebo, with the greatest absolute benefit of alirocumab
seen in patients with baseline LDL-C levels >2.6 mmol/L
(100 mg/dL).205 In a subgroup analysis of the ODYSSEY
OUTCOMES trial, patients with DM (n=5444) had double the
absolute risk reduction compared with pre-DM (n=8246) and
non-DM (n=5234) subjects (2.3 vs. 1.2%, respectively).206 At
present, these results should be regarded as exploratory.
6.4.1.4 Fibrates
In patients with high triglyceride levels [>_2.3 mmol/L (200 mg/dL)],
lifestyle advice (with a focus on weight reduction and alcohol abuse, if
relevant) and improved glucose control are the main targets. Both
the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD)
and ACCORD studies demonstrated that administration of fenofi-
brate on top of statins significantly reduced CV events, but only in
patients who had both elevated triglyceride and reduced HDL-C lev-
els.191,207 Gemfibrozil should be avoided because of the risk of myo-
pathy. A meta-analysis of fibrate trials reported a significant reduction
in non-fatal MI, with no effect on mortality.208 Fibrates may be admin-
istered in patients with DM who are statin intolerant and have high
triglyceride levels. If triglycerides are not controlled by statins or
fibrates, high-dose omega-3 fatty acids (4 g/day) of icosapent ethyl
may be used.209,103
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Gaps in the evidence
• The optimal LDL-C level needs to be established.
• The effects of fibrates on CV outcomes in patients with trigly-
cerides >2.3 mmol/L are unclear.
• The role of PCSK9 inhibitors in patients with DM remains to
be further elucidated.
6.5 Platelets
Key messages
• Patients with DM and symptomatic CVD should be treated
no differently to patients without DM.
• In patients with DM at moderate CV risk, aspirin for primary
prevention is not recommended.
• In patients with DM at high/very high risk, aspirin may be con-
sidered in primary prevention.
Several abnormalities have been described concerning in vivo and/
or ex vivo platelet function, and increased platelet activation in
patients with DM. Hyperglycaemia,216 low-degree inflammation,217
and increased oxidation may contribute to in vivo platelet activation
and altered responsiveness to antithrombotic drugs in patients with
DM. However, platelet abnormalities and poor antiplatelet drug
responsiveness have also been described in patients with DM with
good metabolic control.218220 A dysmegakaryopoiesis may charac-
terize DM, resulting in increased platelet mass,221 an altered ratio
between platelet count and volume,221,222 megakaryocyte aneu-
ploidy,223 and increased reticulated platelets in the peripheral
blood.219 In addition, platelet thrombin generation appears enhanced,
clot type appears to be altered, and fibrinolysis reduced in patients
with DM.224
6.5.1 Aspirin
Aspirin permanently inhibits cyclooxygenase 1 activity and throm-
boxane A2-dependent platelet aggregation.
225 Small, proof-of-
concept, pharmacodynamic, randomized studies have consistently
shown that once-daily low-dose aspirin may be insufficient to fully
inhibit platelet cyclooxygenase 1 activity in patients with
Recommendations for the management of dyslipidaemia with lipid-lowering drugs
Recommendations Classa Levelb
Targets
In patients with T2DM at moderate CV risk,c an LDL-C target of <2.6 mmol/L (<100 mg/dL) is recommended.210212 I A
In patients with T2DM at high CV risk,c an LDL-C target of <1.8 mmol/L (<70 mg/dL) and LDL-C reduction of at least
50% is recommended.d 210212
I A
In patients with T2DM at very high CV risk,c an LDL-C target of <1.4 mmol/L (<55 mg/dL) and LDL-C reduction of at
least 50% is recommended.d 200,201,210
I B
In patients with T2DM, a secondary goal of a non-HDL-C target of <2.2 mmol/L (<85 mg/dL) in very high CV-risk
patients, and <2.6 mmol/L (<100 mg/dL) in high CV-risk patients, is recommended.d,213,214
I B
Treatment
Statins are recommended as the first-choice lipid-lowering treatment in patients with DM and high LDL-C levels: adminis-
tration of statins is defined based on the CV risk profile of the patientc and the recommended LDL-C (or non-HDL-C)
target levels.187
I A
If the target LDL-C is not reached, combination therapy with ezetimibe is recommended.200,201 I B
In patients at very high CV risk, with persistent high LDL-C despite treatment with a maximum tolerated statin dose, in
combination with ezetimibe, or in patients with statin intolerance, a PCSK9 inhibitor is recommended.203206
I A
Lifestyle intervention (with a focus on weight reduction, and decreased consumption of fast-absorbed carbohydrates and
alcohol) and fibrates should be considered in patients with low HDL-C and high triglyceride levels.191,207
IIa B
Intensification of statin therapy should be considered before the introduction of combination therapy. IIa C
Statins should be considered in patients with T1DM at high CV risk,c irrespective of the baseline LDL-C level.187,215 IIa A
Statins may be considered in asymptomatic patients with T1DM beyond the age of 30 years. IIb C
Statins are not recommended in women of childbearing potential.189,190 III A
CV = cardiovascular; DM = diabetes mellitus; EAS = European Atherosclerosis Society; ESC = European Society of Cardiology; HDL-C = high-density lipoprotein cholesterol;
LDL-C = low-density lipoprotein cholesterol; PCSK9 = proprotein convertase subtilisin/kexin type 9; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
cSee Table 7.
dSee the 2019 ESC/EAS Guidelines for the management of dyslipidaemias for non-HDL-C and apolipoprotein B targets.
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DM218220,226 and increased platelet turnover.219 This would sup-
port testing different regimens [e.g. b.i.d. (twice daily)] of low-dose
aspirin in patients with DM in RCTs.
6.5.1.1 Primary prevention
Although aspirin has unquestionable benefits in the secondary pre-
vention of CVD (see section 6.5.1.2), the situation is less clear in pri-
mary prevention. In 2009, the Antithrombotic Trialists’ Collaboration
published a meta-analysis of primary prevention trials including
95 000 individuals at low risk.227 They reported a 12% reduction in
CVD outcomes with aspirin, but a significant increase in major bleeds,
which cast doubt on the value of aspirin under these circumstances.
Since then, further trials have reported similar or no reduction in CV
outcomes, but the risk of major bleeds is consistent across stud-
ies.228,229 Gender studies of aspirin use have revealed similar bleeding
risks in men and women, and similar 12% reductions in CV events in
both sexes, driven by a decrease in ischaemic stroke in women and
of MI in men.229 Recent large trials in patients at moderate risk, which
(i) excluded DM230 and (ii) specifically recruited patients with DM,231
were unable to progress the argument that aspirin should be used in
primary prevention. The A Study of Cardiovascular Events iN
Diabetes (ASCEND) trial randomized 15 480 patients with DM with
no evident CVD to aspirin 100 mg once daily [o.d. (onmi die)] or pla-
cebo.231 The primary efficacy outcome (MI, stroke, transient ischae-
mic attack, or death from any cause) occurred in 658 patients (8.5%)
on aspirin vs. 743 (9.6%) on placebo (rate ratio 0.88, 95% CI
0.790.97; P=0.01). Major bleeding occurred in 314 (4.1%) patients
on aspirin vs. 245 (3.2%) on placebo (rate ratio 1.29, 95% CI
1.091.52; P=0.003). There were no differences in fatal or intracra-
nial bleeding, and a substantial proportion (25%) of the major
bleeds defined according to ASCEND were in the upper gastrointes-
tinal tract. The number needed to treat/number needed to harm
ratio was 0.8. A recent meta-analysis demonstrated that the proton
pump inhibitors provide substantial protection from upper gastroin-
testinal bleeding with an odds ratio of 0.20.232 It should be empha-
sized that only one in four patients in the ASCEND trial were being
treated with a proton pump inhibitor at the end of the study, and
wider use in trials could potentially amplify the benefit of aspirin in
primary prevention.
It has been recently suggested that body weight233 or size can
lower responsiveness to aspirin, as well as to clopidogrel, requiring
higher daily doses.234 Pharmacokinetic data suggest a lower degree of
platelet inhibition, especially in moderate-to-severely obese
patients.234 However, the benefit of intensified antiplatelet regimens
in obese DM patients remains to be established.
6.5.1.2 Secondary prevention
The best available evidence for aspirin in secondary prevention
remains that discussed in the 2013 ESC Guidelines on DM, pre-
diabetes, and CVDs, developed in collaboration with the EASD72
(see section 7.1).
Gaps in the evidence
• More data on CV prevention are needed for T1DM where
in vivo platelet activation has been reported.236
• There is a need to assess the effect of body mass, especially
of moderate-to-severe obesity on antiplatelet drug respon-
siveness and effectiveness in patients with DM, and to investi-
gate higher dose strategies.
• Whether antithrombotic preventive strategy effects in pre-
DM and DM are similar should be explored.
6.6 Multifactorial approaches
Key messages
• Combined reduction in HbA1c, SBP, and lipids decreases CV
events by 75%.
• Multifactorial treatment is still underused.
6.6.1 Principles of multifactorial management
Patients with glucose perturbations may benefit from the early identi-
fication and treatment of comorbidities and factors that increase CV
risk.237 However, many patients are not achieving risk factor goals for
CVD prevention (Table 9). In EUROASPIRE IV, a BP target <140/90
mmHg was achieved in 68% of patients with CAD without DM, in
Recommendations for the use of antiplatelet therapy in
primary prevention in patients with diabetes
Recommendations Classa Levelb
In patients with DM at high/very high risk,c
aspirin (75 - 100 mg/day) may be considered in
primary prevention in the absence of clear
contraindications.d 231
IIb A
In patients with DM at moderate CV risk,c
aspirin for primary prevention is not
recommended.
III B
Gastric protection
When low-dose aspirin is used, proton pump
inhibitors should be considered to prevent
gastrointestinal bleeding.232,235
IIa A
CV = cardiovascular; DM = diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
cSee Table 7.
dGastrointestinal bleeding, peptic ulceration within the previous 6 months, active
hepatic disease, or history of aspirin allergy.
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.61% of patients with newly detected DM, and in 54% of patients with
previously known DM. An LDL-C target <1.8 mmol/L was achieved
in 16, 18, and 28% of these groups, respectively. Furthermore, the
combined use of four cardioprotective drugs (antiplatelets, beta-
blockers, RAAS blockers, and statins) in these groups was only 53,
55, and 60%, respectively.238
In the Swedish national DM registry, the excess risk of out-
comes decreased by each risk factor within the target range
(HbA1c, LDL-C, albuminuria, smoking, and SBP). In T2DM
with variables at target, the HR for all-cause death was 1.06 (95%
CI 1.001.12), 0.84 (95% CI 0.750.93) for acute MI, and 0.95
(95% CI 0.841.07) for stroke. The risk of hospitalization for HF
was consistently higher among patients with DM than controls
(HR 1.45, 95% CI 1.341.57).239
Intensified, multifactorial treatment for DM in primary care and
early in the disease trajectory was evaluated in the Anglo-Danish-
Dutch Study of Intensive Treatment In People with Screen Detected
Diabetes in Primary Care (ADDITION).240 Follow-up (1 and 5 year)
did not show significant reductions in the frequencies of microvascu-
lar241 or macrovascular events.242 Interestingly, modelled 10 year
CVD risk calculated with the UKPDS risk engine was lower in the
intensive-treatment group after adjustment for baseline CV risk
(2.0, 95% CI 3.1 to 0.9).243
A beneficial effect of a multifactorial intervention in patients with
DM and established microalbuminuria was demonstrated by the
Steno-2 study, in which 160 very high-risk patients with DM were
randomized to intensive, target-driven, multifactorial therapy or con-
ventional management. The targets in the intensively treated group
were HbA1c <6.5% (48 mmol/mol), total cholesterol <4.5 mmol/L
(175 mg/dL), and BP <130/80 mmHg. All patients in this group
received RAAS blockers and low-dose aspirin. This approach
resulted in a reduction in microvascular and macrovascular events of
50% after 7.8 years of follow-up. Long-term follow-up (21 years
from baseline) showed that intensive treatment significantly reduced
end-stage renal disease combined with death to HR 0.53 (95%
CI 0.350.8), and induced a 7.9-year gain of life matched by time free
from incident CVD.37,244 This study also showed that the risk of hos-
pitalization for HF reduced by 70%.245
The Japan Diabetes Optimal Integrated Treatment Study for 3
Major Risk Factors of Cardiovascular Diseases (J-DOIT3) studied the
effect of an intensive multifactorial intervention with stringent goals
in Japanese patients with DM aged 4569 years with risk factors.
Results showed significantly improved HbA1c, SBP, DBP, and LDL-C
compared with conventional therapy. There was a non-significant
trend towards reduction of the primary composite outcome, com-
prising non-fatal MI, stroke, revascularization, or all-cause death (HR
0.81, 95% CI 0.631.04; P=0.094). Post hoc analysis showed that cer-
ebrovascular events were reduced in the intensive-therapy group
(HR 0.42, 95% CI 0.240.74; P=0.002), while no differences were
seen for all-cause death and coronary events.246
Among 1425 patients with known DM and CAD participating in
the Euro Heart Survey, 44% received a combination of aspirin, a
beta-blocker, a RAAS blocker, and a statin. Patients on this combina-
tion had significantly lower all-cause death (3.5 vs. 7.7%; P=0.001) and
fewer combined CV events (11.6 vs. 14.7%; P=0.05) after 1 year of
follow-up.247
Table 9 Summary of treatment targets for the management of patients with diabetes
Risk factor Target
BP • Target SBP 130 mmHg for most adults, <130 mmHg if tolerated, but not <120 mmHg
• Less-stringent targets, SBP 130 - 139 in older patients (aged >65 years)
Glycaemic control: HbA1c • HbA1c target for most adults is <7.0% (<53 mmol/mol)
• More-stringent HbA1c goals of <6.5% (48 mmol/mol) may be suggested on a personalized basis if this can
be achieved without significant hypoglycaemia or other adverse effects of treatment
• Less-stringent HbA1c goals of <8% (64 mmol/mol) or <_9% (75 mmol/mol) may be adequate for elderly
patients (see section 6.2.1)
Lipid profile: LDL-C • In patients with DM at very high CV risk,a target LDL-C to <1.4 mmol/L (<55 mg/dL) and LDL-C reduction of at least 50%.
• In patients with DM at high risk,a target LDL-C to <1.8 mmol/L (<70 mg/dL) and LDL-C reduction of at least 50%.
• In patients with DM at moderate CV risk,a aim for an LDL-C target of <2.6 mmol/L (<100 mg/dL)
Platelet inhibition In DM patients at high/very high CV risk
Smoking Cessation obligatory
Physical activity Moderate-to-vigorous, >_150 min/week, combined aerobic and resistance training
Weight Aim for weight stabilization in overweight or obese patients with DM, based on calorie balance, and weight reduction
in subjects with IGT, to prevent the development of DM.
Dietary habits Reduction of caloric intake is recommended in obese patients with T2DM to lower body weight; there is no ideal
percentage of calories from carbohydrate, protein, and fat for all people with DM.
BP = blood pressure; CV = cardiovascular; DM = diabetes mellitus; HbA1c = haemoglobin A1c; IGT = impaired glucose tolerance; LDL-C = low-density lipoprotein choles-
terol; SBP = systolic blood pressure; T2DM = type 2 diabetes mellitus.
aSee Table 7.
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Gaps in the evidence
• The optimal strategy for multifactorial treatment in primary
and secondary intervention has not been established.
• Sex differences have not been evaluated in the setting of mul-
tifactorial intervention.
7 Management of coronary artery
disease
Key messages
• T2DM and pre-DM are common in individuals with ACS and
chronic coronary syndromes (CCS), and are associated with
an impaired prognosis.
• Glycaemic status should be systematically evaluated in all
patients with CAD.
• Intensive glycaemic control may have more favourable CV
effects when initiated early in the course of DM.
• Empagliflozin, canagliflozin, and dapagliflozin reduce CV
events in patients with DM and CVD, or in those who are at
very high/high CV risk.
• Liraglutide, semglutide and dulaglutide reduce CV events in
patients with DM and CVD, or who are at very high/high CV
risk.
• Intensive secondary prevention is indicated in patients with
DM and CAD.
• Antiplatelet drugs are the cornerstone of secondary CV
prevention.
• In high-risk patients, the combination of low-dose rivaroxaban
and aspirin may be beneficial for CAD.
• Aspirin plus reduced-dose ticagrelor may be considered for
<_3 years post-MI.
• Antithrombotic treatment for revascularization does not dif-
fer according to DM status.
• In patients with DM and multivessel CAD, suitable coronary
anatomy for revascularization, and low predicted surgical
mortality, coronary artery bypass graft (CABG) is superior to
percutaneous coronary intervention (PCI).
7.1 Medical treatment
Glucose abnormalities are common in patients with acute and stable
CAD, and are associated with a poor prognosis.16,18,249
Approximately 2030% of patients with CAD have known DM, and
of the remainder, up to 70% have newly detected DM or IGT when
investigated with an OGTT.9,250,251 Patients with CAD, without
known glucose abnormalities, should have their glycaemic state eval-
uated as outlined in sections 4 and 5.
It is important to acknowledge that recommendations for the sec-
ondary prevention of CAD in patients with DM are mostly based on
evidence from subgroup analyses of trials that enrolled patients with
and without DM.72 Because of the higher CV event rates consistently
observed in patients with DM, the absolute benefit often appears
amplified while the relative benefit remains similar.238,247 General
recommendations for patients with CCS and ACS are outlined in
other ESC Guidelines.252255
There is evidence that improved glycaemic control defers the
onset, reduces the progression, and (in some circumstances) may
partially reverse markers of microvascular complications in patients
with DM. Accordingly, early, effective, and sustained glycaemic con-
trol is advocated in all DM guidelines to mitigate the risks of hypergly-
caemia. Achieving this without detriment and with benefit to the CV
system is an important challenge, particularly when selecting glucose-
lowering therapies to suit the individual. Key clinical trials that delin-
eate the effects of glucose-lowering therapies on CV outcomes are
considered below.
7.1.1 Effects of intensified glucose control
7.1.1.1 UKPDS
In UKPDS, 5102 patients with newly diagnosed drug-naı¨ve DM were
randomly assigned to intensive glucose control with a sulfonylurea or
insulin, or to management with diet alone, for a median 10.7 years.
Although a clear reduction in microvascular complications was evi-
dent, the reduction in MI was marginal at 16% (P=0.052).145 In the
study extension phase, the risk reduction in MI remained at 15%,
which became significant as the number of cases increased.149
Furthermore, the beneficial effects persisted for any DM-related end-
point, including death from any cause, which was reduced by 13%. Of
note, this study was performed when modern aspects of multifacto-
rial management (lipid lowering and BP) were unavailable.
7.1.1.2 ACCORD, ADVANCE, and VADT
Three trials reported the CV effects of more-intensive vs. standard
glucose control in patients with DM at high CV risk.138,256258 They
included >23 000 patients treated for 35 years and showed no
CVD benefit from intensified glucose control. ACCORD was termi-
nated after a mean follow-up of 3.5 years because of higher mortality
in the intensive arm (14/1000 vs. 11/1000 patient deaths/year), which
was pronounced in those with multiple CVRFs and driven mainly by
CV mortality. A further analysis found that individuals with poor gly-
caemic control within the intensive arm accounted for the excess CV
mortality.259
7.1.1.3 DIGAMI 1 and 2
DIGAMI 1260 reported that insulin-based intensified glycaemic con-
trol reduced mortality in patients with DM and acute MI (mortality
Recommendations for multifactorial management of
patients with diabetes
Recommendations Classa Levelb
A multifactorial approach to DM management
with treatment targets, as listed in Table 9,
should be considered in patients with DM and
CVD.238,239,245248
IIa B
CVD = cardiovascular disease; DM = diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
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after 3.4 years was 33% in the insulin group vs. 44% in the control
group; P=0.011).261 The effect of intensified glycaemic control
remained 8 years after randomization, increasing survival by 2.3
years.262 These results were not reproduced in DIGAMI 2, which
was stopped prematurely due to slow recruitment of patients.263 In
pooled data, an insulinglucose infusion did not reduce mortality in
acute MI and DM.264 If it is felt necessary to improve glycaemic con-
trol in patients with ACS, this should be carried out cognisant of the
risk of hypoglycaemia, which is associated with poor outcomes in
patients with CAD.265,266 The strategy of metabolic modulation by
glucose-insulin-potassium, to stabilize the cardiomyocyte and
improve energy production, regardless of the presence of DM, has
been tested in several RCTs without a consistent effect on morbidity
or mortality.267,268
In patients undergoing cardiac surgery, glucose control should be
considered.269 Observational data in patients undergoing CABG sug-
gest that the use of continuous insulin infusion achieving moderately
tight glycaemic control is associated with lower mortality, and fewer
major complications, than tighter or more lenient glycaemic con-
trol.270 In the CABG stratum in the Bypass Angioplasty
Revascularization Investigation 2 Diabetes (BARI 2D) trial, long-term
insulin-providing treatment was associated with more CV events
than insulin-sensitization medications.271
The glycaemic targets for people with CAD, and the preferred
classes of drugs for DM, are outlined in section 6.2 and below.
7.1.2 Glucose-lowering agents: new evidence from
cardiovascular outcome trials
7.1.2.1 Established oral glucose-lowering drugs
The CV effects of long-established oral glucose-lowering drugs have
not been evaluated in large RCTs, as with more recent drugs.
7.1.2.1.1 Metformin. In a nested study of 753 patients in UKPDS com-
paring conventional therapy with metformin, metformin reduced MI
by 39%, coronary death by 50%, and stroke by 41% over a median
period of 10.7 years in newly diagnosed overweight patients with
T2DM without previous CVD.146 Metformin also reduced MI and
increased survival when the study was extended for a further 810
years of intensified therapy, including the use of other drugs.149
Observational and database studies provide supporting evidence that
long-term use of metformin improves CV prognosis.272,273 Still, there
have been no large-scale randomized CV outcome trials (CVOTs)
designed to assess the effect of metformin on CV events.
7.1.2.1.2 Sulfonylureas and meglinides. CV risk reduction with a sulfony-
lurea is more effective than modest lifestyle interventions alone, but
is less effective than metformin.145,146,274276 Sulfonylureas carry the
risk of hypoglycaemia and, since the 1960s, there has been an ongoing
debate on the CV safety of sulfonylureas. However, the CAROLINA
(CARdiovascular Outcome Study of LINAgliptin Versus Glimepiride
in Type 2 Diabetes) study, comparing the DPP4 inhibitor linagliptin
vs. the sulfonylurea glimiperide, showed comparable CV safety of
both drugs in patients with T2DM over 6.2 years.277 Nateglinide did
not reduce major CV events in the Nateglinide And Valsartan in
Impaired Glucose Tolerance Outcomes Research (NAVIGATOR)
trial, a 5 year prospective study of IGT and CVD, or high CV risk.278
7.1.2.1.3 Alpha-glucosidase inhibitor. Acarbose did not alter MACE in
patients with IGT and CVD during the large, 5 year, prospective ACE
trial.129
7.1.2.1.4 Thiazolidinediones. The PROspective pioglitAzone Clinical
Trial In macroVascular Events (PROactive) of pioglitazone was a neu-
tral trial for its composite primary outcome (HR 0.90, 95% CI
0.801.02; P=0.095).279 Because of this, reported secondary out-
comes should be viewed as hypothesis generating only. These
included a nominally significant reduction of the secondary composite
endpoint by 16% (HR 0.84, 95% CI 0.720.98; P=0.027),279 and the
risk of subsequent MI and recurrent stroke by 16 and 47%, respec-
tively,280,281 with a reduction in the risk of recurrent stroke in non-
DM.282 The occurrence of HF was significantly higher with pioglita-
zone than with placebo in the PROactive trial, but without increased
mortality.283 The Thiazolidinediones Or Sulfonylureas and
Cardiovascular Accidents Intervention Trial (TOSCA.IT)—a large,
randomized, but unblinded comparison of pioglitazone vs. sulfony-
lurea as add-on to metformin—was stopped prematurely because of
futility. The composite endpoint and the individual components of
the composite endpoint were similar in the two groups.284 In the IRIS
trial of insulin-resistant subjects without DM, pioglitazone reduced
the combined endpoint of recurrent stroke and MI by 24% vs. pla-
cebo over a median follow-up of 4.8 years.282 Following a meta-
analysis of CV events with the thiazolidinedione rosiglitazone,285 the
regulatory landscape for DM drugs underwent a major change in
2008,286 after which all future DM drugs were required to demon-
strate designated margins of CV safety to achieve or maintain regula-
tory approval. This led to an increase in trials to assess CV outcomes
with these therapies,287,288 most of which were designed to confirm
non-inferiority of the experimental therapy vs. placebo added to
background antihyperglycaemic treatment.
7.1.2.1.5 Insulin. In the ORIGIN trial, 12 537 people (mean age 63.5
years) at high CVD risk—with IFG, IGT, or DM—were randomized
to long-acting insulin glargine [targeting an FPG level of 5.3 mmol/L
(<_95 mg/dL)] or standard care. After a median follow-up of 6.2 years,
the rates of CV outcomes were similar in the two groups.289 In
DEVOTE, a double-blind comparison of ultra-long-acting degludec
o.d. (n=3818) with insulin glargine U100 (n=3819) for 1.8 years in
patients with DM at high CV risk found no significant differences in
MACE (composite of CV death, non-fatal MI, or non-fatal stroke).290
A significant reduction in the frequency of hypoglycaemia was
observed in the degludec arm. 290
7.1.2.2 Newer oral glucose-lowering drugs
7.1.2.2.1 Dipeptidyl peptidase-4 inhibitors. Five large prospective trials in
T2DM populations with different CV risk (Table 10) that assessed the
CV effects of DPP4 inhibitors have reported to date: saxagliptin
[Saxagliptin Assessment of Vascular Outcomes Recorded in Patients
with Diabetes Mellitusthrombolysis in myocardial infarction 53
(SAVOR-TIMI 53)]291 alogliptin [Examination of Cardiovascular
Outcomes with Alogliptin versus Standard of Care (EXAMINE)],292
sitagliptin [Trial Evaluating Cardiovascular Outcomes with Sitagliptin
(TECOS)],293 and linagliptin [Cardiovascular and Renal Microvascular
Outcome Study With Linagliptin in Patients With Type 2 Diabetes
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..Mellitus [CARMELINA]294 and CAROLINA277). Four of these trials
confirmed statistical non-inferiority vs. placebo (which included alter-
native glucose-lowering medication to achieve glycaemic equipoise)
for the primary composite CV outcome examined. However, none
of the DPP4 inhibitors were associated with significant CV benefits in
their trial populations, which comprised patients with a long history
of DM and CVD, or clustered CVD risk factors. In the SAVOR-TIMI
53 trial, saxagliptin was associated with an increase in risk of hospital-
ization for HF,291 compared with a numerical, non-significant increase
with alogliptin in EXAMINE,292 and no HF signal with sitagliptin in
TECOS293 and with linagliptin in CARMELINA.294,295 Subgroup anal-
yses of SAVOR-TIMI 53 suggested that high baseline NT-proBNP,
pre-existing HF, or CKD conferred a greater risk of hospitalization
for HF in saxagliptin-treated subjects.296 Only the CAROLINA study
compared linagliptin vs. glimiperide as an active comparator and
showed comparable CV safety of both drugs.277
7.1.2.2.2 Glucagon-like peptide-1 receptor agonists. Seven CVOTs have
examined the effects of GLP1-RAs on CV events in patients with DM
and high CV risk. In the Evaluation of Lixisenatide in Acute Coronary
Syndrome (ELIXA) trial, lixisenatide 10 or 20 lg o.d. was non-inferior
to placebo, but did not significantly affect a four-point MACE (three-
point MACE plus hospitalization for unstable angina) in patients with
DM post-ACS.297 In the Exenatide Study of Cardiovascular Event
Lowering (EXSCEL) study of a DM population in whom 73% had
experienced a previous CV event, exenatide 2 mg once weekly
showed non-inferiority vs. placebo and a numerical, but non-
significant, 14% reduction of the primary three-point MACE.158 The
intention-to-treat analysis revealed a significant reduction in all-cause
death by exenatide of 14% (P=0.016), but this result has to be consid-
ered exploratory given the hierarchical statistical testing. However, in
the subgroup with known CVD, those treated with exenatide dem-
onstrated a 10% relative risk reduction for MACE (HR 0.90, 95% CI,
0.8160.999; nominal P=0.047).
In the LEADER trial, 9340 patients with DM at high CV risk (81%
with previous CVD) were randomized to liraglutide 0.6 - 1.8 mg o.d.
vs. placebo as add-on to other glucose-lowering drugs. All patients
had a long history of DM and CVRFs that were well controlled. After
a follow-up of 3.1 years, liraglutide significantly reduced the compo-
site three-point primary endpoint (CV death, non-fatal MI, or non-
fatal stroke) by 13%. In addition, liraglutide significantly reduced CV
death and total death by 22 and 15%, respectively, and produced a
non-significant numerical reduction in non-fatal MI and non-fatal
stroke.176 Pre-specified secondary analyses showed lower rates of
development and progression of CKD with liraglutide compared
with placebo.298 The Trial to Evaluate Cardiovascular and Other
Long-term Outcomes with Semaglutide in Subjects with Type 2
Diabetes (SUSTAIN-6) was a phase III pre-approval study in which a
smaller population of 3297 patients with DM and high CV risk (73%
with CVD) were randomized to semaglutide 0.51.0 mg once
weekly vs. placebo. After 2.1 years, semaglutide significantly reduced
the three-point MACE by 26%, an effect driven mainly by a 39%
significant reduction of non-fatal stroke. Moreover, semaglutide led
to a non-significant numerical reduction of non-fatal MI. Semaglutide
also reduced the secondary endpoint of new or worsening nephrop-
athy.299 The Peptide Innovation for Early Diabetes Treatment
(PIONEER)-6 trial, also a phase III pre-approval CVOT, examined the
effect of oral semaglutide o.d. (target dose 14 mg) vs. placebo on CV
outcomes in patients with T2DM and high CV risk. Non-inferiority
for CV safety of oral semaglutide was confirmed with an HR of 0.79
(P < 0.001) in favour of oral semaglutide compared with placebo
over a median follow-up of 16 months. Moreover, semaglutide signifi-
cantly reduced the risk for CV death [15 (0.9%) events with oral sem-
aglutide vs. 30 (1.9%) events with placebo, HR 0.49, P=0.03] and all-
cause death [23 (1.4%) events in the semaglutide vs. 45 (2.8%) events
in the placebo group, HR 0.51, P=0.008].300 However, albeit low in
absolute numbers, there was a significant increase in retinopathy
complications, including vitreous haemorrhage, blindness, or require-
ment for intravitreal agent or photocoagulation, the implications of
which require further study. In the Albiglutide and CV outcomes in
patients with type 2 DM and CVD (Harmony Outcomes) trial, once
weekly albiglutide, a no-longer marketed GLP1-RA, led to a signifi-
cant 22% reduction of three-point MACE compared with placebo in
patients with DM and manifest CVD. In addition, albiglutide signifi-
cantly reduced MI by 25%.301 A recent meta-analysis of five of these
trials suggests that GLP-RAs reduce three-point MACE by 12% (HR
0.88, 95% CI 0.840.94; P < 0.001).302 The Researching
Cardiovascular Events With a Weekly Incretin in Diabetes
(REWIND) trial assessed the effect of once weekly subcutaneous
dulaglutide (1.5 mg) vs. placebo on three-point MACE in 9901 sub-
jects with T2DM, who had either a previous CV event or CVRFs.
During a median follow-up of 5.4 years, the primary composite out-
come occurred in 594 (12.0%) participants in the dulaglutide group
and in 663 (13.4%) participants in the placebo group (HR 0.88, 95%
CI 0.79099; P=0.026).303
Although the mechanisms through which some of these GLP-RAs
reduced CV outcomes have not been established, their long half-lives
may be contributing to their CV benefits. In addition, GLP1-RAs
improve several CV parameters, including a small reduction in SBP
and weight loss, and have direct vascular and cardiac effects that may
contribute to the results.304 The gradual divergence of the event
curves in the trials suggests that the CV benefit is mediated by a
reduction in atherosclerosis-related events.
7.1.2.2.3 Sodium-glucose co-transporter 2 inhibitors. Four CVOTs with
SGLT2 inhibitors [Empagliflozin Cardiovascular Outcome Event Trial
in Type 2 Diabetes Mellitus PatientsRemoving Excess Glucose
(EMPA-REG OUTCOME), the Canagliflozin Cardiovascular
Assessment Study (CANVAS) Program, Dapagliflozin Effect on
Cardiovascular Events-Thrombolysis In Myocardial Infarction
(DECLARE-TIMI 58), and the Canagliflozin and Renal Events in
Diabetes with Established Nephropathy Clinical Evaluation
(CREDENCE) trial] have been published. In EMPA-REG OUTCOME,
7020 patients with DM of long duration (57% >10 years)
282 ESC Guidelines
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and CVD were randomized to empagliflozin 10 or 25 mg o.d., or pla-
cebo; patients were followed for a mean of 3.1 years.305 The patient
population was well treated with good management of risk factors
(mean BP 135/77 mmHg and mean LDL-C 2.2 mmol/L). Empagliflozin
significantly reduced the risk of the three-point composite primary out-
come (CV death, non-fatal MI, or non-fatal stroke) by 14% compared
with placebo. This reduction was driven mainly by a highly significant
38% reduction in CV death (P < 0.0001), with separation of the empa-
gliflozin and placebo arms evident as early as 2 months into the trial.
There was a non-significant 13% reduction of non-fatal MI (P=0.30)
and a non-significant 24% increased risk of non-fatal stroke.306 In a sec-
ondary analysis, empagliflozin was associated with a 35% reduction in
hospitalization for HF (P < 0.002), with separation of the empagliflozin
and placebo groups evident almost immediately after treatment initia-
tion, suggesting a very early effect on HF risk. Empagliflozin also
reduced overall mortality by 32% (P < 0.0001), a highly significant
effect, translating into a number needed to treat of 39 over 3 years to
prevent one death. These findings were consistent in all subgroups.
Additional analyses from EMPA-REG OUTCOME revealed that the
CV benefit was gained by those with and without HF at baseline, the
latter comprising10% of the study cohort.307
The CANVAS Program integrated data from two RCTs
(CANVAS and CANVAS-R), in which 10 142 patients with DM at
high CV risk were randomized to canagliflozin 100300 mg o.d. vs.
placebo.308 After 3.1 years, canagliflozin significantly reduced a com-
posite three-point MACE by 14% (P=0.02), but did not significantly
alter CV death or overall death.309 Similar to the findings in EMPA-
REG OUTCOME, canaglifozin significantly reduced HF hospitaliza-
tion. However, canagliflozin led to an unexplained increased inci-
dence in lower limb fractures and amputations (albeit low numbers),
a finding that was not replicated in a recent large cohort study.310
DECLARETIMI 58 examined the effect of 10 mg dapagliflozin
o.d. vs. placebo in 17 160 patients with DM and CVD, or multiple
CVRFs, among them 10 186 without atherosclerotic CVD.311 After a
median follow-up of 4.2 years, dapagliflozin met the pre-specified cri-
terion for non-inferiority for the composite three-point MACE com-
pared with placebo. In the two primary efficacy analyses, dapaglifozin
did not significantly reduce MACE, but resulted in a lower rate of the
combined endpoint of CV death or HF hospitalization (4.9 vs. 5.8%;
HR 0.83, 95% CI 0.73 - 0.95; P=0.005). This was driven by a lower
rate of HF hospitalizations (HR 0.73, 95% CI 0.61 - 0.88), but no
between-group difference in CV death (HR 0.98, 95% CI 0.82 - 1.17).
The benefit of dapagliflozin with respect to CV death or HF hospital-
ization was similar in the subgroup with CVD, as well as those with
multiple risk factors only. A meta-analysis of the three trials suggested
consistent benefits on reducing the composite of HF hospitalization
or CV death, as well as on the progression of kidney disease, regard-
less of existing atherosclerotic CVD or a history of HF, while the
reduction in MACE was only apparent in patients with established
CVD.312 The CREDENCE trial313 randomized 4401 patients with
T2DM and albuminuric CKD (eGFR 30 to <90 mL/min/1.73 m2) to
canagliflozin or placebo, and showed a relative reduction of the pri-
mary renal outcome of 30% by canagliflozin after a median follow-up
of 2.6 years. In addition, canagliflozin significantly reduced the pre-
specified secondary CV outcomes of three-point MACE (HR 0.80,
95% CI 0.67 - 0.95; P=0.01) and hospitalization for HF (HR 0.61, 95%
CI 0.470.80; P < 0.001) compared with placebo in this very high-
CV risk group of patients (see section 11).313
The CV benefits of SGLT2 inhibitors are mostly unrelated to the
extent of glucose lowering and occur too early to be the result of
weight reduction. The rapid separation of placebo and active arms in
the four studies in terms of reduction in HF hospitalizations indicates
that the beneficial effects achieved in these trials are more likely the
result of a reduction in HF-associated events. They could involve
effects on haemodynamic parameters, such as reduced plasma vol-
ume, direct effects on cardiac metabolism and function, or other CV
effects.314317
7.1.2.3 Implications of recent cardiovascular outcome trials
For the first time in the history of DM, we have data from several
CVOTs that indicate CV benefits from the use of glucose-lowering
drugs in patients with CVD or at very high/high CV risk. The results
obtained from these trials, using both GLP1-RAs (LEADER,
SUSTAIN-6, Harmony Outcomes, REWIND, and PIONEER 6) and
SGLT2 inhibitors (EMPA-REG OUTCOME, CANVAS, DECLARE-
TIMI 58, and CREDENCE), strongly suggest that these drugs should
be recommended in patients with T2DM with prevalent CVD or
very high/high CV risk, such as those with target-organ damage or
several CVRFs (see Table 7), whether they are treatment naı¨ve or
already on metformin. In addition, based on the mortality benefits
seen in LEADER and EMPA-REG OUTCOME, liraglutide is recom-
mended in patients with prevalent CVD or very high/high CV risk,
and empagliflozin is recommended in patients with prevalent CVD,
to reduce the risk of death. The recommendation for empagliflozin is
supported by a recent meta-analysis which found high heterogeneity
between CVOTs in mortality reduction.312 The benefits seen with
GLP1-RAs are most likely derived through the reduction of
arteriosclerosis-related events, whereas SGLT2 inhibitors seem to
reduce HF-related endpoints. Thus, SGLT2 inhibitors are potentially
of particular benefit in patients who exhibit a high risk for HF. In sub-
jects with newly diagnosed T2DM without CVD and at moderate
risk, the results of UKPDS suggest a beneficial effect of metformin in
primary prevention. Although the trial-based evidence for metformin
monotherapy from UKPDS is not as strong as with the novel drugs
tested in recent CVOTs, it is supported by extensive observations
from everyday clinical practice. In the recent CVOTs, a majority of
patients received metformin before and concurrently with the newer
drug under test. However, because metformin was similarly present
in the active and placebo groups, it is unlikely to explain the beneficial
effects of the newer drugs under test. Thus, the choice of drug to
reduce CV events in patients with T2DM should be prioritized based
on the presence of CVD and CV risk (Figure 3).
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Figure 3 Treatment algorithm in patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease, or high/very high CV risk Treatment
algorithms for (A) drug-naı¨ve and (B) metformin-treated patients with diabetes mellitus. ASCVD = atherosclerotic cardiovascular disease: CV = cardiovas-
cular; CVD = cardiovascular disease; DM = diabetes mellitus; DPP4i = dipeptidyl peptidase-4 inhibitor; eGFR = estimated glomerular filtration rate; GLP1-
RA = glucagon-like peptide-1 receptor agonist; HbA1c = haemoglobin A1c; HF = heart failure; SGLT2i = sodium-glucose co-transporter 2 inhibitor;
SU = sulphonylureas; T2DM = type 2 diabetes mellitus; TZD = thiazolidinedione. aSee Table 7. bUse drugs with proven CVD benefit.
ESC Guidelines 285
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/article-abstract/41/2/255/5556890 by 81728827 user on 15 June 2020
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..7.1.3 Specific cardiovascular therapies
7.1.3.1 Beta-blockers
In CCS, beta-blockers are effective at reducing both exercise-
induced angina and asymptomatic ischaemic episodes, while improv-
ing exercise capacity.254 Their favourable impact on prognosis is
questionable, and was not confirmed by a propensity score-matched
analysis of patients included in a large observational study.320 Long-
term beta-blocker administration in patients with DM has recently
been questioned by a prospective observational study, as well as a
post hoc analysis from the ACCORD study, suggesting increased all-
cause death in DM patients treated with beta-blockers.321,322 Further
assessment is needed in the future.
In contrast, the benefit of long-term administration of oral beta-
blockers in the post-MI phase is established in patients with HF and
LV ejection fraction (LVEF) <40%, as outlined in section 8.4.2.252,323
Carvedilol and nebivolol may be preferred because of their ability to
improve insulin sensitivity, with no negative effects on glycaemic
control.324,325
7.1.3.2 Blockers of the reninangiotensinaldosterone system
Treatment with ACEIs is recommended to prevent major CV events,
and HF, in all patients with CCS or ACS and systolic LV dysfunction,
based on a systematic review of RCTs.326 An ARB should be adminis-
tered in patients intolerant of ACEIs. Finally, mineralocorticoid recep-
tor antagonists (MRA) are recommended in patients with LV systolic
dysfunction or HF after MI.252,327
7.1.3.3 Lipid-lowering drugs
Details of lipid-lowering drugs are outlined in section 6.4.1.
7.1.3.4 Nitrates and calcium channel blockers
Nitrates (preferably short-acting) and calcium channel blockers are
indicated for relief of angina symptoms,255 and are frequently used
when beta-blockers are contraindicated or not tolerated, or in addi-
tion to beta-blockers if patients remain symptomatic, but offer no
prognostic benefit.255
7.1.3.5 Other anti-ischaemic drugs
Ranolazine is a selective inhibitor of the late sodium current, effective
in the treatment of chronic angina.255 When added to one or more
antianginal drugs in patients with DM, ranolazine further reduced the
number of ischaemic episodes and the use of nitrates compared with
placebo.328 Ranolazine also has metabolic effects and may lower
HbA1c levels in patients with DM.329 Trimetazidine is an anti-
ischaemic metabolic modulator that improves glucose control and
cardiac function in patients with DM,330,331 as well as effort-induced
myocardial ischaemia in patients with CCS.332,333 The drug was
reviewed by the European Medicines Agency in 2012, and is contrain-
dicated in Parkinson’s disease and motion disorders.334 Ivabradine
inhibits the If current—the primary modulator of spontaneous dia-
stolic depolarization in the sinus node—resulting in heart rate lower-
ing and antianginal effects. These drugs should be considered as
second line treatment.255,335
Recommendations for glucose-lowering treatment for patients with diabetes
Recommendations Classa Levelb
SGLT2 inhibitors
Empagliflozin, canagliflozin, or dapagliflozin are recommended in patients with T2DM and CVD, or at very high/high CV
risk,c to reduce CV events.306,308,309,311
I A
Empagliflozin is recommended in patients with T2DM and CVD to reduce the risk of death.306 I B
GLP1-RAs
Liraglutide, semaglutide, or dulaglutide are recommended in patients with T2DM and CVD, or at very high/high CV risk,c
to reduce CV events.176,299300,302303
I A
Liraglutide is recommended in patients with T2DM and CVD, or at very high/high CV risk,c to reduce the risk of death.176 I B
Biguanides
Metformin should be considered in overweight patients with T2DM without CVD and at moderate CV risk.146,149 IIa C
Insulin
Insulin-based glycaemic control should be considered in patients with ACS with significant hyperglycaemia (>10 mmol/L
or >180 mg/dL), with the target adapted according to comorbidities.260262
IIa C
Thiazolidinediones
Thiazolidinediones are not recommended in patients with HF. III A
DPP4 inhibitors
Saxagliptin is not recommended in patients with T2DM and a high risk of HF.291 III B
ACS = acute coronary syndromes; CV = cardiovascular; CVD = cardiovascular disease; DM = diabetes mellitus; DPP4 = dipeptidyl peptidase-4; GLP1-RA = glucagon-like pep-
tide-1 receptor agonist; HF = heart failure; SGLT2 = sodium-glucose co-transporter 2; T2DM = type 2 diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
cSee Table 7.
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..7.1.3.6 Antiplatelet and antithrombotic drugs
There is no evidence at the moment to support different antiplatelet
strategies in patients with ACS or CCS with vs. without DM (see also
section 6.5).72,252,253,336
7.1.3.6.1 Aspirin. In secondary prevention, low-dose (75160 mg)
aspirin, alone or in combination (see section 7.1.3.6.2 below), remains
the recommended drug in patients with DM.72
7.1.3.6.2 P2Y12 receptor blockers. Clopidogrel provides an alternative
for aspirin-intolerant patients, and is combined with low-dose aspirin
as dual antiplatelet therapy (DAPT) (clopidogrel 75 mg o.d. and aspirin
75160 mg o.d.) in patients with ACS and those undergoing PCI, with
unchanged evidence since the 2013 Guidelines.72 A post hoc analysis of
the CHARISMA (Clopidogrel for High Atherothrombotic Risk and
Ischemic Stabilization, Management and Avoidance) trial suggested that
clopidogrel, added to background aspirin, may increase overall and CV
death in DM patients with microalbuminuria (>_30 lg/mL).337 In
patients with ACS, DAPT with prasugrel338 or ticagrelor339 on a back-
ground of low-dose aspirin was superior to DAPT with clopidogrel in
the DM subgroup, with a benefit similar to that in the population with-
out DM. Patients with DM tended to have a greater reduction in
ischaemic events with prasugrel than clopidogrel,338 without an
increase in major bleeding. The Prevention of Cardiovascular Events in
Patients with Prior Heart Attack Using Ticagrelor Compared to
Placebo on a Background of Aspirin-Thrombolysis In Myocardial
Infarction 54 (PEGASUS-TIMI 54) trial compared adding ticagrelor 60
or 90 mg b.i.d. vs. placebo to a background of low-dose aspirin in
patients who experienced an MI 1 - 3 years before recruitment into
the study.340 The relative risk reduction of MACE with ticagrelor was
similar in the DM and non-DM cohorts (HR 0.84, 95% CI 0.720.99
and HR 0.84, 95% CI 0.740.96, respectively). Ticagrelor was associ-
ated with an increase in major bleeding, which was similar in the two
groups (HR 2.56, 95% CI 1.524.33 and HR 2.47, 95% CI 1.733.53
in DM vs. non-DM, respectively).340
7.1.3.6.3 Novel oral anticoagulant drugs. In the Anti-Xa Therapy to
Lower cardiovascular events in Addition to Standard therapy in sub-
jects with Acute Coronary Syndrome-TIMI 51 (ATLAS-ACS_TIMI
51) trial in patients with a recent ACS (32% DM), a low dose of the
activated factor Xa blocker rivaroxaban (2.5 mg b.i.d.) added to DAPT
significantly reduced CV death, MI, or stroke compared with placebo
(9.1 vs. 10.7%; HR 0.84, 95% CI 0.720.97; P=0.02).341 This benefit
was associated with a significant increase in major, non-CABG-related
bleeding (1.8 vs. 0.6%) and intracranial haemorrhage (0.4 vs. 0.2%) in
the rivaroxaban arm, with no difference in fatal bleeding.341 The
Cardiovascular Outcomes for People Using Anticoagulation
Strategies (COMPASS) trial recruited 27 395 patients with stable
atherosclerotic disease and showed that low-dose aspirin (100 mg
o.d.) combined with a low dose of rivaroxaban (2.5 mg b.i.d.) was
superior to aspirin alone in preventing MI, stroke, or CV death (4.1 vs.
5.4%, respectively; HR 0.76, 95% CI 0.660.86; P < 0.001).342 Major
bleeding, but not fatal or intracranial bleeding, was increased (HR 1.7,
95% CI 1.72.05; P<0.001). The net clinical benefit favoured the com-
bination (HR 0.80, 95% CI 0.700.91; P<0.001 vs. aspirin alone).
Approximately 38% of the overall COMPASS population had DM,
and the proportional benefitrisk profile of the aspirin/rivaroxaban
combination over aspirin alone was similar in both populations.343
Of potential major importance was the finding that in patients with
lower extremity artery disease (LEAD), adverse limb events plus
major amputations were reduced by 46% (see section 10.2.3). Of the
patients enrolled in the COMPASS trial, 24 824 were specifically diag-
nosed with stable CAD (CCS).
7.1.3.6.4 Other anticoagulant strategies. A variety of antiplatelet and
antithrombotic strategies have been used in patients with ACS
undergoing PCI. These include glycoprotein IIb/IIIa inhibitors, unfrac-
tionated heparin, and bivalirudin. The indications for their use are dis-
cussed in the 2018 ESC/European Association for Cardio-Thoracic
Surgery (EACTS) Guidelines on myocardial revascularization.344
Recommendations for the management of patients with
diabetes and acute or chronic coronary syndromes
Recommendations Classa Levelb
ACEIs or ARBs are indicated in patients with DM
and CAD to reduce the risk of CV events.326,345347
I A
Statin therapy is recommended in patients with DM
and CAD to reduce the risk of CV events.211,348
I A
Aspirin at a dose of 75160 mg/day is recom-
mended as secondary prevention in patients with
DM.349
I A
Treatment with a P2Y12 receptor blocker ticagre-
lor or prasugrel is recommended in patients with
DM and ACS for 1 year with aspirin, and in those
who undergo PCI or CABG.350,351
I A
Concomitant use of a proton pump inhibitor is
recommended in patients receiving DAPT or oral
anticoagulant monotherapy who are at high risk of
gastrointestinal bleeding.253,336,352
I A
Clopidogrel is recommended as an alternative anti-
platelet therapy in case of aspirin intolerance.353
I B
Prolongation of DAPT beyond 12 monthsc should
be considered, for up to 3 years, in patients with
DM who have tolerated DAPT without major
bleeding complications.341,342,354356
IIa A
The addition of a second antithrombotic drug on
top of aspirin for long-term secondary prevention
should be considered in patients without high
bleeding risk.d 341,342,354356
IIa A
Beta-blockers may be considered in patients with
DM and CAD.320322
IIb B
Recommendations on glucose targets are outlined in section 6.2.1.
Recommendations on glucose-lowering drugs for DM are outlined in section 7.1.2.
ACEI = angiotensin-converting enzyme inhibitor; ACS = acute coronary syn-
dromes; ARB = angiotensin receptor blocker; b.i.d. = twice daily (bis in die);
CABG = coronary artery bypass graft; CAD = coronary artery disease; CCS =
chronic coronary syndromes; CV = cardiovascular; DAPT = dual antiplatelet
therapy; DM = diabetes mellitus; eGFR = estimated glomerular filtration rate;
PCI = percutaneous coronary intervention.
aClass of recommendation.
bLevel of evidence.
cFull-dose clopidogrel or reduced-dose ticagrelor (60 mg b.i.d.).
dPrior history of intracerebral haemorrhage or ischaemic stroke, history of
other intracranial pathology, recent gastrointestinal bleeding or anaemia due to pos-
sible gastrointestinal blood loss, other gastrointestinal pathology associated with
increased bleeding risk, liver failure, bleeding diathesis or coagulopathy, extreme old
age or frailty, or renal failure requiring dialysis or with eGFR <15 mL/min/1.73 m2.
ESC Guidelines 287
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/article-abstract/41/2/255/5556890 by 81728827 user on 15 June 2020
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
7.2 Revascularization
The anatomical pattern of CAD in patients with DM influences prog-
nosis and the response to revascularization. Angiographic studies
have shown that patients with DM are more likely to have left main
CAD and multivessel CAD, and that coronary pathology is more fre-
quently diffuse and involves the small vessels.357 In addition, DM fre-
quently has comorbidities, such as CKD, cerebrovascular disease,
and LEAD, which adversely affect outcomes after coronary revascu-
larization. The indications for myocardial revascularization, for both
symptomatic and prognostic reasons, are the same in patients with
and without DM, and have been summarized in the 2018 ESC/
EACTS Guidelines on myocardial revascularization.344 In the BARI
2D trial, patients with DM and stable CAD were randomized to opti-
mal medical treatment alone or to revascularization (either PCI or
CABG) plus optimal medical treatment.358 After 5 years, no signifi-
cant differences were noted in the combined endpoint of death, MI,
or stroke between groups. Paralleling the observation in non-DM,
the negative impact of incomplete revascularization has also been
documented in patients with DM.359 In the setting of chronic HF of
ischaemic origin, only one RCT (involving 1212 patients) has com-
pared revascularization (with CABG) plus optimal medical manage-
ment vs. optimal medical management alone in patients with LVEF
<_35%, and found a significant survival benefit in patients allocated to
revascularization at a mean follow-up of 9.8 years.360 The benefit
observed among patients with DM was of the same degree, but did
not reach statistical significance. In non-ST-segment elevation ACS, a
meta-analysis of nine RCTs including 9904 patients suggested a simi-
lar benefit at 12 months in terms of death, non-fatal MI, or hospitaliza-
tion for an ACS from an early invasive strategy compared with a
conservative strategy in patients with and without DM.361 Yet,
because of higher baseline risk, the absolute risk reduction was more
pronounced in those with DM. A recent meta-analysis of data from
individual patients (n=5324) suggested that at a median follow-up of
6 months, an early invasive strategy compared with a delayed strategy
was associated with reduced mortality in patients with DM (HR 0.67,
95% CI 0.450.99) in the absence of a reduction in recurrent MI.362
7.2.1 Percutaneous coronary intervention vs. coronary
artery bypass graft surgery
DM should be considered as a distinct disease entity that is critical for
the selection of myocardial revascularization strategies in multivessel
disease.
Three RCTs have compared the two revascularization modalities
in patients with DM, mostly in the setting of stable multivessel CAD
using mainly first-generation drug-eluting stents (DES), but one of
them was prematurely terminated and underpowered.363 In the
Coronary Artery Revascularization in Diabetes (CARDia) trial, 510
patients with multivessel or complex single-vessel CAD were
randomized to CABG or PCI, with a bare-metal stent (BMS) or a
first-generation DES.364 There were no differences between the
groups for the primary endpoint of 1 year death, MI, or stroke, but
this trial was also underpowered. Repeat revascularization occurred
more frequently with PCI (P < 0.001). The Future Revascularization
Evaluation in Patients with Diabetes Mellitus (FREEDOM) trial
randomized 1900 patients with multivessel CAD, but no left main
stenosis, to elective CABG or PCI with a first-generation DES.365
The primary endpoint of all-cause death, non-fatal MI, or stroke at 5
years occurred in 26.6% of patients in the PCI group and in 18.7%
patients in the CABG group (P=0.005). The incidences of death (16.3
vs. 10.9%; P=0.049) and MI (13.9 vs. 6.0%; P < 0.001) were higher in
the PCI group, while the incidence of stroke was lower (2.4 vs. 5.2%;
P=0.03). While patients on insulin had higher event rates, no signifi-
cant interaction for the primary endpoint was observed between
insulin status and treatment effect.366 In addition, no interaction was
observed between treatment effect and degree of coronary com-
plexity, as assessed by the Synergy between Percutaneous Coronary
Intervention with TAXUS and Cardiac Surgery (SYNTAX) score.
In the DM subgroup (n=452) enrolled in the SYNTAX trial, there
were no differences between PCI with a first-generation DES and
CABG in the composite endpoint of death, stroke, or MI at 5 years.
However, the 5 year rates of major adverse CV and cerebrovascular
events (MACCE) (PCI 46.5% vs. CABG 29.0%; P < 0.001), and the
need for repeat revascularization (HR 2.75; P < 0.001) were higher in
the PCI group.367
Overall, the meta-analysis of 3052 patients with DM randomized
to PCI with mainly first-generation DES vs. CABG reported a higher
risk of death or MI with PCI (relative risk 1.51; P=0.01), while the risk
of stroke was lower (relative risk 0.59; P=0.01).368 A sensitivity analy-
sis showed that the superiority of CABG over PCI in terms of
MACCE was more pronounced with complex CAD (high SYNTAX
score). The most recent meta-analysis of 11 RCTs, involving 11 518
patients allocated to PCI with stents (BMS or DES) or CABG,
showed that 5 year all-cause mortality was 11.2% after PCI and 9.2%
after CABG (HR 1.20, 95% CI 1.061.37; P=0.0038).369 Among
patients with DM (38% of the cohort), the corresponding mortality
rates were 15.7 and 10.1% (HR 1.44, 95% CI 1.201.74; P=0.0001),
respectively, while no difference was observed among patients with-
out DM (Pinteraction=0.0077). These findings support a benefit for
patients with DM from surgery compared with PCI.
With respect to newer-generation DES, a meta-analysis of RCTs
including 8095 patients with DM showed a significant reduction in MI,
stent thrombosis, and MACE in patients allocated to newer-genera-
tion everolimus-eluting stents compared with those receiving a first-
generation DES.370 However, in the subset of patients with DM
(n=363) enrolled in the Randomized Comparison of Coronary
Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in
the Treatment of Patients with Multivessel Coronary Artery Disease
(BEST) study, the rate of the primary endpoint of death, MI, or target
vessel revascularization (TVR) at 2 years was significantly higher in
the PCI than the CABG arm (19.2 vs. 9.1%; P=0.007).371 Finally,
among the 505 patients with DM in the Evaluation of XIENCE versus
Coronary Artery Bypass Surgery for Effectiveness of Left Main
Revascularization (EXCEL) trial, the primary endpoint of death, MI,
or stroke at 3 years occurred in 21.2% of patients in the PCI arm and
19.4% in the CABG arm (HR 1.04, 95% CI 0.701.55).372 It remains
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.to be determined whether the use of newer-generation DES will, at
least in part, reduce the gap in outcomes favouring CABG in patients
with DM and multivessel CAD, and whether the extended follow-up
in the EXCEL trial will again show no statistically significant differen-
ces between PCI and CABG for left main disease. In non-ST-segment
elevation ACS, limited data are available comparing PCI and CABG.
In a registry of 2947 patients with DM and stabilized ACS, CABG was
compared with PCI with DES.373 The primary outcome measure of
the study was a composite of death, MI, and non-fatal stroke. The
benefit of CABG over PCI was significant at 30 days (HR 0.49, 95% CI
0.340.71) and at a median follow-up of 3.3 years (HR 0.67, 95% CI
0.550.81). A recent observational study investigated outcomes
with PCI or CABG for multivessel CAD and LV dysfunction in 1738
propensity-matched patients with DM. CABG compared with PCI
was associated with significantly lower risks of MACE and mortality
at a mean follow-up of 5.5 years.374 The survival advantage of CABG
was observed in patients with LVEF 3549% as well as in those with
LVEF <35%.360,374,375
The best surgical coronary revascularization strategy and graft
selection in patients with DM is still subject to debate. The superior
graft patency of the internal mammary artery, and its impact on sur-
vival when grafted to the left anterior descending (LAD) coronary
artery, would make the use of bilateral internal mammary arteries the
most logical and beneficial strategy.376 However, the superiority of
bilateral internal mammary artery (BIMA) grafting over a single inter-
nal mammary artery (SIMA) in terms of mortality has been confirmed
only by observational studies and respective meta-analysis.377 Factors
not related to graft patency, such as the patient’s general status and
other unmeasured confounders, may have accounted for the survival
benefit of BIMA grafting in the observational series.378 The Arterial
Revascularization Trial (ART) compared BIMA with SIMA and addi-
tional veins in 1554 patients, and at 10 years showed no significant dif-
ferences in the rate of death or the composite outcome of death, MI,
or stroke.379,380 The radial artery may be the preferred second graft
in view of better long-term patency of the radial artery compared
with the saphenous vein, but further studies are needed381 (see the
2018 ESC/EACTS Guidelines on myocardial revascularization for fur-
ther information344).
The appropriate revascularization modality in patients with DM
and multivessel disease should be discussed by the Heart Team, tak-
ing into consideration individual cardiac and extracardiac characteris-
tics, as well as preferences of the well-informed patient. Overall,
current evidence indicates that in stable patients with coronary anat-
omy suitable for both procedures and low predicted surgical mortal-
ity, CABG is superior to PCI in reducing the composite risk of death,
MI, or stroke, as well as death. However, in patients with DM with
low complexity of coronary anatomy (SYNTAX score <_22), PCI has
achieved similar outcomes to CABG with respect to death and the
composite of death, MI, or stroke. Therefore, PCI may represent an
alternative to CABG for low complexity of the coronary anatomy,
while CABG is recommended for intermediate-to-high anatomical
complexity (SYNTAX score >22).
7.2.2 Adjunctive pharmacotherapy
As a general rule, adjunctive pharmacotherapy in the setting of myo-
cardial revascularization does not differ between DM and non-DM
(see section 7.1.3.6 for antithrombotic therapy and section 7.1.2 for
glucose lowering). There are insufficient data to support the practice
of stopping metformin 2448 h before angiography or PCI, as the
risk of lactic acidosis is negligible. In patients with CKD, metformin
should be stopped before the procedure. Renal function should be
carefully monitored after PCI in all patients with baseline renal impair-
ment or on metformin. If renal function deteriorates in patients on
metformin undergoing coronary angiography/PCI, metformin should
be withheld for 48 h or until renal function has returned to its initial
level.
Recommendations for coronary revascularization in
patients with diabetes
Recommendations Classa Levelb
It is recommended that the same revasculari-
zation techniques are implemented (e.g. the
use of DES and the radial approach for PCI,
and the use of the left internal mammary
artery as the graft for CABG) in patients with
and without DM.344
I A
It is recommended that renal function should
be checked if patients have taken metformin
immediately before angiography and that met-
formin should be withheld if renal function
deteriorates.
I C
Optimal medical therapy should be consid-
ered to be the preferred treatment in patients
with CCS and DM unless there are uncon-
trolled ischaemic symptoms, large areas of
ischaemia, or significant left main or proximal
LAD lesions.358
IIa B
For details see 2018 ESC/EACTS Guidelines on myocardial revascularization.344
CABG = coronary artery bypass graft; CCS = chronic coronary syndromes; DES
= drug-eluting stent; DM = diabetes mellitus; EACTS = European Association for
Cardio-Thoracic Surgery; ESC = European Society of Cardiology; LAD = left
anterior descending coronary artery; PCI = percutaneous coronary intervention.
aClass of recommendation.
bLevel of evidence.
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Gaps in the evidence
• The pathophysiological mechanisms underlying the develop-
ment of CAD and the worse prognosis in patients with DM
need to be further elucidated.
• The effects of secondary preventive measures in patients
with CAD and DM are mainly based on subgroup analyses of
trials enrolling patients with and without DM.
• Studies comparing different antithrombotic strategies in
patients with DM and CAD are lacking.
• Optimal glycaemic control for the outcomes of ACS and sta-
ble CAD, as well as after coronary revascularization, remain
to be established.
• Mechanisms of CV event reduction by the newer therapies
need to be determined.
• The role of hypoglycaemia in the occurrence of CV events/
mortality needs to be established.
• Following revascularization, the rate of adverse events
remains higher in patients with vs. without DM; specific pre-
ventive therapies should be investigated.
• Although newer-generation DES have improved outcomes in
patients with DM, RCTs are needed to determine whether
they can reduce the gap in outcomes between CABG and
PCI.
8 Heart failure and diabetes
Key messages
• Patients with pre-DM and DM are at increased risk of devel-
oping HF.
• Patients with DM are at greater risk of HF with reduced ejec-
tion fraction (HFrEF) or HF with preserved ejection fraction
(HFpEF); conversely, HF increases the risk of DM.
• The coexistence of DM and HF imparts a higher risk of HF
hospitalization, all-cause death, and CV death.
• Guideline-based medical and device therapies are equally
effective in patients with and without DM; as renal dysfunc-
tion and hyperkalaemia are more prevalent in patients with
DM, dose adjustments of some HF drugs (e.g. RAAS block-
ers) are advised.
• First-line treatment of DM in HF should include metformin
and SGLT2 inhibitors; conversely, saxagliptin, pioglitazone,
and rosiglitazone are not recommended for patients with
DM and HF.
DM is an important risk factor for HF.405407 In trials of glucose-
lowering medications, HF was seen in 430% of partici-
pants.292,299,306,408 Unrecognized HF may also be frequent in patients
DM: observational data indicate that HF is present in 28% of patients
Recommendations for the type of revascularization in patients with diabetes with stable coronary artery disease, suit-
able coronary anatomy for both procedures, and low predicted surgical mortality
Recommendations according to the extent of CAD (see Figure 4) CABG PCI
Classa Levelb Classa Levelb
One-vessel CAD
Without proximal LAD stenosis IIb C I C
With proximal LAD stenosis382389 I A I A
Two-vessel CAD
Without proximal LAD stenosis IIb C I C
With proximal LAD stenosis389391 I B I C
Three-vessel CAD
With low disease complexity (SYNTAX scorec 022)363365,367369,371,392398 I A IIb A
With intermediate or high disease complexity (SYNTAX scorec >22)363365,367369,371,392398 I A III A
Left main CAD
With low disease complexity (SYNTAX scorec 022)369,397,399404 I A I A
With intermediate disease complexity (SYNTAX scorec 2332)369,397,399404 I A IIa A
With high disease complexity (SYNTAX scorec >_33)369,397,399404 I A III B
CABG = coronary artery bypass graft; CAD = coronary artery disease; DM = diabetes mellitus; LAD = left anterior descending coronary artery; PCI = percutaneous coronary
intervention; SYNTAX = Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery.
aClass of recommendation.
bLevel of evidence.
cSYNTAX score calculation: http://www.syntaxscore.com.
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..(25% HFrEF and 75% HFpEF).409 Patients with DM free of HF at
baseline are 25 times more likely to develop HF.410,411 The risk
of HF is also increased in those with HbA1c levels in the pre-DM
range (>_5.56.4%), who have a 20 - 40% higher risk of HF.412 HF
itself is associated with a greater prevalence of DM and other dysgly-
caemic states, and is considered a risk factor for the development of
DM, most likely related to an insulin-resistant state.413416 Available
data indicate that the prevalence of DM in HF is similar, irrespective
of LVEF category [HFpEF, HF with mid-range ejection fraction
(HFmrEF) and HFrEF (see Table 11 below)].417419 Indeed,
3040% of patients with HF have been reported to have pre-DM
or DM in trials of HFrEF345,420,421 and HFpEF.422425 Findings from a
large pan-European registry indicated that 36% of outpatients with
stable HF had DM,426 while in patients hospitalized for acute HF, DM
was present in <_50%.427 Importantly, patients with HF without DM
are at increased risk of DM,413,428 and the risk is aggravated by the
severity of HF and the use of loop diuretics.428
8.1 Prognostic implications of diabetes
mellitus in heart failure
A significant association exists between DM and adverse outcomes in
HF, with the strongest predictive value of DM for outcomes seen in
patients with HFrEF.421,423,426,429432 CV mortality, including death
caused by worsening HF, is also5090% higher in patients with HF
and DM, regardless of HF phenotype.421,432434 Two trials have
shown that pre-DM and undiagnosed DM in patients with HF are
associated with a higher risk of death, and adverse clinical out-
comes.421,431,435 In addition, in patients with worsening HFrEF, newly
diagnosed pre-DM was independently associated with a higher long-
term risk of all-cause and CV death, which underlies the importance
of screening for pre-DM in this population.436 In acute HF, DM
increases the risks of in-hospital death,427 1 year all-cause death,437
and 1 year HF rehospitalization.427
8.2 Mechanisms of left ventricular
dysfunction in diabetes mellitus
Major causes of HF in patients with DM are CAD, CKD (see section
11), hypertension, and direct effects of insulin resistance/hyperglycae-
mia on the myocardium.438 CAD is often accelerated, severe, diffuse,
and silent, and increases the risk of MI and ischaemic myocardial dys-
function.411,439441 Hypertension control is associated with a lower
risk of HF development.439 Observational data have also identified
LEAD, a longer duration of DM, ageing, increased body mass index,
and CKD as predictors of HF in patients with DM.411,439441
Complex pathophysiological mechanisms may be responsible for the
development of myocardial dysfunction, even in the absence of CAD
or hypertension.442 The existence of diabetic cardiomyopathy has
CABG PCI
Class 1 Class IIa
Class IIb Class III
1-vessel or 2-vessel CAD,
no proximal LAD
1-vessel or 2-vessel CAD,
proximal LAD
Intermediate or
high complexity
3-vessel CAD
Left main CAD
Low complexity
Intermediate complexity
High complexity
Low complexity
©
ES
C
 2
01
9
Figure 4 Recommendations for coronary revascularization. SYNTAX
score calculation: http://www.syntaxscore.com. CABG = coronary artery
bypass grafting; CAD = coronary artery disease; High complexity =
SYNTAX score >_33; Intermediate complexity = SYNTAX score 2332;
LAD = left anterior descending coronary artery; Low complexity =
SYNTAX score 022; PCI = percutaneous coronary intervention;
SYNTAX = Synergy between Percutaneous Coronary Intervention with
TAXUS and Cardiac Surgery.
Table 11 Heart failure phenotypes323
HFpEF HFmrEF HFrEF
Criterion 1 Symptoms and/or signsa Symptoms and/or signsa Symptoms and/or signsa
Criterion 2 LVEF >_50% LVEF 4049% LVEF <40%
Criterion 3 1. Elevated natriuretic peptidesb 1. Elevated natriuretic peptidesb None
2. At least one additional criterion: 2. At least one additional criterion:
a) structural heart disease (i.e. LVH and/or LAE) a) structural heart disease (i.e. LVH and/or LAE)
b) diastolic dysfunctionc b) diastolic dysfunctionc
HF = heart failure; HFmrEF = heart failure with mid-range ejection fraction; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection
fraction; LAE = left atrial enlargement; LVEF = left ventricular ejection fraction; LVH = left ventricular hypertrophy; NT-proBNP = N-terminal pro-B-type natriuretic peptide.
aSigns may not be present at an early stage or in patients receiving diuretics.
bElevation of B-type natriuretic peptide >_35 pg/mL and/or NT-proBNP >_125 pg/mL.
cFor example, E/e0 >_13, and a mean e’ septal and lateral wall <9 cm/s on echocardiography.
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not been confirmed.438,443 The body of evidence for diabetic cardio-
myopathy mostly comes from experimental and smaller observatio-
nal studies.438,444448
8.3 Phenotypes of left ventricular
dysfunction in diabetes mellitus
LV dysfunction in patients with DM may present as HFpEF, HFmrEF, or
HFrEF (Table 11). LV diastolic dysfunction is frequent in both pre-DM
and overt DM, and severity correlates with insulin resistance and the
degree of glucose dysregulation.449453 DM and HFpEF are frequently
seen together in older, hypertensive, and female patients with DM.454
8.4 Treatment of heart failure in diabetes
mellitus
Treatment of HF encompasses pharmacological and device therapies
with confirmed benefits in RCTs, in which 3040% of patients had
DM. Treatment effects are consistent with and without DM, with the
exception of aliskiren, which is not recommended in patients with
DM due to the risk of serious adverse events.455,456
8.4.1 Renin-angiotensin-aldosterone system and
neprilysin inhibitors
ACEIs and ARBs have similar treatment effects in patients with HFrEF,
with and without DM.457462 RAAS blockers should be started at a
low dose and up-titrated to the maximally tolerated dose.459,463 There
is evidence for a positive effect of ACEIs and ARBs on the prevention
of DM.464 MRAs reduce death and HF hospitalization in HFrEF.465,466
As RAAS blockers increase the risk of worsening renal function and
hyperkalaemia in patients with DM, routine surveillance of serum crea-
tinine and potassium levels is advised.467470 The angiotensin receptor
neprilysin inhibitor sacubitril/valsartan has shown superior efficacy to
enalapril in the reduction of CV death and HF hospitalization in
patients with HFrEF. However, the treatment effect was less pro-
nounced in patients with baseline DM.421 The beneficial effect of sacu-
bitril/valsartan over enalapril is consistent across the spectrum of
baseline HbA1c.421,471 Sacubitril/valsartan therapy has also resulted in
a greater reduction in HbA1c levels and a lower rate of insulin initiation
over 3 year follow-up compared with enalapril in patients with DM.472
8.4.2 Beta-blockers
Beta-blockers are effective at reducing all-cause death and hospital-
ization for HFrEF in patients with DM.473476 Treatment benefits
strongly support beta-blocker use in patients with HFrEF and DM.
8.4.3 Ivabradine
Ivabradine improves the treatment of HFrEF in sinus rhythm, particu-
larly with regard to the reduction of HF hospitalization and the
improvement of LV function.335
8.4.4 Digoxin
Digoxin may reduce the risk of HF hospitalization in HFrEF treated
with ACEIs.477
8.4.5 Diuretics
Despite a lack of evidence for the efficacy of either thiazide or loop
diuretics in the reduction of CV outcomes in patients with HF,
diuretics prevent and treat symptoms and signs of fluid congestion in
patients with HF.478
8.4.6 Device therapy and surgery
Device therapies [implantable cardioverter defibrillator (ICD), car-
diac resynchronization therapy (CRT), and CRT with an implantable
defibrillator (CRT-D)] have similar efficacies and risks in patients with
and without DM.479481 These therapies should be considered
according to treatment guidelines in the general population. In a clini-
cal trial of CABG in HFrEF and two- or three-vessel CAD, there was
no difference in the efficacy of surgical revascularization with or with-
out DM.482 Heart transplantation could be considered in end-stage
HF, but a large, prospective study of transplanted patients indicated a
decreased likelihood of 10 year survival of patients with DM.483
8.5 Effect of oral glucose-lowering agents
on heart failure
8.5.1 Metformin
Metformin is safe at all stages of HF with preserved or stable moder-
ately reduced renal function (i.e. eGFR >30 mL/min), and results in a
lower risk of death and HF hospitalization compared with insulin and
sulfonylureas.484,485 Concerns regarding lactic acidosis have not been
substantiated.486
8.5.2 Sulfonylureas
Data on the effects of sulfonylureas on HF are inconsistent. A signal of
an adverse safety profile showed an 2060% higher death rate and
an 2030% increased risk of HF compared with metformin.487,488
Addition of a sulfonylurea to metformin was associated with a higher
risk of adverse events and death, compared with the combination of
metformin and a DPP4 inhibitor.489 However, in the UKPDS,
NAVIGATOR, and ADOPT studies, there was no increased HF
signal.145,278,490
8.5.3 Thiazolidinediones
Thiazolidinediones are not recommended in patients with DM and
symptomatic HF.279,491494
8.5.4 Dipeptidyl peptidase-4 inhibitors
Saxagliptin significantly increased the risk of HF hospitalization291 and
is not recommended in patients with DM with HF. Alogliptin was
associated with a non-significant trend towards HF hospitalization.292
Sitagliptin and linagliptin had a neutral effect.293,294 Vildagliptin had no
significant effect of LVEF but led to an increase in LV volumes.495
8.5.5 Glucagon-like peptide-1 receptor agonists
All GLP1-RAs had a neutral effect on the risk of HF hospitalization in
their placebo-controlled RCTs, suggesting that they should be con-
sidered in patients with DM and HF.272274
8.5.6 Sodium-glucose co-transporter 2 inhibitors
Empagliflozin reduced the risk of HF hospitalization by 35% in
patients with and without previous HF, while patients hospitalized for
HF were at a lower risk of death.306 Canagliflozin also significantly
reduced the risk of HF hospitalization by 32%.496 Dapagliflozin signifi-
cantly reduced the combined endpoint of CV death and HF
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hospitalization, a result driven mainly by lower rates of HF hospital-
ization.311 SGLT2 inhibitors are recommended for patients with DM
at high risk of HF. See also section 7.1.2.2.3.
Gaps in the evidence
• Studies are needed to better understand the bidirectional
relationship between DM and HF, including the pathophysiol-
ogy of diabetic cardiomyopathy.
• Considering the divergent evidence for an association
between DPP4 inhibitors and HF risk, research is needed to
further clarify this association.
• How do SGLT2 inhibitors improve HF outcomes?
• Research is needed to confirm whether SGLT2 inhibitors
lower the risk of HF in non-DM (HF and pre-DM).
Recommendations for the treatment of heart failure in
patients with diabetes
Recommendations Classa Levelb
ACEIs and beta-blockers are indicated in sympto-
matic patients with HFrEF and DM, to reduce the
risk of HF hospitalization and death.458,461,473476,497
I A
MRAs are indicated in patients with HFrEF and
DM who remain symptomatic, despite treatment
with ACEIs and beta-blockers, to reduce the risk
of HF hospitalization and death.465,466
I A
Device therapy with an ICD, CRT, or CRT-D is
recommended in patients with DM, as in the gen-
eral population with HF.479481
I A
ARBs are indicated in symptomatic patients with
HFrEF and DM who do not tolerate ACEIs, to
reduce the risk of HF hospitalization and
death.457,459,460
I B
Sacubitril/valsartan is indicated instead of ACEIs to
reduce the risk of HF hospitalization and death in
patients with HFrEF and DM who remain sympto-
matic, despite treatment with ACEIs, beta-block-
ers, and MRAs.421,471
I B
Diuretics are recommended in patients with
HFpEF, HFmrEF, or HFrEF with signs and/or
symptoms of fluid congestion, to improve
symptoms.478
I B
Cardiac revascularization with CABG surgery has
shown similar benefits for the reduction of long-
term risk of death in patients with HFrEF with and
without DM, and is recommended for patients
with two- or three-vessel CAD, including a signifi-
cant LAD stenosis.482
I B
Ivabradine should be considered to reduce the
risk of HF hospitalization and death in patients
with HFrEF and DM in sinus rhythm, with a resting
heart rate >_70 b.p.m., who remain symptomatic
despite treatment with beta-blockers (maximal
tolerated dose), ACEIs/ARBs, and MRAs.335
IIa B
Aliskiren (a direct renin inhibitor) is not recom-
mended for patients with HFrEF and DM because
of a higher risk of hypotension, worsening renal
function, hyperkalaemia, and stroke.455
III B
ACEIs = angiotensin-converting enzyme inhibitors; ARBs = angiotensin receptor
blockers; b.p.m. = beats per minute; CABG = coronary artery bypass graft; CAD =
coronary artery disease; CRT = cardiac resynchronization therapy; CRT-D = cardiac
resynchronization therapy with implantable defibrillator; DM = diabetes mellitus; HF
= heart failure; HFmrEF = heart failure with mid-range ejection fraction; HFpEF =
heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejec-
tion fraction; ICD = implantable cardioverter defibrillator; LAD = left anterior
descending coronary artery; MRAs = mineralocorticoid receptor antagonists
aClass of recommendation.
bLevel of evidence.
Recommendations for the treatment of patients with
diabetes to reduce heart failure risk
Recommendations Classa Levelb
SGLT2 inhibitors (empagliflozin, canagliflozin,
and dapagliflozin) are recommended to lower
risk of HF hospitalization in patients with
DM.306,311,496
I A
Metformin should be considered for DM
treatment in patients with HF, if the eGFR is
stable and >30 mL/min/1.73 m2.484,485
IIa C
GLP1-RAs (lixisenatide, liraglutide, semaglu-
tide, exenatide, and dulaglutide) have a neutral
effect on the risk of HF hospitalization, and
may be considered for DM treatment in
patients with HF.158,176,297,299,300,303,498,499
IIb A
The DPP4 inhibitors sitagliptin and linagliptin
have a neutral effect on the risk of HF hospi-
talization, and may be considered for DM
treatment in patients with HF.293,294
IIb B
Insulin may be considered in patients with
advanced systolic HFrEF.500
IIb C
Thiazolidinediones (pioglitazone and rosiglita-
zone) are associated with an increased risk of
incident HF in patients with DM, and are not
recommended for DM treatment in patients
at risk of HF (or with previous HF).279,491493
III A
The DPP4 inhibitor saxagliptin is associated
with an increased risk of HF hospitalization,
and is not recommended for DM treatment in
patients at risk of HF (or with previous HF).291
III B
DM = diabetes mellitus; DPP4 = dipeptidyl peptidase-4; eGFR = estimated glo-
merular filtration rate; GLP1-RA = glucagon-like peptide-1 receptor agonist; HF
= heart failure; HFrEF = heart failure with reduced ejection fraction; SGLT2 =
sodium-glucose co-transporter type 2; T2DM = type 2 diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
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• Does the combination of a SGLT2 inhibitor and sacubitril/val-
sartan lead to excessive diuresis/hypotension?
• Future research should address the risks of polypharmacy, in
terms of adherence, adverse reactions, and interactions,
especially among vulnerable patients with HF and DM, such
as those who are elderly and/or frail with multiple
comorbidities.
9 Arrhythmias: atrial fibrillation,
ventricular arrhythmias, and
sudden cardiac death
Key messages
• Atrial fibrillation (AF) is common in patients with DM, and
increases mortality and morbidity.
• Screening for AF should be recommended for patients with
DM aged >65 years by pulse palpation or wearable devices.
AF should always be confirmed by ECG.
• Anticoagulation is recommended in all patients with DM and
AF.
• Sudden cardiac death is more common in patients with DM,
especially in women.
• In HF patients with DM, QRS duration and LVEF should be
measured regularly to determine eligibility for CRT ± ICD.
9.1 Atrial fibrillation
A recent study reported that DM is an independent risk factor for
AF, especially in young patients.501 Several factors, such as auto-
nomic, electromechanical, and structural remodelling, and glycaemic
fluctuations, seem to be implicated in AF pathophysiology in the set-
ting of DM.502 Atrial premature beats are also common in patients
with DM and may predispose to the development of AF. Patients
with DM have an increased risk of acute HF at the time of new-onset
AF, as a result of loss of atrial kick and impaired LV filling.427
When DM and AF coexist, there is a substantially higher risk of all-
cause death, CV death, stroke, and HF.502 These findings suggest that
AF identifies subjects with DM who are likely to obtain greater bene-
fits from aggressive management of CVRFs. Because AF is asympto-
matic or mildly symptomatic in a substantial proportion of patients,
screening for AF can be recommended in patients with DM and AF
must be confirmed by 12 lead ECG, Holter recordings, or event
recorders demonstrating a duration of >30 s.
9.1.1 Diabetes and risk of stroke in atrial fibrillation
DM increases the risk of stroke in paroxysmal or permanent AF.503
Current Guidelines recommend that oral anticoagulant therapy, with
non-vitamin K antagonist (VKA) oral anticoagulants (NOACs; dabiga-
tran, apixaban, rivaroxaban, or edoxaban) or VKAs, should be consid-
ered.503 Kidney function should be carefully evaluated in patients
with DM when prescribing a NOAC to avoid over-dosage due to
reduced drug elimination.503
9.2 Ventricular arrhythmias and sudden
cardiac death
9.2.1 Ventricular premature beats and paroxysmal
ventricular tachycardia
Palpitations, premature ventricular beats, and non-sustained ventricular
tachycardia (VT) are common in patients with DM. Diagnostic workup
and treatment of ventricular arrhythmias does not differ between DM
and non-DM patients.504 In patients with DM with frequent sympto-
matic premature ventricular beats or episodes of non-sustained VT,
the presence of underlying structural heart disease should be exam-
ined by exercise ECG, echocardiography, coronary angiography, or
magnetic resonance imaging. The risk of cardiac events is usually dic-
tated by underlying heart disease rather than ectopic beats. In highly
symptomatic patients with premature ventricular beats or non-
sustained VT, beta-blockers, calcium antagonists, class Ic drugs (flecai-
nide or propafenone), or catheter ablation (in cases of an absence of
structural heart disease) can be used to suppress arrhythmias.505
9.2.2 Sustained ventricular arrhythmias
The diagnosis and treatment of sustained VT, or resuscitated ventricu-
lar fibrillation, is similar for patients with or without DM.504 Diagnosis
of underlying structural heart disease with imaging techniques and cor-
onary angiography is usually needed, if no obvious trigger factors such
as electrolyte imbalance or acute infarction can be identified. Most
patients with sustained VT or aborted cardiac arrest without a diag-
nosed trigger need an ICD to prevent sudden death.504,506
9.2.3 Sudden cardiac death in diabetes
Epidemiological studies have shown that patients with DM or pre-
DM are at increased risk of sudden cardiac death.507509 Women at
all ages have a lower risk for sudden cardiac death than men, but in
the presence of DM the risk of sudden cardiac death in both men and
women is quadrupled.510 In the Candesartan in Heart Failure
Assessment of Reduction in Mortality and Morbidity (CHARM) study
programme, DM was an independent predictor of mortality, includ-
ing sudden cardiac death, in HF irrespective of LVEF.432 In post-MI
patients, the incidence of sudden cardiac death was higher in those
with DM.511 The incidence of sudden cardiac death was substantially
increased in patients with DM with an LVEF <35%.511 After acute MI,
LVEF should be measured in patients irrespective of DM to identify
candidates for ICD implantation. In HF patients with DM, the QRS
width and LVEF should be determined to identify candidates for CRT
± ICD.505 In HF patients with HFrEF, beta-blockers, RAAS blockers
(including sacubitril/valsartan), and MRAs are recommended to
reduce the risk of sudden cardiac death.
The causes underlying increased vulnerability to electrical instability
in patients with DM are unclear and are likely to involve several factors.
Simultaneous glucose and ambulatory ECG monitoring has shown that
bradycardia, and atrial and ventricular ectopic beats, are more com-
mon during nocturnal hypoglycaemia in patients with DM.512 This
observation suggests a possible mechanism for increased death rates
(dead-in-bed syndrome) during intensive glycaemic control.
Nephropathy, autonomic neuropathy, prolonged QTc interval,
hypoglycaemia, and comorbidities related to DM are thought to
increase the risk of sudden cardiac death. On the basis of the available
evidence, it seems that glucose intolerance, even in pre-DM, is
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associated with the progressive development of a variety of abnormal-
ities that adversely affect survival and predispose to sudden arrhythmic
death. Apart from the measurement of LVEF, identification of inde-
pendent predictors in patients with DM has not progressed to a point
where it is possible to devise risk stratification for prevention.
Gaps in the evidence
• The role of novel wearable gadgets is not well established in
the home-based diagnosis of AF and should be tested in well-
designed clinical trials.
• The roles of several non-invasive risk markers of sudden car-
diac death—such as heart rate variability, QTc interval, albu-
minuria, hypoglycaemia, etc.—are not sufficiently well
established to be used in clinical decision-making for the pre-
vention of sudden unexpected death.
• The impact of novel antidiabetic drugs on sudden cardiac
death is not known.
• Prophylactic ICD therapy in patients with DM is not well
established.
10 Aortic and peripheral arterial
diseases
Key messages
• LEAD is a common complication of DM, with increasing
prevalence with duration and/or the coexistence of other
CVD risk factors.
• At any stage of LEAD, the coexistence of DM is associated
with poorer prognosis.
• Patients with DM are at higher risk of chronic limb-
threatening ischaemia (CLTI) as the first clinical manifestation
of LEAD, supporting regular screening with ABI measurement
for early diagnosis.
• The management of, and indications for, different treatment
strategies are similar in patients with LEAD with or without
DM, although the options for revascularization may be
poorer because of diffuse and distal lesions.
• The management of carotid artery disease is similar in DM
and non-DM patients.
10.1 Aortic disease
Several studies have shown a decreased risk of abdominal aortic
aneurysm in patients with DM, the reasons for which are unex-
plained.519 In turn, short- and long-term outcomes after abdominal
aortic aneurysm repair are poorer in patients with DM.520 However,
in the absence of any specific study on abdominal aortic aneurysm
screening and management in patients with DM, the recommenda-
tions on population screening for abdominal aortic aneurysm, as pro-
posed in the 2014 Guidelines on the diagnosis and treatment of
aortic diseases,521 remain valid in patients with DM.
10.2 Lower extremity arterial disease
According to the 2017 ESC Guidelines on the diagnosis and treat-
ment of PADs,522 this term includes conditions affecting all arteries,
except for the aorta, and the coronary and the intracranial arteries.
Recommendations for the management of arrhythmias
in patients with diabetes
Recommendations Classa Levelb
Oral anticoagulation with a NOAC, which is pre-
ferred over a VKA, is recommended in patients with
DM aged >65 years with AF and a CHA2DS2-VASc
score >_2, if not contraindicated.503
I A
i. ICD therapy is recommended in DM patients with
symptomatic HF (New York Heart Association
class II or III) and LVEF <_35% after 3 months of
optimal medical therapy, who are expected to sur-
vive for at least 1 year with good functional status.
ii. ICD therapy is recommended in DM patients
with documented ventricular fibrillation or hae-
modynamically unstable VT in the absence of
reversible causes, or within 48 hours of MI.506
I A
Beta-blockers are recommended for patients with
DM with HF and after acute MI with LVEF <40%,
to prevent sudden cardiac death.512
I A
Screening for AF by pulse palpation should be
considered in patients aged >65 years with DM
and confirmed by ECG, if any suspicion of AF, as
AF in patients with DM increases morbidity and
mortality.501,513517
IIa C
Oral anticoagulation should be considered on an
individual basis in patients aged <65 years with
DM and AF without any other thrombo-embolic
risk factors (CHA2DS2-VASc score <2).
503
IIa C
Assessment of the risk of bleeding (i.e. HAS-BLED
score) should be considered when prescribing antith-
rombotic therapy in patients with AF and DM.503
IIa C
Screening for risk factors for sudden cardiac death,
especially measurement of LVEF, should be consid-
ered in patients with DM and previous MI or HF.
IIa C
Ruling out structural heart disease should be con-
sidered in patients with DM and frequent prema-
ture ventricular contractions.504
IIa C
Hypoglycaemia should be avoided, as it can trigger
arrhythmias.512,518
IIa C
AF = atrial fibrillation; CHA2DS2-VASc = Congestive heart failure, Hypertension,
Age >_75 years (Doubled), Diabetes mellitus, Stroke or transient ischaemic attack
(Doubled), Vascular disease, Age 6574 years, Sex category; DM = diabetes mel-
litus; ECG = electrocardiogram; HAS-BLED = Hypertension, Abnormal renal/
liver function, Stroke, Bleeding history or predisposition, Labile international nor-
malized ratio, Elderly (>65 years), Drugs/alcohol concomitantly; HF = heart fail-
ure; ICD = implantable cardioverter defibrillator; LVEF = left ventricular ejection
fraction; MI = myocardial infarction; NOAC = non-vitamin K antagonist oral anti-
coagulant; VKA = vitamin K antagonist; VT = ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
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..10.2.1 Epidemiology and natural history
LEAD is a frequent vascular complication of DM, with one-third of
patients hospitalized for LEAD having DM.523 Prolonged DM dura-
tion, suboptimal glycaemic control, the coexistence of other CVRFs,
and/or other end-organ damage (e.g. proteinuria) increase LEAD
prevalence.523 LEAD in pre-DM is infrequent in the absence of other
risk factors.524 In patients with DM, LEAD more frequently affects
arteries below the knee; as a consequence, the revascularization
options, as well as their chances of success, are reduced.523 In
patients with DM, LEAD is often diagnosed at a later stage (e.g. a
non-healing ulcer), because of concomitant neuropathy with
decreased pain sensitivity. All of these factors increase the risk of
limb infection.525
Clinically, patients with DM often have atypical forms of pain on
exertion that do not meet the typical criteria for intermittent claudi-
cation.526 CLTI is the clinical presentation of advanced disease, char-
acterized by ischaemic rest pain, but which may be absent in patients
with DM. About 5070% of all patients with CLTI have DM. The
2017 ESC Guidelines on the diagnosis and treatment of PADs pro-
posed the Wound, Ischemia, and foot Infection (WIfI) classification to
stratify amputation risk and the potential benefits of revascularization
(Table 12).522
10.2.2 Screening and diagnosis
Screening and early diagnosis are of major importance in patients
with DM. Clinical evaluation includes medical history, symptom
assessment, and examination for neuropathy on a yearly basis. The
ABI is the current method for LEAD screening. An ABI <0.90 is diag-
nostic for LEAD, with 80% sensitivity and 95% specificity in all popula-
tions.523 However, the accuracy of ABI is lower in patients with DM
(see below).527 Beyond LEAD, an ABI <0.90 (or >1.40) is associated
with an increased risk of death and CV events (Figure 5).528
If symptoms suggest LEAD but the ABI result is normal, sensitivity
can be improved by post-exercise ABI or the toebrachial index
(TBI) at rest.522,529 With intermittent claudication, the treadmill test
is helpful for the assessment of walking distance. An ABI >1.40 is
mostly related to medial calcinosis but is associated with LEAD in
50% of cases.530 Other tests are useful for the diagnosis of LEAD in
the presence of medial calcinosis, including Doppler waveform analy-
sis of the ankle arteries or the TBI, which may be helpful because
medial calcinosis barely affects digital arteries. A TBI <0.70 is diagnos-
tic for LEAD.529
The value of duplex as first-line imaging for confirmation of
LEAD,522 CT angiography and/or magnetic resonance imaging in
planned revascularization, and other more detailed imaging tests are
©
ES
C
 2
01
9
Clinical suspicion (symptoms or physical examination) in diabetes patients
ABIb
>1.30 1.01–1.30
Significant LEAD
unlikely
Reassess every
2–3 years
0.91–1.00 <0.90
Normal TBI or
Duplex
Abnormal
LEAD present
Consider secondary prevention
measures.
Refer to a specialist
if ABI <0.70
NO
consider PAD screening based on ABIa
YES
refer to the ESC Guidelines on
PAD for diagnosis work-up
Figure 5 Screening for lower extremity artery disease in patients with diabetes. ABI = anklebrachial index; DM = diabetes mellitus; ESC = European
Society of Cardiology; LEAD = lower extremity artery disease; PAD = peripheral arterial disease; TBI = toebrachial index. aABI-based screening should
be performed once when DM is diagnosed, and then after 10 years of DM if the results from the initial examination were normal (can be considered after
5 years of diagnosis if other risk factors such as smoking exist). Patients should be assessed every year for symptoms and pulses should be checked. ABI-
based screening is proposed in the absence of any clinical suspicion of PAD. bIn case of borderline results (e.g. 0.89), repeat the measurement and average
the results to increase accuracy. If TBI is available, this can be done in conjunction with the ABI.
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fully described in 2017 ESC Guidelines on the diagnosis and treat-
ment of PADs.522
10.2.3 Management of lower extremity artery disease in
diabetes mellitus
The medical management of LEAD in patients with DM is not signifi-
cantly different from that recommended for patients with CVD in
general (see sections 5 and 6). The main COMPASS trial results
reported the benefit of (i) rivaroxaban 2.5 mg b.i.d. plus aspirin 100
mg o.d. against (ii) rivaroxaban 5 mg b.i.d. or (iii) aspirin 100 mg o.d. in
27 395 patients with stable atherosclerotic vascular disease, indicating
a significant reduction in the primary outcome of CV death, stroke,
or MI, which led to early termination of the trial.342 In a substudy of
7240 patients with CAD or LEAD with a mean follow-up of 23
months (44% with DM), major adverse limb events including amputa-
tion were significantly decreased with combination therapy (HR 0.54;
P=0.0037).531 These benefits were observed at the cost of major
bleeding risk (HR 1.61; P=0.0089). The significant reduction in major
adverse limb events in this COMPASS substudy raises the possibility
of a novel therapeutic regimen in high-risk vascular patients to ameli-
orate the complications of LEAD.532,533
Patients with intermittent claudication should take part in exercise
training programmes (>3045 min, at least three times per week) as
regular intensive exercise improves walking distance, although with
less pronounced benefits in patients with DM.534
In patients with CLTI, strict glycaemic control is associated with
improved limb outcomes.535,536 However, revascularization must be
attempted when possible, and amputation only considered when revas-
cularization options fail.522 Revascularization should also be considered
in severe/disabling claudication. With respect to the revascularization
modality of choice, we refer the reader to dedicated Guidelines.522
There has not been a specific trial on revascularization strategies in
patients with DM; however, a review of 56 studies including patients
with DM suggested higher limb salvage rates after revascularization
(7885% at 1 year) compared with conservative management.537
10.3 Carotid artery disease
Thromboembolism from a carotid artery stenosis is the mechanism
underlying 1015% of all strokes. In brief, carotid artery disease
must be rapidly ruled out in all patients presenting with transient
ischaemic attack or stroke. In patients with DM without a history of
cerebrovascular disease, there is no evidence that carotid screening
improves outcomes and systematic screening is not recommended.
Asymptomatic carotid disease is frequently treated conservatively,
and the patient is followed-up with duplex ultrasound. Carotid revascu-
larization should be considered in asymptomatic patients in the presence
of one or more indicators of increased stroke risk (previous transient
ischaemic attack/stroke, ipsilateral silent infarction, stenosis progression,
or high-risk plaques), and if the estimated peri-operative stroke or death
rate is <3% and the patient’s life expectancy is >5 years.522
In symptomatic patients, carotid revascularization is indicated if the
stenosis is >70%, and should be considered if the stenosis is >50%,
assuming that the estimated peri-operative stroke or death rate is
<6%.522
RCTs comparing carotid endarterectomy with carotid artery stenting
in the peri-procedural period have shown an excess of minor strokes
with carotid artery stenting, and more episodes of myocardial ischaemia
and cranial nerve palsies with endarterectomy. Post-operatively, both
Table 12 Assessment of the risk of amputation: the Wound, Ischaemia, and foot Infection classification522
Wound Ischaemia foot Infection
Score ABI Ankle pressure
(mmHg)
Toe pressure
or TcPO2
0 No ulcer (ischaemic rest pain) >_0.80 >100 >_60 No symptoms/signs of infection
1 Small, shallow ulcer
(distal leg or foot), no gangrene
0.600.79 70100 4059 Local infection involving only skin
and subcutaneous tissue
2 Deep ulcer (exposed bone, joint,
or tendon) ± gangrenous changes
limited to toes
0.400.59 5070 3039 Local infection involving deeper than
skin/subcutaneous tissue
3 Extensive deep ulcer, full thickness
heel ulcer ± extensive gangrene
<0.40 <50 <30 Systemic inflammatory response syndrome
One-year amputation risk
Estimated risk of amputation at 1 year for each combination
Ischaemia – 0 Ischaemia – 1 Ischaemia – 2 Ischaemia – 3
W-0 VL VL L M VL L M H L L M H L M M H
W-1 VL VL L H VL L M H L M H H M M H H
W-2 L L M H M M H H M H H H H H H H
W-3 M M H H H H H H H H H H H H H H
fI-0 fI-1 fI-2 fI-3 fI-0 fI-1 fI-2 fI-3 fI-0 fI-1 fI-2 fI-3 fI-0 fI-1 fI-2 fI-3
ABI = anklebrachial index; DM = diabetes mellitus; fI = foot Infection, H = high risk, L = low risk, M = moderate risk; PAD = peripheral arterial disease; TcPO2 = transcutane-
ous oxygen pressure; VL = very low risk, W = wound; WIfI = Wound, Ischaemia, and foot Infection.
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treatments offer similar protection from recurrent stroke and have simi-
lar rates of repeat interventions.538 Carotid endarterectomy remains
the standard of care, while stenting may be considered as an alternative
in patients at high risk of endarterectomy.522
With respect to the impact of DM on carotid revascularization, a
meta-analysis of 14 observational studies involving 16 264 patients
showed that those with DM had a higher risk of peri-operative stroke
and death.539 Carotid Revascularization Endarterectomy versus
Stenting Trial (CREST) was the only trial comparing carotid endarter-
ectomy and carotid artery stenting to enrol enough patients with DM
(n=759) for subgroup analysis. Although restenosis rates were low at
2 years after carotid stenting (6.0%) and carotid endarterectomy
(6.3%), DM was a predictor of restenosis with both techniques.540
Gaps in the evidence
• The regularity and mode of vascular screening in patients
with DM have not been adequately assessed.
• The use of antithrombotic therapies at different clinical stages
has been poorly addressed.
• Specific trials are needed to help clinicians to choose different
pharmacological strategies according to the presence of PAD.
Recommendations for the diagnosis and management of peripheral arterial disease in patients with diabetes
Recommendations Classa Levelb
Carotid artery disease
In patients with DM and carotid artery disease it is recommended to implement the same diagnostic workup and therapeutic
options (conservative, surgical, or endovascular) as in patients without DM.
I C
LEAD diagnosis
Screening for LEAD is indicated on a yearly basis, with clinical assessment and/or ABI measurement. I C
Patient education about foot care is recommended in patients with DM, and especially those with LEAD, even if
asymptomatic. Early recognition of tissue loss and/or infection, and referral to a multidisciplinary team,c is mandatory to
improve limb salvage.522
I C
An ABI <0.90 is diagnostic for LEAD, irrespective of symptoms. In case of symptoms, further assessment, including duplex
ultrasound, is indicated.
I C
In case of elevated ABI (>1.40), other non-invasive tests, including TBI or duplex ultrasound, are indicated. I C
Duplex ultrasound is indicated as the first-line imaging method to assess the anatomy and haemodynamic status of lower
extremity arteries.
I C
CT angiography or magnetic resonance angiography is indicated in case of LEAD when revascularization is considered. I C
In case of symptoms suggestive of intermittent claudication with normal ABI, a treadmill test and post-exercise ABI should be
considered.522
IIa C
In patients with DM with CLTI with below-the-knee lesions, angiography, including foot run-off, should be considered before
revascularization.
IIa C
LEAD management
In patients with DM and symptomatic LEAD, antiplatelet therapy is recommended.541 I A
As patients with DM and LEAD are at very high CV risk,d an LDL-C target of <1.4 mmol/L (<55 mg/dL), or an LDL-C reduc-
tion of al least 50% is recommended.200,201,210
I B
In patients with DM with CLTI, the assessment of the risk of amputation is recommended; the WIfI scoree is useful for this
purpose.494,522
I B
In case of CLTI, revascularization is indicated whenever feasible for limb salvage.542 I C
In patients with DM with CLTI, optimal glycaemic control should be considered to improve foot outcome. IIa C
In patients with DM and chronic symptomatic LEAD without high bleeding risk, a combination of low-dose rivaroxaban (2.5
mg b.i.d.) and aspirin (100 mg o.d.) should be considered.f 531
IIa B
ABI = anklebrachial index; b.i.d. = twice daily (bis in die); CLTI = chronic limb-threatening ischaemia; CT = computed tomography; CV = cardiovascular; DM = diabetes melli-
tus; eGFR = estimated glomerular filtration rate; LDL-C = low-density lipoprotein cholesterol; LEAD = lower extremity artery disease; o.d. = once daily (omni die); PAD =
peripheral arterial disease; TBI = toebrachial index; WIfI = Wound, Ischaemia, and foot Infection.
aClass of recommendation.
bLevel of evidence.
cIncluding a diabetologist and a vascular specialist.
dSee Table 7.
eSee Table 12.
fHigh bleeding risk is defined as history of intracerebral haemorrhage or ischaemic stroke, history of other intracranial pathology, recent gastrointestinal bleeding or anaemia
due to possible gastrointestinal blood loss, other gastrointestinal pathology associated with increased bleeding risk, liver failure, bleeding diathesis or coagulopathy, extreme old
age or frailty, or renal failure requiring dialysis or with eGFR <15 mL/min/1.73 m2.
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..11. Chronic kidney disease in
diabetes
Key messages
• CKD is associated with a high prevalence of CVD and should
be considered in the highest risk group for risk factor
management.
• Screening for kidney disease in patients with DM requires
serum creatinine measurement to enable the calculation of
eGFR and urine tests of albumin excretion.
• Optimizing glycaemic and BP control may slow decline in kid-
ney function.
• ACEIs and ARBs are the preferred antihypertensive drugs in
patients with albuminuria.
• Therapeutic reductions in albuminuria are associated with
‘renoprotection’.
• Data from recent CVOTs suggest that SGLT2 inhibitors and
GLP1-RAs, may confer renoprotection.
• In the CREDENCE trial, canagliflozin reduced the relative risk
of the primary renal outcome by 30% compared with
placebo.
CKD developing in the context of DM is a major health issue,
which is associated with the highest risk of CVD23 and should there-
fore be managed accordingly. CKD is defined as a reduction in eGFR
to <60 mL/min/1.73m2 and/or persistent proteinuria (e.g. urinary
albumin:creatinine ratio >3 mg/mmol), sustained over >_90 days. The
most widely used classified system, developed by Kidney Disease:
Improving Global Outcomes, stratifies patients according to both
their eGFR (‘G’ stage) and their urinary albumin excretion (‘A’ stage)
in a two-dimensional manner (Table 13).543 Monitoring of DM should
include the assessment of kidney function by both blood and urine
testing to determine the eGFR and albumin:creatinine ratio, respec-
tively. Approximately 30% of patients with T1DM and 40% with
T2DM will develop CKD.544 A decline in eGFR makes glycaemic con-
trol more challenging and increases the risks of drug-induced adverse
events such as hypoglycaemia.545
11.1 Management
11.1.1 Glycaemic control
Improving glycaemia may reduce the risk of progression of nephrop-
athy,546 but is more complex in diabetic kidney disease because a fall
in eGFR restricts the use of several oral glucose-lowering drugs.545
For example, although metformin is useful and possibly beneficial in
stage 1 - 3 CKD, an observational study from Taiwan reported a 35%
increase in death in metformin users with stage 5 CKD, a finding that
was not replicated with other glucose-lowering agents. Metformin
should therefore be used with caution as the eGFR drops towards 30
mL/min/1.73m2. Accumulation of renally excreted sulfonylureas may
increase the likelihood of hypoglycaemia.547 As kidney function dete-
riorates, the use of insulin in place of oral regimens is likely to assist in
achieving better glycaemic control, particularly as patients near renal
replacement therapy. The GLP1-RAs liraglutide, dulaglutide, and
semaglutide can even be administered with an eGFR >15 mL/min/
1.73 m2.
11.1.2 New approaches to nephroprotection
Data on composite kidney endpoints from recent CVOTs suggest
that some of the newer oral antihyperglycaemic drugs have beneficial
renal effects. Nephroprotection has been observed in two GLP1-RA
(liraglutide176 and semaglutide299) and three SGLT2 inhibitor (empa-
gliflozin,548 canagliflozin,309 dapagliflozin311) CVOTs. These trials did
not include patients with advanced CKD and nephroprotection was
not the adjudicated primary outcome. In response to these prelimi-
nary findings, several studies have been initiated to investigate renal
outcomes [DAPA-CKD (clinicaltrialts.gov ID: NCT03036150),
EMPA-Kidney,549 and CREDENCE550]. The Canagliflozin and Renal
Events in Diabetes with Established Nephropathy Clinical Evaluation
trial313 assigned patients with T2DM and eGFR 30 to <90 mL/min/
1.73m2 (urinary albumin:creatinine ratio 33.9565 mg/mmol) to
either canagliflozin 100 mg/day or placebo. The trial was stopped pre-
maturely by the safety committee after an interim analysis demon-
strated superiority. A total of 4401 patients were followed for 2.6
years and the relative risk of the primary outcome (a composite of
end-stage renal disease, a doubling of serum creatinine levels, or renal
or CV death) was reduced by 30% (43.2 vs. 61.2/1000 patient-years,
Table 13 Chronic kidney disease classification by estimated glomerular filtration rate and albuminuria543
eGFR (mL/min/1.73 m2) Albuminuria categories (albumin:creatinine ratio spot urine)
A1 (<3 mg/mmol) A2 (330 mg/mmol) A3 (>30 mg/mmol)
G1 (>_90) No CKD G1 A2 G1 A3
Increasing risk#
G2 (6089) No CKD G2 A2 G2 A3
G3a (4559) G3a A1 G3a A2 G3a A3
G3b (3044) G3b A1 G3b A2 G3b A3
G4 (1529) G4 A1 G4 A2 G4 A3
G5 (<15) G5 A1 G5 A2 G5 A3
Increasing riskfi
Green = low risk; yellow = medium risk; orange = high risk; red = very high risk.
CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate.
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.P=0.00001). Secondary outcomes, including the composite of CV
death or hospitalization for HF; the composite of CV death, MI, or
stroke; and the analysis of hospitalization for HF alone, all demon-
strated significant benefits with canagliflozin. These findings in a high-
risk population of patients with T2DM and renal impairment validate
the secondary outcome observations in the CVOTs, and confirm the
importance of SGLT2 inhibitors in managing DM, CKD, and associ-
ated CVD. The CREDENCE trial also demonstrated that the SGLT2
inhibitor canagliflozin may be used with benefit down to an eGFR of
30 mL/min/1.73m2.
Gaps in the evidence
• Lack of renal primary outcome trials with GLP1-RAs in
patients with DM.
• Whether the nephroprotection shown in the CREDENCE
trial is a class effect of SGLT2 inhibition or specific to canagli-
flozin remains to be determined.
12 Patient-centred care
Key message
• Group-based structured education programmes improve dis-
ease knowledge, glycaemic control, disease management, and
empowerment in patients with DM.
12.1 General aspects
Supporting patients in achieving and sustaining lifestyle changes on an
individualized basis, using defined therapeutic goals, continues to be a
challenge.551 For instance, 3349% of patients with DM fail to meet
targets for glycaemic, cholesterol, or BP control, and even fewer
meet targets for all three measures.552 Whereas a wide range of stud-
ies have documented the effects of self-management education and
support programmes in patients with DM on DM outcomes, and in
patients with CVD delivered separately, the evidence underpinning
the best approach to deliver educational or self-management inter-
ventions targeted at both DM and CVD is limited. A patient-centred
approach is considered an important way to help strengthen patients’
capabilities for self-managing their conditions,553 and should also be
the basis of healthcare professional-patient interactions in patients
with DM and CVD.
Patient-centred care is an approach that facilitates shared control
and decision-making between patient and provider. It emphasizes a
focus on the whole person and their experiences of illness within
social contexts, rather than a single disease or organ system, and it
develops a therapeutic alliance between patient and provider.554 It is
also a care strategy that is respectful and responsive to individual
patient preferences, needs, and values,555 and it places the patient as
an ‘active drug’ at the centre of care, working in collaboration with
healthcare professionals. Different approaches on how to integrate
patient-centred care in clinical practice exist. One such approach
comprises six interactive components, including validating the
patients’ experiences, considering the broader context in which the
illness is experienced, working towards mutual understandings
between healthcare professionals and patients, engaging in health
promotion, taking a partnership approach to the healthcare profes-
sional-patient relationship, and being realistic about goals.556 In addi-
tion, patients with low socio-economic status are more likely to have
Recommendations for the prevention and management
of chronic kidney disease in patients with diabetes
Recommendations Classa Levelb
It is recommended that patients with DM are
screened annually for kidney disease by assess-
ment of eGFR and urinary albumin:creatinine
ratio.543
I A
Tight glucose control, targeting HbA1c (<7.0%
or <53 mmol/mol) is recommended to
decrease microvascular complications in
patients with DM.145149
I A
It is recommended that patients with hyper-
tension and DM are treated in an individual-
ized manner, targeting a SBP to 130 mmHg
and <130 mmHg if tolerated, but not
<120 mmHg. In older people (aged >65 years)
the SBP goal is to a range of
130139 mmHg.155,159,181183
I A
A RAAS blocker (ACEI or ARB) is recom-
mended for the treatment of hypertension in
patients with DM, particularly in the presence
of proteinuria, microalbuminuria, or
LVH.167170
I A
Treatment with an SGLT2 inhibitor (emplagli-
flozin, canagliflozin, or dapagliflozin) is associ-
ated with a lower risk of renal endpoints and
is recommended if eGFR is 30 to <90 mL/min/
1.73 m2).306,311,313,496
I B
Treatment with the GLP1-RAs liraglutide and
semaglutide is associated with a lower risk of
renal endpoints, and should be considered for
DM treatment if eGFR is >30 mL/min/
1.73m2.176,299
IIa B
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor
blocker; BP = blood pressure; CKD = chronic kidney disease; DM = diabetes
mellitus; eGFR = estimated glomerular filtration rate; GLP1-RA = glucagon-like
peptide-1 receptor agonist; HbA1c = haemoglobin A1c; LVH = left ventricular
hypertrophy; RAAS = reninangiotensinaldosterone system; SBP = systolic
blood pressure; SGLT2 = sodium-glucose co-transporter 2.
aClass of recommendation.
bLevel of evidence.
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..DM557 and CVD.558 Limited health literacy is a major barrier to dis-
ease prevention, disease management, and positive outcomes.
Attention to health literacy skills in healthcare provider-patient inter-
actions are thus important in patients with DM and CVD.559
The effects of education and self-management strategies have
been evaluated on both DM outcomes and CVD risk factors. A
systematic review including patients with DM found that group-
based, structured education programmes resulted in clinically
relevant improvements in glycaemic control, DM knowledge, tri-
glyceride levels, BP, medication reduction, and self-management
for 1214 months. Benefits for 24 years, including decreased
DM-related retinopathy, were apparent when group classes were
provided on an annual basis.560 A systematic review with meta-
analysis showed that group-based, structured DM self-
management patient education programmes reduced HbA1c,
FPG, and body weight, and improved DM knowledge, self-
management skills, and empowerment.561 Another study com-
pared the effectiveness of group-based structured interventions
with individual structured interventions or usual care for patients
with DM. Outcomes favoured reductions in HbA1c for group-
based structured education programmes compared with con-
trols.562 Studies of self-management education programmes indi-
cate that they are cost-effective in the long-term.563
Empowerment strategies including individual consultations, phone
calls, web-based sessions, and the use of a booklet were evaluated
across 11 studies. Outcomes included HbA1c levels, self-efficacy, lev-
els of DM knowledge, and quality of life. In addition, some of the stud-
ies assessed secondary outcomes in the form of CVD risk factors.
These studies were carried out in both T1DM and T2DM patients, in
primary and secondary care. Improvements with individual empow-
erment strategies were shown in self-efficacy, levels of DM knowl-
edge, and quality of life. However, no statistically significant
improvement was found for HbA1c levels.564
Patients with pre-DM benefit from structured empowerment
interventions and lifestyle education to reduce progression to
DM,565567 and beneficial effects on CVD risk factors, such as BP and
total cholesterol, have been reported.82,568 The Diabetes Prevention
Program provides the strongest evidence for DM prevention in indi-
viduals with pre-DM.569
In patients with DM after an ACS, four RCTs included in a system-
atic review evaluated the effectiveness of structured self-
management interventions plus an intensified comprehensive cardiac
rehabilitation programme. The review concluded that there is cur-
rently no evidence to support the effectiveness of combined inter-
ventions in promoting self-management behaviour with regard to
clinical, psychological, or behavioural outcomes.570 In patients under-
going PCI, a retrospective study found that patients with DM bene-
fited from cardiac rehabilitation, with regard to all-cause death, to a
similar degree as those without DM.571 However, several studies
have also indicated that cardiac rehabilitation uptake is low in patients
with DM.571,572
Gaps in the evidence
• Further research is required to determine the effects of
group- and individual-based structured patient education pro-
grammes on CVD risk factors.
• The effects of patient-centred interventions on micro- and
macrovascular complications are unknown.
• More research is needed to develop robust combined self-
management interventions, including cost-effectiveness evalu-
ations of joint DM and CVD interventions; future studies
should compare different modes delivering individual empow-
erment strategies.
• In patients with CVD and concomitant DM, barriers to car-
diac rehabilitation should be explored, and future prospective
studies should investigate the benefit of cardiac rehabilitation
programmes.
• Uptake of empowerment programmes in different ethnic
groups requires evaluation.
• Possible differences between men and women with regards
to optimal delivery of patient-centred care, structured educa-
tion, and self-management programmes should be explored.
Recommendations for patient-centred care of patients
with diabetes
Recommendations Classa Levelb
Group-based structured education pro-
grammes are recommended in patients with
DM, to improve DM knowledge, glycaemic
control, disease management, and patient
empowerment.560562
I A
Patient-centred care is recommended to facili-
tate shared control and decision-making,
within the context of patient priorities and
goals.553,554,573
I C
Provision of individual empowerment strat-
egies should be considered to enhance self-
efficacy, self-care, and motivation in patients
with DM.564,574579
IIa B
DM = diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
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13 ‘What to do’ and ‘what not to do’ messages from the Guidelines
Diagnosis of disorders of glucose metabolism
Recommendations Classa Levelb
It is recommended that screening for potential T2DM in patients with CVD is initiated with HbA1c and FPG, and that an
OGTT is added if HbA1c and FPG are inconclusive.1318
I A
It is recommended that an OGTT is used to diagnose IGT.24,1622 I A
It is recommended that the diagnosis of DM is based on HbA1c and/or FPG, or on an OGTT if still in doubt.14,9,10,1622 I B
Use of laboratory, ECG, and imaging testing for CV risk assessment in asymptomatic patients with DM
Routine assessment of microalbuminuria is indicated to identify patients at risk of developing renal dysfunction or at high
risk of future CVD.27,38
I B
A resting ECG is indicated in patients with DM diagnosed with hypertension or with suspected CVD.38,39 I C
Carotid ultrasound intimamedia thickness screening for CV risk assessment is not recommended.62,73,78 III A
Routine assessment of circulating biomarkers is not recommended for CV risk stratification.27,31,3537 III B
Risk scores developed for the general population are not recommended for CV risk assessment in patients with DM. III C
Lifestyle modifications in DM and pre-DM
Smoking cessation guided by structured advice is recommended in all individuals with DM and pre-DM.27,117 I A
Lifestyle intervention is recommended to delay or prevent the conversion of pre-DM states, such as IGT, to T2DM.85,86 I A
Reduced calorie intake is recommended for lowering excessive body weight in individuals with pre-DM
and DM.c 82,83,89,90
I A
Moderate-to-vigorous physical activity, notably a combination of aerobic and resistance exercise for >_ 150 min/week, is
recommended for the prevention and control of DM, unless contraindicated, such as when there are severe comorbidities
or a limited life expectancy.d 110,111113,119
I A
Vitamin or micronutrient supplementation to reduce the risk of DM or CVD in patients with DM is not
recommended.79,120
III B
Glycaemic control in DM
It is recommended to apply tight glucose control, targeting a near-normal HbA1c (<7.0% or <53 mmol/mol), to decrease
microvascular complications in patients with DM.145149
I A
It is recommended that HbA1c targets are individualized according to the duration of DM, comorbidities, and age.122,150 I C
Avoidance of hypoglycaemia is recommended.136,139,140,151 I C
Management of blood pressure in patients with DM and pre-DM
Treatment targets
Antihypertensive drug treatment is recommended for people with DM when office BP is >140/90 mmHg.155,178180 I A
It is recommended that a patient with hypertension and DM is treated in an individualized manner. The BP goal is to target
SBP to 130 mmHg and <130 mmHg if tolerated, but not <120 mmHg.In older people (aged >65 years), the SBP goal is to
a range of 130-139 mmHg.155,159,160,181183
I A
It is recommended to target DBP to <80 mmHg, but not <70 mmHg.160 I C
Treatment and evaluation
Lifestyle changes [weight loss if overweight, physical activity, alcohol restriction, sodium restriction, and increased con-
sumption of fruits (e.g. 23 servings), vegetables (e.g. 23 servings), and low-fat dairy products] are recommended in
patients with DM and pre-DM with hypertension.161163,166
I A
A RAAS blocker (ACEI or ARB) is recommended in the treatment of hypertension in patients with DM, particularly in the
presence of microalbuminuria, albuminuria, proteinuria, or LV hypertrophy.167170
I A
It is recommended that treatment is initiated with a combination of a RAAS blocker with a calcium channel blocker or a
thiazide/thiazide-like diuretic.167171
I A
Management of dyslipidaemia with lipid-lowering agents
Targets
In patients with T2DM at moderate CV risk,e an LDL-C target of <2.6 mmol/L (<100 mg/dL) is recommended.210212 I A
In patients with T2DM at high CV risk,e an LDL-C target of <1.8 mmol/L (<70 mg/dL) and LDL-C reduction of at least
50% is recommended.f 210212
I A
Continued
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In patients with T2DM at very high CV risk,e an LDL-C target of <1.4 mmol/L
(<55 mg/dL) and LDL-C reduction of at least 50% is recommended.f 200,201,210
I B
In patients with T2DM, a secondary goal of a non-HDL-C target of <2.2 mmol/L (<85 mg/dL) in very high-CV risk patients
and <2.6 mmol/L (<100 mg/dL) in high-CV risk patients is recommended.213,214
I B
Treatment
Statins are recommended as the first-choice lipid-lowering treatment in patients with DM and high LDL-C levels: adminis-
tration of statins is defined based on the CV risk profile of the patiente and the recommended LDL-C (or non-HDL-C)
target levels.187
I A
If the target LDL-C is not reached, combination therapy with ezetimibe is recommended.200,201 I B
In patients at very high CV risk, with persistent high LDL-C despite treatment with maximal tolerated statin dose, in com-
bination with ezetimibe, or in patients with statin intolerance, a PCSK9 inhibitor is recommended.203206
I A
Statins are not recommended in women of childbearing potential.189,190 III A
Antiplatelet therapy in primary prevention in DM
In patients with DM at moderate CV risk,e aspirin for primary prevention is not recommended III B
Glucose-lowering treatment in DM
SGLT2 inhibitors
Empagliflozin, canagliflozin, or dapagliflozin are recommended in patients with T2DM and CVD, or at very high/high CV
risk,e to reduce CV events.306,308,309,311
I A
Empagliflozin is recommended in patients with T2DM and CVD to reduce the risk of death.306 I B
GLP-1 RAs
Liraglutide, semaglutide, or dulaglutide are recommended in patients with T2DM and CVD, or at very high/high CV risk,e
to reduce CV events.176,299300,302303
I A
Liraglutide is recommended in patients with T2DM and CVD, or at very high/high CV risk,e to reduce the risk of death.176 I B
Thiazolidinediones
Thiazolidinediones are not recommended in patients with HF. III A
DPP4 inhibitors
Saxagliptin is not recommended in patients with T2DM and a high risk of HF.291 III B
Management of patients with DM, and ACS or CCS
ACEIs or ARBs are indicated in patients with DM and CAD to reduce the risk of CV events.326,345347 I A
Statin therapy is recommended in patients with DM and CAD to reduce the risk of CV events.211,348 I A
Aspirin at a dose of 75160 mg/day is recommended as secondary prevention in patients with DM.349 I A
Treatment with a P2Y12 receptor blocker, ticagrelor or prasugrel, is recommended in patients with DM and ACS for 1
year with aspirin, and in those who undergo PCI or CABG.350,351
I A
Concomitant use of a proton pump inhibitor is recommended in patients receiving DAPT or oral anticoagulant monother-
apy who are at high risk of gastrointestinal bleeding.253,336,352
I A
Clopidogrel is recommended as an alternative antiplatelet therapy in case of aspirin intolerance.353 I B
Coronary revascularization in patients with DM
It is recommended that the same revascularization techniques are implemented (e.g. the use of DES and the radial
approach for PCI, and the use of the left internal mammary artery as the graft for CABG) in patients with and without
DM.344
I A
It is recommended to check renal function if patients have taken metformin immediately before angiography and withhold
metformin if renal function deteriorates.
I C
Treatment of HF in patients with DM
ACEIs and beta-blockers are indicated in symptomatic patients with HFrEF and DM, to reduce the risk of HF hospitaliza-
tion and death.458,461,473476,497
I A
MRAs are indicated in patients with HFrEF and DM who remain symptomatic despite treatment with ACEIs and beta-
blockers, to reduce the risk of HF hospitalization and death.465,466
I A
Device therapy with an ICD, CRT, or CRT-D is recommended in patients with DM, as in the general population with
HF.479481
I A
ARBs are indicated in symptomatic patients with HFrEF and DM who do not tolerate ACEIs, to reduce the risk of HF hos-
pitalization and death.457,459,460
I B
Sacubitril/valsartan is indicated instead of ACEIs to reduce the risk of HF hospitalization and death in patients with HFrEF
and DM who remain symptomatic, despite treatment with ACEIs, beta-blockers, and MRAs.421,471
I B
Continued
ESC Guidelines 303
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/article-abstract/41/2/255/5556890 by 81728827 user on 15 June 2020
Diuretics are recommended in patients with HFpEF, HFmrEF, or HFrEF with signs and/or symptoms of fluid congestion,
to improve symptoms.478
I B
Cardiac revascularization with CABG surgery has shown similar benefits for the reduction of long-term risk of death in
patients with HFrEF with and without DM, and is recommended for patients with two- or three-vessel CAD, including a
significant LAD stenosis.482
I B
Aliskiren (a direct renin inhibitor) is not recommended for patients with HFrEF and DM because of a higher risk of hypo-
tension, worsening renal function, hyperkalaemia, and stroke.455
III B
T2DM treatment to reduce HF risk
Recommendations Classa Levelb
SGLT2 inhibitors (empagliflozin, canagliflozin, and dapagliflozin) are recommended to lower risk of HF hospitalization in
patients with DM.306,311,496
I A
Thiazolidinediones (pioglitazone and rosiglitazone) are associated with an increased risk of incident HF in patients with
DM, and are not recommended for DM treatment in patients at risk of HF (or with previous HF).279,491493
III
A
The DPP4 inhibitor saxagliptin is associated with an increased risk of HF hospitalization, and is not recommended for DM
treatment in patients at risk of HF (or with previous HF).291
III
B
Management of arrhythmias in patients with DM
Oral anticoagulation with a NOAC, which is preferred over VKAs, is recommended in DM patients aged >65 years with
AF and a CHA2DS2- VASc score >_2, if not contraindicated.
503 I A
a. ICD therapy is recommended in DM patients with symptomatic HF (New York Heart Association class II or III) and
LVEF <_35% after 3 months of optimal medical therapy, who are expected to survive for at least 1 year with good func-
tional status.
b. ICD therapy is recommended in DM patients with documented ventricular fibrillation or haemodynamically
unstable VT in the absence of reversible causes, or within 48 hours of MI.506
I A
Beta-blockers are recommended for patients with DM with HF and after acute MI with LVEF <40%, to prevent sudden
cardiac death.512
I A
Diagnosis and management of PAD in patients with DM
Carotid artery disease
In patients with DM and carotid artery disease it is recommended to implement the same diagnostic workup and thera-
peutic options (conservative, surgical, or endovascular) as in patients without DM.
I C
LEAD diagnosis
Screening for LEAD is indicated on a yearly basis, with clinical assessment and/or ABI measurement. I C
Patient education about foot care is recommended in patients with DM, and especially those with LEAD, even if
asymptomatic. Early recognition of tissue loss and/or infection, and referral to a multidisciplinary team,g is mandatory to
improve limb salvage.522
I C
An ABI <0.90 is diagnostic for LEAD, irrespective of symptoms. In case of symptoms, further assessment, including duplex
ultrasound, is indicated.
I C
In case of elevated ABI (>1.40), other non-invasive tests, including TBI or duplex ultrasound, are indicated. I C
Duplex ultrasound is indicated as the first-line imaging method to assess the anatomy and haemodynamic status of lower
extremity arteries.
I C
CT angiography or magnetic resonance angiography is indicated in case of LEAD when revascularization is considered. I C
LEAD management
In patients with DM and symptomatic LEAD, antiplatelet therapy is recommended.541 I A
As patients with DM and LEAD are at very high CV risk,d an LDL-C target of <1.4 mmol/L (<55 mg/dL) or an LDL-C
reduction of at least 50% is recommended.e 200,201,210
I B
In patients with DM with CLTI, the assessment of the risk of amputation is recommended; the WIfI scoreh is useful for
this purpose.494,522
I B
In case of CLTI, revascularization is indicated whenever feasible for limb salvage.542 I C
Prevention and management of CKD in patients with DM
It is recommended that patients with DM are screened annually for kidney disease by assessment of eGFR and urinary
albumin:creatinine ratio.543
I A
Tight glucose control, targeting HbA1c <7.0% (or <53 mmol/mol), is recommended to decrease microvascular complica-
tions in patients with DM.145149
I A
Continued
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Author/Task Force Member Affiliations:
Victor Aboyans, Department of Cardiology, Dupuytren University
Hospital, Limoges, France; Clifford J. Bailey, Life and Health
Sciences, Aston University, Birmingham, United Kingdom; Antonio
Ceriello, Cardiovascular and Metabolic Diseases, IRCCS
MultiMedica, Milan, Italy; Victoria Delgado, Cardiology, Leiden
University Medical Center, Leiden, Netherlands; Massimo Federici,
Department of Systems Medicine, University of Rome Tor Vergata,
Rome, Italy; Gerasimos Filippatos, University of Athens, Athens,
Greece and University of Cyprus, Nicosia, Cyprus; Diederick E.
Grobbee, Julius Center for Health Sciences and Primary Care,
University Medical Center, Utrecht, Netherlands; Tina Birgitte
Hansen, Department of Cardiology, Zealand University Hospital,
Roskilde, Denmark and Department of Regional Health Research,
University of Southern Denmark, Odense, Denmark; Heikki V.
Huikuri, Internal Medicine, University of Oulu, Oulu, Finland;
Isabelle Johansson, Cardiology Unit, Department of Medicine K2,
Karolinska Institute and Karolinska University Stockholm, Sweden;
Peter Ju¨ni, Applied Health Research Centre, Li Ka Shing Knowledge
Institute of St. Michael’s Hospital, Toronto, Canada; Maddalena
Lettino, Cardiology, Cardiovascular Department, San Gerardo
Hospital ASST Monza, Monza, Italy; Nikolaus Marx, Internal
Medicine I, RWTH Aachen University, Aachen, Germany; Linda G.
Mellbin, Cardiology Unit, Department of Medicine Solna, Karolinska
Institute, Stockholm, Sweden; Carl J. €Ostgren, Department of
Medical and Health Sciences, Linkoping University, Linkoping, Sweden;
Bianca Rocca, Pharmacology, Catholic University School of
Medicine, Rome, Italy; Marco Roffi, Cardiology, University Hospitals,
Geneva, Switzerland; Naveed Sattar, Cardiovascular and Medical
Sciences, University of Glasgow, Glasgow, United Kingdom; Petar M.
Seferovic, Heart Failure Center, Belgrade University Medical Center,
University of Belgrade, Faculty of Medicine, Belgrade, Serbia; Miguel
Sousa-Uva, Cardiac Surgery, Hospital Santa Cruz, Carnaxide,
Portugal; Paul Valensi, Endocrinology Diabetology Nutrition, Jean
Verdier Hospital, APHP, Paris Nord University, CINFO, CRNH-IdF,
Bondy, France; David C. Wheeler, Department of Renal Medicine,
University College London, London, United Kingdom.
It is recommended that patients with hypertension and DM are treated in an individualized manner, SBP to 130 mmHg
and <130 mmHg if tolerated, but not <120 mmHg. In older people (aged >65 years) the SBP goal is to a range of
130139 mmHg.155,159,181183
I A
A RAAS blocker (ACEI or ARB) is recommended for the treatment of hypertension in patients with DM, particularly in
the presence of proteinuria, microalbuminuria, or LVH.167170
I A
Treatment with an SGLT2 inhibitor (emplagliflozin, canagliflozin, or dapagliflozin) is associated with a lower risk of renal
endpoints and is recommended if eGFR is 30 to <90 mL/min/1.73 m2).306,311,313,496
I B
Patient-centred care in DM
Group-based structured education programmes are recommended in patients with DM, to improve DM knowledge, gly-
caemic control, disease management, and patient empowerment.560562
I A
Patient-centred care is recommended to facilitate shared control and decision-making within the context of patient prior-
ities and goals.553,554,573
I C
ABI = anklebrachial index; ACEI = angiotensin-converting enzyme inhibitor; ACS = acute coronary syndromes; AF = atrial fibrillation; ARB = angiotensin receptor blocker; BP =
blood pressure; CABG = coronary artery bypass graft; CAD = coronary artery disease; CCS = chronic coronary syndromes; CHA2DS2-VASc = Congestive heart failure,
Hypertension, Age >_75 years (Doubled), Diabetes mellitus, Stroke or transient ischaemic attack (Doubled), Vascular disease, Age 6574 years, Sex category; CKD = chronic kidney
disease; CLTI = chronic limb-threatening ischaemia; CRT = cardiac resynchronization therapy; CRT-D = cardiac resynchronization therapy with implantable defibrillator; CT = com-
puted tomography; CV = cardiovascular; CVD = cardiovascular disease; DAPT = dual antiplatelet therapy; DBP = diastolic blood pressure; DES = drug-eluting stent; DM = diabetes
mellitus; DPP4 = dipeptidyl peptidase-4; EAS = European Atherosclerosis Society; ECG = electrocardiogram; eGFR = estimated glomerular filtration rate; ESC = European Society of
Cardiology; FPG = fasting plasma glucose; GLP1-RA = glucagon-like peptide-1 receptor agonist; HAS-BLED = Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or
predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol concomitantly; HbA1c = haemoglobin A1c; HDL-C = high-density lipoprotein cholesterol; HR =
heart failure; HFmrEF = heart failure with mid-range ejection fraction; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; ICD
= implantable cardioverter defibrillator; IGT = impaired glucose tolerance; LAD = left anterior descending coronary artery; LDL-C = low-density lipoprotein cholesterol; LEAD =
lower extremity artery disease; LV = left ventricular; LVEF = left ventricular ejection fraction; LVH = left ventricular hypertrophy; MI = myocardial infarction; MRAs = mineralocorticoid
receptor antagonists; NOAC = non-vitamin K antagonist oral anticoagulant; OGTT = oral glucose tolerance test; PAD = peripheral arterial disease; PCI = percutaneous coronary inter-
vention; PCSK9 = proprotein convertase subtilisin/kexin type 9; RAAS = reninangiotensinaldosterone system; SBP = systolic blood pressure; SGLT2 = sodium-glucose co-trans-
porter 2; T2DM = type 2 diabetes mellitus; TBI = toebrachial index; VKA = vitamin K antagonist; VT = ventricular tachycardia; WIfI = Wound, Ischaemia, and foot Infection.
aClass of recommendation.
bLevel of evidence.
cA commonly stated goal for obese patients with DM is to lose around 5% of baseline weight.
dIt is recommended that all individuals reduce the amount of sedentary time by breaking up periods of sedentary activity with moderate-to-vigorous physical activity in bouts of
>_10 min (broadly equivalent to 1000 steps).
eSee Table 7.
fSee the 2019 ESC/EAS Guidelines for the management of dyslipidaemias for non-HDL-C and apolipoprotein B targets.
gIncluding a diabetologist and a vascular specialist.
hSee Table 12.
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